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ABSTRACT 
 
Advanced vaccine research approaches need to explore on biodegradable nanoparticles (NPs) based 
vaccine carrier that can serve as antigen delivery systems as well as immuno-stimulatory action to induce 
both innate and adaptive immune response. The biodegradable polymeric particles like polylactide-co-
glycolide (PLGA) or polylactide (PLA), not only work as a delivery system but also, provide adjuvant 
activity and marks in the development of long -lasting immunity. In this PhD dissertation work, the 
immunogenicity of PLA and PLGA NPs encapsulating outer membrane protein (Omp) antigen 
(Aeromonas hydrophila and Vibrio cholerae) were evaluated. Initially, Various NPs formulations of PLA 
and PLGA loaded with model protein (Bovine Serum Albumin) or drug (Clindamycin hydrochloride) 
were prepared by solvent evaporation method varying drug/protein: polymer concentration and optimized 
for size, encapsulation efficiency, drug loading,  morphology etc. A. hydrophila Omp antigen loaded 
PLA-Omp (223.5± 13.19 nm) and PLGA-Omp (166.4± 21.23 nm) NPs were prepared using double 
emulsion method by efficiently encapsulating the antigen reaching the encapsulation efficiency 44 ± 4.58 
% and 59.33± 5.13 % respectively. Despite low antigen loading in PLA-Omp, it exhibited considerably 
slower antigen release in vitro than PLGA-Omp NPs. Upon intraperitoneal immunization in fish, Labeo 
rohita with all antigenic formulations (PLA-Omp NP, PLGA-Omp NP, FIA-Omp, PLA NP, PLGA NP, 
PBS as control), significantly higher bacterial agglutination titre and haemolytic activity were observed in 
the case of PLA-Omp and PLGA-Omp immunized groups compared to rest of the groups at both 21 days 
and 42 days.The antigen specific antibody response was significantly increased and persisted up to 42 
days of post immunization by PLA-Omp, PLGA-Omp, FIA-Omp.PLA-Omp NPs showed a better 
immune response (higher bacterial agglutination titre, haemolytic activity, specific antibody titre, higher 
percent survival upon A. hydrophila challenge) than PLGA-Omp in L. rohita confirming its better 
efficacy. Comparable antibody response of PLA-Omp and PLGA-Omp with FIA-Omp treated groups 
suggested that PLA and PLGA could be a replacement for Freund’s adjuvant (for stimulating antibody 
response) to overcome many side effects offering long lasting immunity. Similarly, V. cholerae Omp 
antigen loaded PLA-Omp (196.24± 34.25 nm) and PLGA-Omp (165.34± 3.5 nm) NPs were prepared 
using double emulsion method by efficiently encapsulating the antigen reaching the encapsulation 
efficiency 57.85 ± 4.15 % and 69.18± 1.68 respectively. After intraperitoneal immunization in BALB/c 
mice, the type and strength of immune responses elicited (cellular and humoral) by formulated NPs were 
evaluated. The antibody titre (IgG1, IgG2a) were significantly higher (P<0.05; Kruskal-Wallis test and 
post hoc Dunn multiple comparisons) in PLA-Omp NPs, PLGA-Omp NPs treated groups than respective 
PLA and PLGA NPs treated groups from 7 days to 56 days as confirmed by ELISA tests. Also, PLA-
Omp NPs and PLGA-Omp NPs induced significantly higher (P<0.05; Kruskal-Wallis test and post hoc 
Dunn multiple comparisons) antigen specific IgG titers than Omp antigen treated groups at all-time 
intervals except 0 day. From the spleen cell analysis (Cell surface phenotype through FACs study), a 
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significantly higher cellular activation was observed in the case of PLA-Omp and PLGA-Omp NPs in 
comparison to Omp antigen alone. Enhanced immune responses elicited by PLA-Omp and PLGA-Omp 
NPs might be attributed to strong memory T cell response (higher effector memory T cell), efficient 
induction of dendritic cell (DC) activation (higher MHC I, MHC II, CD 86 expression) and follicular 
helper T cell differentiation in spleen favoring the generation of antibody responses. Another study aimed 
at developing a DNA vaccine as well as a delivery system to boost antigenic outer membrane protein 
(Omp) that would act as potential vaccine candidate was conducted. NPs based delivery systems for 
plasmid DNA (pDNA) (which encode conserved Omp) administration might be keys to improve the 
transfection efficiency in vivo even at a lower dose. The conserved antigenic protein sequences 
[omp(211-382), omp(211-382)opt, omp(703-999) and omp(703-999)opt] of outer membrane protein were 
identified using bioinformatics tools. The sequences were cloned into a pVAX-GFP expression vector 
and successfully transformed into E. coli (DH5α). The large scale pDNA production was achieved with 
shake flask cultures and the pDNA was purified by hydrophobic interaction chromatography (HIC). The 
formulated PLGA-chitosan NP/plasmid DNA nano complex of ~200 nm (199.25 ± 22.29 nm and 205.25 
±33.59) was transfected in the into CHO cells that confirmed improved transfection efficiency 
(fluorescence intensity measurement corresponding to GFP expression level from the FACs study) at a 
lower dose. The DNA entrapment assay demonstrated the possible protection of pDNA inside the pDNA-
NP complex. The protection from enzymatic digestion that NP complex confers to pDNA was evaluated 
and confirmed by gel electrophoresis after treatment with DNase. Further, physio-chemical 
characterizations of formulated nano complex and extensive transfection studies have proved the 
functionality of the system in vitro. Overall, the successful formulations of NP based antigen delivery 
system with all desirable physiochemical characteristics were obtained under highly controlled conditions 
and reproducibility. The immunological evaluation studies suggest that PLA/PLGA NPs based delivery 
system could be a novel antigen carrier for fish and mice ensuring its application for commercial value 
and product development. Further work based on present optimized results can be taken forward for next 
level vaccine design and approval. 
Keywords: PLA; PLGA; Omp; nanoparticles; adjuvant; antigen carrier; immune response. 
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Chapter I 
Introduction 
 
1.1. Background 
Today’s  leading research on vaccine approaches mostly focuses on the development of naturally 
acquiring immunity by inoculation of non-pathogenic but still immunogenic components of the 
pathogen or closely related organisms. Generally, these conventional approaches have been most 
successful in developing vaccines that can elicit an immune response based on antigen-specific 
antibody and cytotoxic T-lymphocyte (CTL) responses [1], [2]. The growing issues of vaccine 
safety are in alarming rate owing to their weak immunogenicity, imperfect immunization 
procedures, and failure to acquire booster doses to potentiate prime doses. So, these issues have 
paved the way towards research for developing new generation preventive and therapeutic 
vaccine. Adjuvants are the immunological agents that act to accelerate, enhance and prolong 
antigen-specific immune responses when used along with specific antigens. Adjuvants are used 
for multiple purposes; to accelerate a robust  immune response by enhancing immunogenicity, 
provide antigen dose sparing, reduce booster immunization requirements, offers prolonged and 
improved protection [3], [4]. There is a crucial requirement for enhanced and effective vaccine 
formulations (with or without adjuvant) having minimal compositions like purified proteins, 
recombinant proteins and synthetic peptides, etc. for specific disease antigen in question. 
Adjuvants in vaccine formulations vary to a greater extent due to many issues; e.g. the chemical 
nature, mode of action, the safety and efficacy of adjuvants. The adverse effects concerned with 
the prolonged use of adjuvants use are the hyperactivation of the immune system, neurotoxicity, 
and many detrimental effects. There is also an urgent requirement for the development of novel 
carriers which could be target specific to achieve therapeutic drug concentration. Therefore, a 
relatively new system which is stable with antigen combination and can provide comparable 
immunity to that of adjuvants eventually can be treated as a complete replacement for the 
existing adjuvants in use should take the lead for development of advanced vaccine 
formulations. 
Therefore, a better delivery system which could mimic the natural infection, reduce the need for 
booster immunization and also could address the other complications hopes to improve the 
vaccine efficacy. Controlled delivery systems comprising biodegradable nano-encapsulated 
peptide or protein antigens are of immense interest because they can potentially deliver the
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antigens to the preferred locations at predetermined rates and durations to produce an optimal 
immune response. Various biodegradable polymeric particles like polylactide-co-glycolide 
(PLGA) or polylactide (PLA), not only work as an antigen delivery system but also afford 
adjuvant activity and marks in the development of long-lasting immunity after a single dose of 
injection. The polymeric NPs can be surface altered and functionalized either by adsorbing 
amphiphilic excipients onto pre-formed particles or by covalently linking excipients to the core-
forming polymer prior to NP preparation to improve their biodistribution. The NPs can also be 
conjugated to targeting ligands which direct particles to specific cells/tissues. Among possible 
delivery systems, nanoparticles (NP) based delivery of DNA vaccines to APCs, is a very 
promising approach used for optimizing DNA vaccine formulation for immunotherapy [5], [6]. 
1.2. Vaccines and vaccination 
A vaccine may be defined as “biological preparation of microorganisms or their antigenic 
components which can provide acquired immunity against the appropriate pathogens, but it does 
not itself cause disease” [7] or simply as “a dead or attenuated (non-pathogenic) form of the 
pathogen”[8]. In addition to the immunogenic components, vaccines consist of an 
adjuvant/delivery system that aid in the induction of innate and adaptive responses, and 
stabilizers/surfactants that contribute to the immunogens staying intact during storage and 
administration. In general, vaccines are further sorted into a number of sub-categories mainly 
based on the condition of the antigen. These include heat or formalin inactivated whole 
microorganisms, antigen subunits (peptides, proteins, toxoids and its conjugates) and 
live/attenuated microorganisms, as well as plasmid DNA (pDNA) vaccines encoding immune 
inducing peptides/proteins of pathogenic origin. 
1.3. Adjuvants and vaccine delivery systems 
Adjuvants (from Latin word, adjuvare: to aid) are essential components of most clinically used 
vaccines. In a broad sense, adjuvants are pharmacological agents that can accelerate, reinforce, 
improve or modify the effect of antigen. Adjuvants can be used for various purposes: to enhance 
immunogenicity, to accelerate the immune response, provide antigen dose sparing, reduce the 
need for booster immunizations, increase the period of protection, or improve efficacy in 
immune compromised individuals [9].Vaccine delivery systems are commonly particulate 
adjuvants and comprise constructs such as emulsions (oil-in-water and water-in-oil), mineral 
salts (Al (OH)3), virus-like particles (VLPs), liposomes, immune stimulating complexes 
(ISCOMs) and nano/microparticles of chitosan, alginate and poly (lactide-co-glycolide) 
(PLGA)[9]–[15]. Despite the long history, the exact mechanism of adjuvant action is poorly 
understood. The general understanding is that adjuvants improve the immune response by; (1) 
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increasing the immunogenicity of highly purified or recombinant antigens (reduce the dose of 
antigen); (2) enhancing the magnitude, speed and duration of the immune response; (3) 
modulating antibody specificity, avidity, subclass or isotype distribution; (4) stimulating CTL 
responses; and/or (5) generating antigen depots and/or pulsed antigen release [2], [16], [17]. 
1.4. Nanoparticle vaccine 
Nanovaccines that comprise of nanoparticles are emerging as novel approach to the 
methodology of vaccination. The motivation for nanoparticles as vaccine systems develops from 
the idea that several components essential for vaccine efficacy can be rationally assembled, 
optimized independently, and incorporated into a single vehicle to induce an effective immune 
response. Various advantages have been shown by the researchers working and investigating the 
different aspects related to nano vaccine. Nanoparticle-based vaccination strategy offers 
significant distinct advantages over conventional vaccines e.g. (1) nanoparticles can efficiently 
protect their cargo from degradation in physiological conditions, (2) Size and shape of NPs can 
be specifically adjusted to mimic characteristics of pathogens, allowing effective draining 
through the lymphatic system and subsequent internalization in APCs, (3) Furthermore, size and 
charge strongly affect biodistribution and retention of particles in lymph nodes and spleens thus  
promoting effector and memory immune responses, (4) Surface modification of NPs also 
provides additional opportunities for enhancing target specific delivery by conjugation of 
receptor ligands or antibodies, (5) nanoparticle based co-delivery of antigens and adjuvants 
targeted to the specific APCs, that leads to optimal antigen presentation and immune activation, 
(6) Again, the cytosolic delivery of antigens within APCs can be achieved by NP systems 
intended to promote endosomal escape, thus allowing for effective antigen cross-presentation 
and induction of cytotoxic CD8+ T lymphocyte (CTL) response. 
Biodegradable NPs can be made from a range of materials such as polysaccharides, amino acids 
and synthetic biodegradable polymers. The selection of the ideal polymer is based on diverse 
designs and application criteria. It depends on various factors such as 1) size of the preferred 
nanoparticles, 2) nature of the drug (stability, aqueous solubility, etc.) to be enclosed in the 
polymer, 3) extent of biocompatibility and biodegradability, 4) surface functionality and 5) drug 
release profile., The procedures for the preparation of  nanoparticles, based upon selection of 
preferred criteria, can be categorized as following 1) dispersion of preformed polymers, 2) ionic 
gelation method for hydrophilic polymers and 3) polymerization of monomers. Despite the 
availability of a large number of vaccines in the market, their cost per dose and delivery of 
multiple doses are the limiting factors of these vaccines. Furthermore, the requirement for cold 
storage is another drawback of conventional vaccines. So, the efforts have been taken to develop 
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biodegradable polymeric NPs as vaccine delivery systems to induce both humoral and cellular 
immune responses. Entrapment efficiency, release kinetics and additional physical features like 
construction, size assortment and porosity, which determine the potency of the formulation, can 
be controlled by using a suitable aggregation of different polymers.  
 
1.5. Nanoparticle – delivery system 
In recent years, significant research has been done using nanoparticles as drug delivery vehicles 
for immunization. The benefit of using polymeric nanoparticles is to allow encapsulation of 
bioactive molecules and protect them against hydrolytic and enzymatic degradation. 
Nanoparticles loaded with plasmid DNA offer sustained release due to their quick escape from 
the degradative endo-lysosomal. Because of their endolysosomal escape and intracellular uptake, 
nanoparticles could discharge DNA at a constant rate resulting in continuous gene expression. 
Nanoparticulate vaccine delivery system can also be helpful to enhance the weaker immune 
response generated by synthetic peptide vaccines [18]. 
 
1.6. Nanoparticle carrier system 
The alternative drug delivery approach (nanoscale) typically incorporates one or more of the 
following materials: biologics, polymers, carbon-based materials, silicon-based materials, or 
metals. Biodegradable polymer nanoparticles, characteristically comprising of polylactic acid 
(PLA), polyglycolic acid (PGA), or Poly lactic-co-glycolic acid (PLGA), are being studied for 
the delivery of proteins and genes, anticancer drugs, etc. Other polymers being studied for 
nanoscale drug carriers consist of poly(3-hydroxybutanoic acid) (PHB), poly alkyl 
cyanoacrylate, poly(organophosphazene), poly(caprolactone) (PCL), poly(ethylene glycol) 
(PEG), poly(ethylene oxide) (PEO), and copolymers such as PLA-PEG. There have been a 
diversity of materials used to engineer solid nanoparticles, both with and without surface 
functionality. Possibly, the majority of polymers are the aliphatic polyesters, specifically the 
hydrophobic PLA [poly(lactic acid)], the hydrophilic PGA [poly(glycolic acid)] and their 
copolymer PLGA [poly(lactide- co-glycolide)]. 
1.6.1. Poly (lactic acid) (PLA) 
PLA (polylactic acid) polymer has been extensively studied in medical implants, suture, and 
drug delivery systems since 1980s. PLA is a biocompatible and biodegradable polymer which is 
metabolized into monomeric units of lactic acid in the body. Lactic acid is a natural intermediate 
by-product of anaerobic respiration, which is converted into glucose by the liver during the Cori 
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cycle. Glucose then is utilized as an energy source in the body. The use of PLA nanoparticles is, 
therefore, safe and devoid of any major toxicity. 
 
1.6.2. Poly lactic-co-glycolic acid (PLGA) 
Poly (lactic-co-glycolic acid) (PLGA) NPs have unbelievable perspective in the applications 
connecting diagnostics,  targeting and therapy. It is the most widely used biodegradable 
synthetic polymer nanocarrier with a relatively long history of biomedical usage. PLGA based 
vaccines delivery is a promising approach for boosting immune responses against a range of 
antigens such as recombinant proteins, peptide and DNA [5]. The poly (lactic-co-glycolic acid) 
(PLGA) copolymer can act as an attractive delivery system because of its superb 
biocompatibility, high safety profile[19], [20].It undergoes non-enzymatic hydrolysis in the body 
to produce biodegradable metabolite monomers such as lactic acid and glycolic acid that are 
natural metabolites (Figure 1.1). The lactic acid and glycolic acids are generally found in the 
body and participate in a number of biochemical and physiological pathways. So, there is very 
minimal systemic toxicity associated with the use of PLGA for the biomedical applications. In 
addition, the release kinetics of this system can be easily manipulated by varying the ratio of 
PLA: PGA. The PLGA particle size has been varied and surface modifications have been 
introduced into vaccine formulations for use in oral, mucosal, and systemic delivery. The sizes, 
surface modification, and release profiles of PLGA particles were shown to influence the 
immunogenicity of entrapped antigens. 
1.7. Protein Vaccine and delivery strategy 
Recent advances in vaccinology demonstrate that proteins and peptides are the basis of a new 
generation vaccine. Protein vaccines are composed of purified or recombinant proteinaceous 
antigens from a pathogen, such as a bacterium or virus. When administered, it can elicit a 
protective immune response against the pathogen. High molecular weight, structural fragility, 
hydrophilicity, and complexity are the main hurdles to the use of protein drugs [21]. Indeed, 
these macromolecules can easily undergo denaturation, degradation and eventually inactivation 
(physical, chemical, and enzymatic machinery) during formulation, storage, and delivery [22], 
[23].The use of a properly designed carrier for the sustained and targeted delivery of protein 
antigen offers several advantages compared with traditional administration: it can enhance the 
amount of drug that reaches the targeted site, improve the transportation mechanism and protect 
the drug against degradation, inactivation, and metabolization phenomena. Nanoparticles, such 
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as polymeric micelles, liposomes, lipoplexes and polyplexes have been extensively investigated 
as targeted drug carrier systems over the past three decades. 
1.8. DNA Vaccination and delivery strategy 
DNA vaccination or genetic immunization represents a novel strategy, which can serve as a 
viable alternative to conventional vaccine approaches. During the past two decades, the DNA 
vaccines have been investigated and tried to induce immune responses against a range of 
infectious pathogens and tumor antigens [24]. The novelty and usefulness of DNA vaccines stem 
from the several unique features, namely, they are conceptually safe, non-replicating and non-
infectious, thereby overcome safety concern associated with live-attenuated vaccines. The DNA 
vaccine can be manufactured on large-scale with high purity and stability in a cost-effective 
manner and can be preserved without the need for a cold chain. More importantly, DNA vaccine 
can induce antigen-specific mucosal (IgA), humoral (protective neutralizing antibodies) and 
cellular (cytotoxic T lymphocytes) immune responses [25]. The mechanism of a DNA vaccine 
can in many ways be compared to that of a virus, as it requires the similar cellular machinery in 
order to replicate and also triggers immune responses normally seen with viral infections. Unlike 
conventional viral vaccines based on subunits or killed the virus, a DNA vaccine may conserve 
the structure and hence also antigenicity of a transgenic antigen/protein. A significant obstacle to 
the successful development of DNA vaccine is their low immunogenicity in humans and in large 
animals. Numerous factors may contribute to their poor immunogenicity including low 
transfection efficiency of naked DNA, insufficient antigen expression, and intra and extracellular 
barriers in the host[26]. The viral and nonviral vectors are used to enhance DNA delivery and 
transfection efficiency. Viral vectors are very efficient, but they are associated with several 
safety concerns such as immune response to vector itself, difficulty in manufacturing, limited 
DNA carrying capacity and oncogenicity of transduced cells. On the other hand, non-viral 
vectors are gaining increased interest because of their improved safety profile, ease of 
preparation and adjuvant properties [27].The non-viral carriers that are currently investigated for 
DNA vaccine delivery include biodegradable PLGA NPs, cationic liposomes, cationic block 
copolymers, polycationic dendrimers, and cationic polymers (poly-L-lysine, polyethyleneimine 
and chitosan). In the case of synthetic polymers like PLGA, besides DNA protection, the 
encapsulation permits a controlled DNA delivery system to be designed with controllable 
degradation times and release kinetics of DNA for sustained gene expression over a required 
time. 
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1.8.1. Aeromonas hydrophila 
A. hydrophila is a pathogenic gram-negative bacterium associated with lower vertebrates like 
fish, amphibians [28]. Aeromoniasis, an important fish disease is caused by this bacterium [29]. 
A. hydrophila infections in fishes have been reported from time to time in many Asian countries 
including China, Thailand, Philippines and India [30]. 
1.8.2. Vibrio cholerae 
Vibrio cholerae is a "comma" shaped Gram-negative bacteria [31] with a single, polar flagellum 
for movement. V. cholerae can cause syndromes ranging from asymptomatic to cholera gravis. 
Symptoms include abrupt onset of watery diarrhea (a grey and cloudy liquid), occasional 
vomiting, and abdominal cramps [32]. Dehydration can lead to death in a few hours to days in 
untreated children. Cholera affects an estimated 3-5 million people worldwide and causes 
100,000-130,000 deaths a year as of 2010 [33]. Cholera remains both epidemic and endemic in 
many areas of the world. This occurs mainly in the developing world [34] due to poor sanitary 
and socioeconomic conditions. 
1.9. Outer membrane protein as vaccine target 
The OM of pathogenic gram-negative bacteria is mainly responsible for establishing initial 
adherence, modulate host-pathogen interaction, overall survival of the organism and propagation 
of virulence factor [35]. It also has protective antigenicity, because OM components are easily 
recognized as a foreign antigen by immunological defense systems of the hosts. Outer 
membrane proteins (Omps) are located at host–bacterial interface in pathogenic gram-negative 
bacteria and are important for host immune responses and as targets for drug therapy. The Outer 
Membrane (OM) of A. hydrophila is a complex structure which mainly consists of 
lipopolysaccharide (LPS), phospholipids and a group of outer membrane proteins (Omps). Omps 
are located at host–bacterial interface in A. hydrophila and can be targeted for drug therapy [36]. 
Similarly, the Outer Membrane (OM) of V. cholerae is a complex structure that mainly consists 
of lipopolysaccharide (LPS), phospholipids and a group of outer membrane proteins (Omps). 
High levels of transcripts for OmpU and multiple OM structures (OmpS, OmpV, OmpK, OmpC, 
OmpW, and OmpA) were present along with a number of conserved hypothetical proteins 
[37].Virulence-related outer membrane proteins (Omps) are essential to bacterial survival within 
macrophages and for eukaryotic cell invasion that could be an alternative candidate for 
development of subunit vaccine against V. cholerae. 
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1.10. Motivation 
A better delivery system which could mimic the natural infection, reduce the need for booster 
immunization and also could address the other complications hopes to improve the vaccine 
efficacy. Various biodegradable polymeric particles like polylactide-co-glycolide (PLGA) or 
polylactide (PLA), not only work as a delivery system but also provide adjuvant activity and 
marks the development of long-lasting immunity after a single injected dose. So, a relatively 
new system which is stable with antigen combination and can provide comparable immunity to 
that of adjuvants, eventually, can be treated as a complete replacement for the existing adjuvants 
in use and should take the lead for development of advanced vaccine formulations. The strategy 
here is to develop such a system. Omps are highly immunogenic due to their exposed epitopes 
on the cell surface. There are safety concerns with the use of oil adjuvant (Freund´s incomplete 
adjuvant; FIA) in multivalent vaccine formulations for fish due to the generation of adverse side 
effects (e.g., adhesions). Therefore, alternative molecules or certain combinations of them 
(targeting specific cellular responses) as adjuvants are desirable in order to enhance overall 
immunogenicity and efficacy without reducing protection levels. There are only a few reports 
available on PLA/PLGA NP based vaccine formulations with adjuvant like effects and sustained 
target specific release to generate an optimal immune response for which more elaborate and 
conclusive studies are needed to define the protective roles of PLA/PLGA nanoparticulate 
system. PLA/PLGA NPs encapsulating Omp antigen from A. hydrophila and V. cholerae would 
be a better antigenic carrier model in fish and mice respectively. These NP delivery systems 
would increase the antigen persistence invivo, improve the initial antigen exposure to immune 
system after immunization. The combined action of PLA/PLGA NPs and OMP would result in 
the generation of enhanced and prolonged adjuvant-induced antigen-specific immune responses. 
Among possible delivery systems, nanoparticles (NP) based delivery of DNA vaccines to APCs, 
is an emerging and promising approach used for optimizing DNA vaccine formulation for 
immunotherapy. Nanoparticles based delivery systems for plasmid DNA (pDNA) (which encode 
Omp gene of interest) administration may be the key to improve transfection efficiency invivo 
even at lower doses. 
1.11. Objectives  
In the present study, various NPs formulations of PLA and PLGA loaded with model protein 
(BSA) or drug (clindamycin hydrochloride) were prepared by solvent evaporation method 
varying drug/protein: polymer concentration and optimized for size, encapsulation efficiency, 
drug loading,  morphology, etc. Then, PLA/PLGA NPs encapsulating Omp antigen from A. 
hydrophila were formulated and their efficacy were compared with adjuvant formulations to 
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develop a better antigenic carrier model in fish. Similarly, the efficacy is also compared between 
PLA encapsulated and PLGA encapsulated Omp NP-immunized groups and a correlation is 
established evaluating the results of innate and adaptive immune response studies in L. rohita. In 
another attempt, PLA/PLGA-Omp (Omp from V. cholerae) nanoparticles were formulated with 
desired physicochemical properties and evaluation of type and strength of immune responses 
(Humoral and cellular) elicited by formulated NPs was elucidated by comparing all possible 
combinations in mice. 
Thus, the specific objectives of the current study are 
1. Preparation and characterization of PLA and PLGA loaded with model protein (BSA) or 
drug (Clindamycin hydrochloride) NPs varying drug/protein:polymer concentration  
2. Preparation, Characterization and In vitro study of biodegradable and biocompatible 
based PLA and PLGA nanoparticles with encapsulation of OMP antigens. 
3. Parenteral immunization of PLA/PLGA nanoparticle encapsulating outer membrane 
protein (Omp) from A. hydrophila; Evaluation of immunostimulatory action in lower 
vertebrate (fish). 
4. Evaluation of the immune responses (specific) in mice model after intraperitoneal 
immunization of Omp antigen (V. cholerae) encapsulated PLA/PLGA nanoparticles 
5. Development of DNA vaccines to boost antigenic OMP (outer membrane protein) 
antigenicity. 
6. In Silico identification of outer membrane protein (Omp) and subunit vaccine design 
against pathogenic V. cholerae. 
 
1.12. Thesis outline 
This thesis has been organized into 7 chapters and each chapter contains self-describing 
illustrations, necessary tables and figures. Chapter 1 includes a general introduction about 
vaccine and vaccination, nanoparticle-based vaccine delivery, biodegradable nanoparticles and 
their use in nanomedicine. Chapter 2 covers relevant literature to the current work. Chapter 3 
includes the preparation of PLA and PLGA NPs loaded with BSA (model protein) or drug 
(Clindamycin hydrochloride) and optimization studies for size, charge, encapsulation efficiency, 
drug loading, etc. Chapter 4 contains objective 3 that describe the immunological evaluation of 
PLA/PLGA nanoparticle encapsulating outer membrane protein (Aeromonas hydrophila) in 
fish(L. rohita). Chapter 5 includes objective 4 which describe the formulation of PLA/PLGA-
Omp (Omp of V. cholerae) nanoparticles with desired physicochemical properties and 
evaluation of type and strength of immune responses elicited by formulated NPs was elucidated 
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by evaluating antigen-specific antibody response and cellular response studies in mice. Chapter 6 
includes objective 5 that describe the development of pDNA vaccine as well as a delivery 
system to boost antigenic outer membrane protein (Omp) that would act as a potential vaccine 
candidate. Chapter 7 summarizes major findings of all objectives. 
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Chapter 2 
Review of Literature 
The major goals of today’s vaccine research mostly aimed at the development of acquired 
immunity naturally by inoculation of immunogenic components (non-pathogenic) of the 
pathogen or closely related organisms. In general, these conventional approaches have been most 
successful for developing vaccines that can induce an immune response based on antigen-
specific antibody and cytotoxic T-lymphocyte (CTL) responses [1], [2].  The growing issues of 
vaccine safety are in alarming rate owing to their weak immunogenicity, imperfect 
immunization procedures and failure to acquire booster doses to potentiate prime doses. So, 
these issues have paved the way towards research for developing new generation preventive and 
therapeutic vaccine. Adjuvants are the immunological agents that act to accelerate, enhance and 
prolong antigen-specific immune responses when used in combination with specific antigens. 
Adjuvants are used for multiple purposes; to accelerate a robust immune response by enhancing 
immunogenicity, provide antigen dose sparing, reduce booster immunization requirements, 
offers prolonged and improved protection [3], [4]. There is a crucial requirement for enhanced 
and effective vaccine formulations (with or without adjuvant) having minimal compositions like 
purified proteins, recombinant proteins and synthetic peptides, etc. for specific disease antigen in 
question. There is also an urgent requirement for the development of novel carriers that could be 
target specific to achieve therapeutic drug concentration. 
Adjuvants in vaccine formulations vary to a greater extent due to many issues; e.g. the chemical 
nature, mode of action, the safety and efficacy of adjuvants. The adverse effects concerned with 
the prolonged use of adjuvants use are the hyperactivation of the immune system, neurotoxicity 
and many detrimental effects. Therefore, a relatively new formulation that is stable with antigen 
combination and can provide comparable immunity to that of adjuvants eventually can be treated 
as a complete replacement for the existing adjuvants in use should take the lead for development 
of advanced vaccine formulations. Currently, controlled delivery systems consisting of 
biodegradable microspheres/nanosphere act as a promising vaccine carrier because it can 
potentially deliver the antigens to the specific locations at predetermined rates and durations to 
generate an optimal immune response. 
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2.1. Nanotechnology: A therapeutic approach 
Nanotechnology can be defined as the manipulation, modeling, exact placement and 
manufacture of material at the nanometer scale. The impact of nanotechnology in different 
fields, including medicine, is immense [38] due to its wide application in the treatment of the 
major health threats including infectious diseases, cancer, metabolic diseases, inflammations and 
autoimmune diseases. The explosive growth of nanotechnology not only offer perfections to 
existing techniques but also helpful in discovering new tools with versatile applications [39].The 
practice of nanotechnology in vaccinology, in particular, has been increasing exponentially in 
the past decade that has evolved the term, “nanovaccinology” [40]. In both therapeutic and 
prophylactic approaches, nanoparticles are used as either a delivery system for sustained and 
target specific antigen delivery and/or as adjuvant (immunostimulant) to enhance the 
antigenicity. A number of approved nano-sized vaccine and drug delivery systems ascertain the 
revolution in disease treatment and prevention [41]–[44]. The manipulation of drug/antigen at 
nanoscale level mostly relies upon the bioactive characteristics such as solubility, controlled 
release, retention time [45].The surface area of the increased functionality of nanoparticles lends 
itself to further biomedical applications [46] and gene therapy [47]. 
Therapeutic nanovaccinology is mostly focused on cancer treatment [48]–[50] and other 
diseases, such as Alzheimer's [51], hypertension [52] and nicotine addiction [42], etc. On the 
other hand, prophylactic nanovaccinology has been applied for the prevention of different 
infectious diseases. There are many prophylactic nano-vaccines that have been approved for 
human use and more are in pre-clinical or clinical trials [53], [54]. 
2.2. Nanoparticles 
A nanoparticle is regarded as a small object that behaves as a whole unit in terms of its 
properties and transport. With the advances in the types of nanoparticles, any particulate 
materials in size range 1–1000 nm are considered as nanoparticles (FDA, 2011), that act as 
excellent drug carriers by enhancing aqueous solubility, targeting drug to specific location and 
increasing resistance time in the body (increasing half-life for clearance/increasing specificity 
for its associated receptors). However, nanomedicine concept is based upon the use of 
nanoparticles at the level of 1-100 nm [47], [55], [56]. Although nanoparticles are considered to 
be in nano dimensions below 100 nm size, but relative increase in size (size >100 nm) is 
generally observed and accepted in the area of drug delivery systems when there is efficient drug 
loading and especially where sufficient amount of  drug may be needed to load onto the particles 
[57]. Nanoparticles are becoming key components in a wide range of applications because of 
their potential applications in biomedical, optical, and electronic fields [58]. 
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Figure 2.1: The size range of nanoparticles used in nanovaccinology 
 
Nanotechnology offers the opportunity to design nanoparticles varying in size, shape, 
composition, and surface properties, for application in the field of medicine [41], [59]. 
Nanoparticles have size similarity with cellular components, due to which they can enter living 
cells using the cellular endocytosis mechanism, in particular, pinocytosis [60]. As a 
revolutionary new 21
st
 century technology, nanotechnology is starting to impact by developing 
theranostic nanoparticles for diagnosis of diseases as well as the drug delivery for disease 
prevention and treatment. The emergence of virus-like particles (VLPs), quantum dots and 
magnetic nanoparticles, marks a conjunction of protein biotechnology with inorganic 
nanotechnology that has achieved a significant progress for Nanomedicine. 
The vaccine antigen is either encapsulated within or coupled onto the surface of the 
nanoparticles. The encapsulated antigen undergoes controlled delivery (pre-determined rate and 
duration) avoiding rapid degradation and short- lived immune response. 
Nanoparticles in conjugation with antigen allow target specific presentation of the antigen to the 
immune system mimicking pathogen infection, thereby provoking a similar response. 
Nanoparticles are also responsible for the prolonged release of antigens to maximize exposure to 
the immune system. The potential of nanoparticles is more explored to deliver vaccines through 
nontraditional approaches such as topical, inhalation or optical delivery as well combining 
multiple antigens in a single particulate system so as to protect against more than one disease 
[61]. 
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Figure 2.2: Schematic representation of different nanoparticle delivery systems (Polymeric nanoparticle, 
Inorganic nanoparticle, Oil-in-water emulsion, Liposome, Virus-like particle, ISCOM) 
 
2.3. Types of nanoparticles 
2.3.1. Polymeric nanoparticles (PNPs) 
Polymeric nanoparticles (PNPs) consist of a polymer that has gained much deliberation due to 
advancement in polymer science and technology. Two types of polymers can be used in nano 
delivery that is natural and synthetic. Biocompatibility and biodegradability are essential 
features for potential application as tissue engineering, drug and gene delivery and new 
vaccination strategies. Most polymers used to prepare nanoparticles consists of synthetic 
polymers are, such as poly(d,l-lactide-co-glycolide) (PLG) [62]–[64], poly(d,l-lactic-co glycolic 
acid)(PLGA) [64]–[69], poly(g-glutamic acid) (g-PGA) [5], [66], poly(ethylene glycol) (PEG) 
[63], and polystyrene [70], [71]. Poly (D, L- lactide-co-glycolide) (PLGA), polylactic acid 
(PLA), are considered to be highly beneficial because of their biodegradable and biocompatible 
nature [65], [72]. They are widely used for human research due to their FDA approval (The 
Food and Drug Administration, U.S.A.). These polymeric nanoparticle- based antigen/drug 
delivery offers several advantages over traditional delivery methods, including the ability for 
drug delivery to a specific site such as an intracellular infection [73], [74], reducing systemic 
toxicity [75] and also to facilitate sustained release of a drug, minimizing dosing regimens [76]. 
 
 
 
 
Chapter 2                                                                                                                                       Review of Literature 
 
15 
 
Table 2.1: Polymeric materials currently being investigated at the nanoscale for drug 
delivery application; advantages and disadvantages. 
Type Polymer Advantages Disadvantages 
Natural cellulose, starch, chitosan, carrageenan, 
alginates, xanthan gum, gellan gum, pectins 
Less toxic 
Biocompatibility 
Biodegradable 
Easily available 
High degree of variability in 
natural materials derived from 
animal sources 
 
Structurally more complex 
 
Extraction process very 
complicated and high cost 
Synthetic poly(lactic acid) (PLA), poly(cyanoacrylates) 
(PACA), poly(acrylic acid), poly(anhydrides), 
poly(amides), poly (ortho esters), 
poly(ethylene glycol), and poly(vinyl alcohol) 
(PVA) and other like poly(isobutyl 
cyanoacrylate) (PIBCA), poly(ethylene oxide) 
(PEO), poly(å- caprolactone) (PCL) 
Biocompatibility Toxic 
Non degradable 
Synthetic process is very 
complicated and high cost 
 
Natural polymers based on polysaccharide have also been used to prepare nanoparticle 
adjuvants, such as chitosan [77]–[79], alginate [80], pullulan [81], [82] and  inulin [83], [84] etc. 
Chitosan-based nanoparticles have been widely investigated due to their biodegradability, 
biocompatibility, nontoxic nature and available in desired shapes and sizes [5], [85], [86]. The 
choice of polymer and the ability to control drug release have made them ideal candidates for 
delivery of vaccines, cancer therapy and delivery of targeted antibiotics, etc. Moreover, 
polymeric nanoparticles based drug delivery can also be applied in tissue engineering as well as 
drug delivery for other animals [87]. 
2.3.2. Inorganic nanoparticles 
Inorganic nanoparticles have measure impact on modern materials science research due to their 
possible technological importance, particularly in the field of bio-nanotechnology, having 
unique physical properties including size-dependent magnetic, optical, electronic and catalytic 
properties [88].Inorganic nanoparticles are able to interact with light and/or magnetic fields, thus 
spreading their possible applications in the areas of fluorescence labeling, magnetic resonance 
imaging (MRI) and stimulus-responsive drug delivery that are crucial to the diagnosis and 
treatment of disease [89]. Inorganic nanoparticles, as a viable alternative to organic forms, could 
be used for vaccine delivery. Many inorganic nanoparticles have been explored for their 
application in vaccine delivery. Despite non-biodegradable nature, the inorganic nanoparticles 
have advantages like unique rigid structure controllable synthesis [70]. The four most common 
inorganic NPs are 1) noble metal, 2) magnetic 3) fluorescence, and 4) multifunctional, e.g., 
luminescent magnetic [90]. Among noble metals, gold nanoparticles (AuNPs) are mostly used in 
vaccine delivery [91], as they can be easily manipulated into different shapes (spherical, rod, 
cubic, etc.) and size [92], and can be surface-engineered by conjugating carbohydrates [93]. 
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Gold nanoparticles have also been used as antigen carrier to target viruses such as influenza [94] 
and foot-and-mouth disease [95], or as a DNA vaccine adjuvant for human immunodeficiency 
virus (HIV) [96].Carbon nanoparticles are another commonly-studied composition for drug and 
vaccine delivery [61]. Multiple copies of protein or peptide antigens can be conjugated onto 
carbon nanotube (CNTs) for delivery and have enhanced the level of antibody response   [97]–
[100]. Silica-based inorganic nanoparticles (SiNPs) are biocompatible in nature and have 
excellent properties as nanocarriers for various biomedical applications, such as tumor targeting, 
real-time multimodal imaging, and vaccine delivery [101], [102]. Calcium phosphate 
nanoparticles can be formulated by using calcium chloride, dibasic sodium phosphate and 
sodium citrate under specific conditions. The biocompatible and nontoxic nature with variable 
size (50–100 nm) [103] of calcium phosphate nanoparticles made them as useful adjuvants for 
DNA vaccines offering mucosal immunity [103], [104]. 
2.3.3. Liposomes 
A liposome is an artificially-prepared spherical vesicle composed of a lamellar phase lipid 
bilayer. Liposomes have been known as potential drug delivery vehicles for nearly four decades 
[105]. Liposomal and polymeric drug conjugates are the two prevailing classes of commercially 
available nanoparticle-based therapeutic products [106]. Liposomes are generally formulated 
from biologically inert lipids that are non-toxic and biodegradable. Liposomes are generally 
formulated from biologically inert lipids that are non-toxic and biodegradable in nature. Loading 
of both hydrophobic and hydrophilic molecules is facilitated by the lipid bi-layered structure of 
liposomes. The beneficial properties of liposomal-mediated delivery in in-vitro studies are 
substantiated by the literature [107]. Liposomes, which are formed by biodegradable and 
nontoxic phospholipids can encapsulate antigen within the core for delivery [108]. There are, 
also, several liposomal therapeutic vaccine formulations against diseases like, hepatitis A 
malaria, tuberculosis, influenza, prostate cancer and colorectal cancer that are at different 
clinical stages [91]. A number of liposome systems have been established and approved for 
human use, such as Inflexal® V and Epaxal® [108], [109]. 
2.3.4. Immunostimulating complex (ISCOM) 
Immune stimulating complexes (ISCOMs) are generally open cage-like spherical structures (40 
nm in diameter) that are spontaneously formed when mixing cholesterol, phospholipids and 
Quillaia saponins together under a specific stoichiometry. These complexes have immune 
stimulating properties and are thus mostly used as a vaccine adjuvant to induce a stronger 
immune response and longer protection [17], [110], [111]. ISCOMs display high adjuvant 
activity against a broad range of bacterial and viral antigens [112]–[114]. 
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2.3.5. Virus-like particles 
Virus-like particles (VLPs), comprised of capsid proteins that can induce an immune response 
without having genetic material required for replication, promote immunogenicity. These have 
been established and approved as vaccines in some cases [115], [116]. In addition, many of these 
VLPs can be used as molecular platforms for genetic fusion or chemical attachment of 
heterologous antigenic epitopes [54]. VLPs take the good aspects of viruses and avoid the bad. 
The naturally-optimized nanoparticle size and repetitive structural order of VLPs are responsible 
for inducing potent immune responses, even in the absence of adjuvant [117]. A variety of VLPs 
and virus-based nanoparticles are being explored for use as vaccines and epitope platforms [54]. 
However, VLPs can also act as a delivery platform where a target antigen from a virus unrelated 
to the VLP used is modularized on the surface of a VLP [118]. 
2.3.6. Self-assembled proteins 
Self-assembling systems that attempt to drive higher levels of quaternary protein structuring 
have emerged for the formulation of nanoparticle-based vaccines. The protein like Ferritin can 
self-assemble into nearly-spherical 10 nm structure. By genetically fusing influenza virus 
haemagglutinin (HA) to ferritin, the recombined protein spontaneously assembled into an 
octahedrally-symmetric particle and then reformed eight trimeric HA spikes [119] to induce an 
enhanced immune response, which typically is processed to destroy rather than build a viral 
structure. 
2.3.7. Emulsions 
Another type of nanoparticles used as adjuvants in vaccines delivery is nano-sized emulsions 
[120], [121]. These nanoparticles can exist as oil-in-water or water-in-oil forms, where the 
droplet size can vary from 50 nm to 600 nm [121]. Emulsions can carry antigens inside their 
core for efficient vaccine delivery [121] or can also be simply mixed with the antigen. One 
commonly used emulsion is MF59TM, an oil-in-water emulsion which has been licensed as a 
safe and potent vaccine adjuvant in over 20 countries [122]. Recently, a tailorable nano-sized 
emulsion (TNE) platform technology has been developed using non-covalent click self-assembly 
for antigen and drug delivery [123], [124]. Targeted delivery of protein antigen to dendritic cells 
was achieved [124]. 
2.4. Nanoparticles Preparation Methods  
Synthesis of nanoparticles has emerged in the last decade as an interaction between 
nanotechnology and biotechnology. Due to the possible wide application of nanoparticles, this 
emerging science put modern material science research at the tip. These nanoparticles are 
designed to exhibit new and/or novel characteristics associated with size, morphology, 
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functionality and distribution pattern [125]. There are several possible means of nanoparticle 
synthesis ranging from totally chemical methods to fully biological processes [125] such as 
reduction in solutions, chemical and photochemical reactions, thermal decomposition, radiation-
assisted [126], electrochemical and finally most recently green synthesis [127]–[129].  
2.4.1. Preparation antigen/drug-loaded polymeric nanoparticles 
Polymeric NPs have attracted much attention due to their ability to deliver drugs/antigens as 
well as being biodegradable in nature. The release kinetics of encapsulated drugs from 
polymeric NPs can be regulated by compositional variation [130].These types of NPs can be 
formulated from a wide range of polymers e.g. poly(α-hydroxy acids), polysaccharides, or 
poly(amino acids) to create a vesicle which can either accommodate or display antigens/drug. 
The most commonly used poly (α-hydroxy acids) based polymeric NPs are either poly (lactic 
acid) (PLA) or poly (lactic-co-glycolic acid) (PLGA) which are often synthesized using a double 
emulsion-solvent evaporation technique [131], [132]. Firstly the polymer (PLA or PLGA) is 
dissolved in an organic solvent followed by the addition of the drug which is then emulsified to 
get a primary emulsion. Then, a water-in-oil-in-water emulsion is formed with the addition of an 
emulsifying agent (e.g., polyvinyl alcohol or polyvinyl pyrrolidone). This results in the 
encapsulation of the antigen in polymeric NPs. The solution is then allowed to solvent 
evaporation and then freeze-dried to prevent degradation of the polymer due to water-catalyzed 
ester hydrolysis [133]–[135]. But, the limitations with this method are lower antigen entrapment 
efficiency and possibility of protein denaturation at the oil-water interface [136]. This limitation 
can be avoided by the addition of stabilizers such as surfactants or sugars, (trehalose or sucrose) 
which provide stability against denaturation by maintaining the protein in its native form. For 
preserving encapsulated protein/antigen stability, the alternative method uses poly(amino acids) 
such as poly (γ-glutamic acid) (γ-PGA), poly(L-arginine), poly(ε-lysine) or poly(L-histidine) 
that avoid emulsion step for NP synthesis [137]–[139]. These amphiphilic copolymers self-
assemble through hydrophobic interactions to form structures comprising a hydrophobic core 
and a hydrophilic outer shell [132], [140].  Furthermore, γ-PGA based polymeric NPS offer 
more stability due to the presence of γ-linked glutamic acids that are not easily recognized by 
common proteases [141]. The poly (amino acid) based nanoparticles are formulated by 
dissolving the polymer in dimethyl sulfoxide (DMSO). The size of NPs is controlled by varying 
the salt concentration resulting in monodispersed forms [142]. The protein-encapsulated γ-
PGANPs can be prepared by emulsifying the protein (in saline) to γ-PGA (in DMSO) followed 
by centrifugation [143]. The resulting encapsulation is stable over an acidic pH range [143]. 
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Figure 2.3: Preparation of antigen-encapsulating nanoparticles by w/o/w emulsion method 
 
Hydrophilic polysaccharide polymeric NPs such as dextran and chitosan are also good 
candidates for vaccine delivery. Chitosan NPs often used because of its favorable characteristics 
e.g. biocompatibility, biodegradability into non-toxic products in vivo [144]. Chitosan NPs can 
be prepared by a self-assembly procedure through chemical modification [145]. Similarly, a 
complex coacervation process is used where particles would spontaneously form due to mixing 
of two hydrophilic colloids together; with chitosan precipitating around plasmid DNA [146]. 
Again, an ionic gelation method has also been used to prepare chitosan NPs which is based on 
the presence of positively charged amino groups in chitosan and the negative charge of 
tripolyphosphate[147]. Sometimes these colloids are further modified by the addition of other 
components like polyethylene glycol in order to aid properties absorption or to slow down 
release. 
2.5. Characterization of Drug-loaded nanoparticles 
Various parameters; size, physical, chemical, morphological properties, drug encapsulation 
efficiency and release profile of antigens are known to play a key role in the designing efficient 
polymeric nanoparticle-based delivery [148]. 
2.5.1. Particle size  
Particle size and its distribution patterns are the most important characteristics of nanoparticle-
based drug delivery systems. They determine the targeting ability, in vivo distribution, biological 
fate and toxicity of nanoparticle systems. In addition, the size can also influence the drug 
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encapsulation, release and stability. The nanoparticles of sub-micron size have numerous 
advantages over microparticles as a potential drug delivery system [149]. Usually, nanoparticles 
have relatively higher intracellular uptake as compared to microparticles and available for a wide 
range of biological targets because of their small size and relative mobility. Although 
nanoparticles are considered to be in nano dimensions below 100 nm size, but relative increase 
in size (size >100 nm) is generally observed and accepted in the area of drug delivery systems 
when there is efficient drug loading and especially where sufficient amount of  drug may be 
needed to load onto the particles [57]. It was also reported that nanoparticles can cross the blood-
brain barrier following the opening of tight junctions by hyperosmotic mannitol that can provide 
sustained delivery of therapeutic agents for diseases like brain tumors. Drug release is also 
influenced by particle size. Smaller NPs have larger surface area. Therefore, most of the drug 
associated would be at or near the particle surface, leading to fast drug release. However, larger 
particles have large cores that permit more amounts of drug to be encapsulated and their slow 
release profile [150].The small sized NPS have a greater chance of aggregation of particles 
during storage and transportation. The formulation of nanoparticles with smaller size with 
enhanced stability is a really a challenge. Polymer degradation can also be controlled by the 
particle size. The rate of polymer (PLGA) degradation was found to increase with increasing 
particle size in vitro that might be due to autocatalytic degradation of the polymer [151]. 
Presently, the fastest and most routine method of determining particle size is by dynamic light 
scattering or photon-correlation spectroscopy. Photon-correlation spectroscopy determines the 
diameter of the particle due to Brownian motion and light scattering properties. The results 
obtained are usually verified by scanning or transmission electron microscopy (SEM or TEM). 
2.5.2. Surface properties of NPs 
The surface hydrophobicity of formulated NPs also determines the amount of adsorbed blood 
components, mostly proteins (Opsonins) that in turn influence the in-vivo outcome of 
nanoparticles [152], [153]. The conventional nanoparticles are rapidly opsonized and cleared by 
the macrophages [154]. It is essential to minimize the opsonization and to prolong the circulation 
of nanoparticles in vivo, which can be accomplished by (a) surface modification by coating of 
nanoparticles with hydrophilic polymers/surfactants; (b) formulation of nanoparticles with 
biodegradable copolymers with hydrophilic components such as polyethylene oxide, 
polyethylene glycol (PEG), poloxamine, poloxamer, and polysorbate 80 (Tween 80).The zeta 
potential of a nanoparticle is commonly used to characterize the surface charge property of 
nanoparticles [155]. Zeta potential otherwise known as the electrokinetic potential at the surface 
of the colloidal particles has a great significance in comparing the stability of colloidal 
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dispersions [156].The zeta potential indicates the degree of repulsion between adjacent particles 
and similarly charged particles in the dispersion. For molecules and particles that are small 
enough, a high zeta potential confers stability (dispersion will resist aggregation).Nanoparticles 
with a zeta potential (surface charge) above (+/-) 30 mV have been shown to be stable in 
suspension, as the surface charge prevents aggregation of the particles [157]. The zeta potential 
can also be used to determine whether a charged active material is encapsulated within the core 
of the nanocapsule or adsorbed onto the surface. 
2.5.3. Drug loading 
The ideal nanoparticulate system should have a high drug-loading capacity thereby reducing the 
drug quantity for the administration. Generally, drug loading can be achieved by two methods: a. 
incorporation method (adding at the time of nanoparticles formulation), b. adsorption/absorption 
technique (Absorbing the drug after formation of nanoparticles) [158]. Encapsulation of protein 
antigens depends on series of factors like polymer nature, method of formulations and molecular 
interaction between polymers, etc. The amount of drug bound to NP depends on the chemical 
structure of the drug/polymer ratio and the conditions of drug loading [159]. Hydrophilic 
polymers show higher encapsulation than hydrophobic polymer due to enhanced molecular 
interactions between the polymer and the drug [160]. Entrapment efficiency is very much 
dependent on the solid-state drug solubility in the matrix material or polymer (solid dispersion or 
dissolution), which is related to the molecular weight, polymer composition, drug polymer 
interaction and the presence of functional end groups [161]–[163]. In the case of 
macromolecules or protein, the higher loading efficiency is achieved when it is loaded at or near 
its isoelectric point (with minimum solubility and maximum adsorption) [164]. For smaller 
molecules, the use of ionic interaction between the drug and matrix materials can be a very 
effective approach to increase the drug encapsulation [165]. 
2.5.4. Drug release 
Drug release and polymer degradation are important factors to develop an ideal nanoparticulate 
system. Generally, drug release from nanoparticles rate depends on many factors: (1) solubility 
of the drug; (2) drug diffusion through the nanoparticle matrix; (3) desorption of the surface 
attached/adsorbed drug; (4) nanoparticle matrix erosion/degradation. Thus, the properties like 
solubility, diffusion and biodegradation of the matrix materials govern the release process [158]. 
The rapid initial burst release is particularly attributed to weakly bound or adsorbed drug to the 
surface of nanoparticles [166].The solubility and diffusivity of the drug in polymer matrix also 
plays measure role in controlling drug release. When the drug is encapsulated by incorporation 
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method, the system offers a relatively small burst effect and better-sustained release 
characteristics [167]. 
The in vitro drug release can be studied by various methods e.g.: (1) dialysis bag diffusion 
technique; (2) side-by-side diffusion cells with artificial/biological membranes; (3) reverse 
dialysis bag technique; (4) agitation followed by centrifugation; (5) Ultrafiltration or centrifugal 
ultrafiltration techniques [158]. Usually, the release study is performed by controlled agitation 
followed by centrifugation.  
2.6. Vaccine-induced immunity 
The objective of vaccination with any formulation is to express the innate and adaptive immune 
responses to infection [168], [169]. The antigen-presenting cells such as dendritic cells play an 
important role in both innate and adaptive immune responses [170]. On recognition of microbial 
surface determinants, antigen-presenting cells (APC) undergo maturation leading to a 
redistribution of MHC (MHC I and MHC II) molecules from intracellular compartments to the 
cell surface, secretion of cytokines, morphological changes of dendritic cells and cytoskeleton 
reorganization [61]. 
The antigens are internalized either through the endocytic pathway or non-endocytic pathways 
[171]. The non-endocytic pathways involve the engulfment of antigen by the APCs 
(phagocytosis) and its degradation by proteolytic enzymes and reactive oxygen species. The 
resulted degraded products (peptides) are then displayed on MHC class II molecules and are 
recognized by CD4+ T cells to stimulate the antibody production and the formation of memory 
T-cells [61]. However, in the case of non-endocytic pathways, antigens derived from the 
pathogen are processed via proteasome which then display peptides on MHC class I molecules 
[172]. The displayed antigen is recognized by CD8+ T cells that have cytotoxic activity toward 
infected host cells. In practice, the response against pathogen infection may encompass a mix of 
all these (MHC I and MHC II response), further complicated by the stimulation of pro-
inflammatory Th17 cells and controlled by regulatory T-cells, but a predominant responses (Th1 
or Th2) may be necessary to resolve the infection [173]. 
2.7. Antigens delivery using nanoparticles 
Antigen-loaded polymeric nanoparticles represent a novel approach for the enhancement of 
antigen-specific humoral and cellular immune responses via selective targeting [5], [170]. 
Dendritic cells (DCs) are known to be initiators and modulators of immune responses by 
processing antigens through both MHC I and MHC II pathways. Immature DCs encounters 
pathogens, specific antigens, or particulate antigens at the introduction site. After phagocytosis, 
the foreign antigen has been taken up into the DCs that present the antigens on MHC class II or 
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MHC class I molecules by cross-priming [172]. Therefore, the antigen delivery to DCs is of key 
importance in the development of effective vaccines. 
OVA encapsulated within γ-PGA-Phe nanoparticles (OVA-NPs) were efficiently taken up into 
DCs, whereas the uptake of OVA alone was hardly detectable [5]. Similarly, other types of 
nanoparticles like PLGA or liposomes are efficiently phagocytosed by the DCs, ensuing in their 
intracellular localization [174], [175]. 
2.8. Nanoparticles mediated dendritic cell activation 
The current research has been focused largely on determining the degree of DC maturation 
induced by exposure to polymeric nanoparticles [176]–[178]. After successful antigen delivery 
to DCs, the control over DC maturation is deeply involved in the development of effective 
vaccines. The maturation of DCs is associated with increased expression of many cell surface 
markers, including some co-stimulatory molecules CD40, CD80, CD83, CD86, MHC class I, 
and MHC class II [179]. 
Upon exposure of these DCs to the nanoparticles, the expression of co-stimulatory molecules 
(maturation markers) was increased in a dose-dependent manner [180]. However, both the 
uptake of nanoparticles and characteristics of the polymers forming the nanoparticles are 
important for the induction of DC maturation. Previous research observed higher effects of DC 
activation by the nanoparticles despite the smaller size. Thus, the DC maturation is affected by 
the surface interactions between the nanoparticles and DCs [143], [181]. DC maturation by 
PLGA nanoparticles was observed by a modest increase in the expression of MHC class II and 
CD86 compared to controls [175]. 
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Table 2.2: Summary of the various types of NPs currently being studied for their use as vaccine carriers. 
 
Type Matrix/expression system Size Antigen (pathogen) Route of 
immunization 
References 
Polymeric Poly(lactic-co-glycolic acid) 
(PLGA); 
Poly(lactic acid) (PLA); 
Poly(glycolic acid) (PGA); 
Poly(hydroxybutyrate) (PHB); 
Chitosan; 
100–200nm 
800nm 
1–5μm 
248 nm 
Docetaxel; 
TetHc (Tetanus); 
Hepatitis B; 
SBm7462 (Boophilus microplus); 
Rv1733c (M. tuberculosis); 
SPf66 (P. falciparum malaria) 
Dtxd (Diphtheria) 
Ovalbumin 
gp120 (HIV-1) 
Intramuscular, 
Intravenous 
[5], [61], [67], [182]–[184] 
Non-degradable Gold; 
Silica; 
Carbon; 
Iron 
2–150nm 
5–470nm 
20–300 nm 
Plasmid DNA expressing hemagglutinin 1 
(Influenza); 
Hepatitis B; 
MSP1 (Plasmodium falciparum) 
BSA 
Intradermal, 
Intramuscular, 
Subcutaneous, 
Intravenous 
[95], [98], [184]–[187] 
Liposomes 
(non-viral lipids 
MPLA; 
Phospholipid S100 and 
cholesterol; 
Phosphatidylcholine and 
cholesterol; 
 
50–500nm 
200 nm 
R32NS1 (malaria); 
Cholera toxin; 
Circumsporozoite (malaria); 
Lipid A;  
CtUBE fusion peptide (H. pylori); 
KWC Y. pestis; 
Polysaccharides 
(Streptococcus pneumoniae 
serotype 14) 
VMP001 
(Plasmodium vivax) 
RTS,S/AS01B (Plasmodium 
falciparum CSP + hepatitis B 
protein hybrid) 
Intramuscular, 
Intravenous, 
Subcutaneous, 
Oral, 
Intranasal 
[61], [67], [184], [188]–[190] 
Virus-like particles Baculovirus 
E. coli 
Mammalian cells 
Yeast 
55–60 nm (HPV) 
100–200 nm (HIV) 
80–120 nm (H1N1) 
27–60 nm 
Major capsid protein, L1 (HPV); 
FMS-like tyrosine kinase receptor-ligand, FL 
(HIV); 
gag precursor protein, pr45 (HIV); 
HIV env cDNA (HIV); 
Haemagglutinin (H1N1); 
Nicotinamide (H1N1) 
Matrix protein M1 (H1N1) 
Intramuscular, 
Subcutaneous, 
Intraperitoneal, 
Oral, 
Intranasal 
[61], [184], [191]–[194] 
ISCOMs Saponin (Quil A) 
Phospholipid 
(phosphatidylethanolamine, 
phosphatidylcholine) 
Cholesterol 
Viral proteins 
40 nm HIV-1(gp120/160) 
FIV(p130) 
E. falciformis (p27) 
Intramuscular, 
Subcutaneous, 
Oral 
[61], [184], [195]–[197] 
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2.9. Gene delivery by polyion complex NPs 
Over the past decades, the interest in the possibility of using gene-based therapy and DNA 
vaccination for treatment of both genetic and acquired diseases such as infections, degenerative 
disorders and cancer, has grown exponentially, mostly due to the development of several 
methods for delivering genes to mammalian cells (viral and non-viral vectors) [198], [199]. 
Genetic or DNA vaccination is the common name for vaccination methods that induce immunity 
by transfecting eukaryotic host cells with DNA that encodes a therapeutic protein, instead of 
injecting antigens in the form of proteins or peptides. This approach (the third vaccine 
revolution) provides a number of potential advantages over other traditional approaches, like 
generation of both humoral and cell-mediated immune responses, improved vaccine stability, the 
absence of any infectious agent and the relative ease of large-scale manufacture with high purity 
[6], [200], [201]. The safety, simplicity, versatility, stability, ease of production, nontoxicity, and 
broad of immunity and long-lasting cytotoxic T lymphocyte responses make DNA vaccines very 
attractive for antiviral/antibacterial/anticancer immunization strategies [25], [202]–[204]. 
The use of plasmids as vectors is an active area of investigation due to their great potential for a 
safe use in prophylactic and therapeutic vaccination. Once administered, DNA vaccines activate 
both humoral and cellular immune responses against targeted illnesses. Novel delivery systems 
for administration of pDNA vaccines are central to address the above-discussed necessities [5], 
[6], [205]. This delivery system should be a modern and sophisticated form of an adjuvant with 
engineered immunological properties. Among possible delivery systems, nanoparticles (NP) 
based delivery of DNA vaccines to APCs, is an emerging and promising approach used for 
optimizing DNA vaccine formulation for immunotherapy [5], [6]. 
DNA delivery is, however, a difficult procedure and an appropriate vector is required for 
efficient protection as well as DNA release. Non-viral gene delivery mainly relies on DNA 
condensation induced by cationic agents. Cationic polymers have been widely preferred to 
condense DNA through electrostatic interactions between negatively charged DNA and the 
positively charged cation [206]. The biocompatible nanopolymers such as poly-(D, L-lactide-co-
glycolide) (PLGA) and chitosan are attractive for DNA delivery applications [5], [61], [207], 
[208]. Chitosan NPs hold promise because of their ability to protect encapsulated nucleic acid-
based antigens from nuclease degradation and promote delivery of adsorbed DNA to APCs 
[209], [210]. In the case of synthetic polymers like PLGA, besides DNA protection, the 
encapsulation permits a controlled DNA delivery system to be designed with controllable 
degradation times and release kinetics of DNA for prolonged gene expression over a required 
time. For example, PLGA undergoes ester hydrolysis in the physiological environment with the 
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formation of biocompatible monomers [211]. Nanoparticles based delivery systems for plasmid 
DNA (pDNA) (which encode target gene of interest) administration may be keys to improve the 
transfection efficiency in-vivo even at a lower dose. To improve the transfection efficiency of 
Chitosan/DNA complexes, γ-PGA/Chitosan/DNA-conjugated nanoparticles were formulated by 
an ionic-gelation method for transdermal gene delivery using a low-pressure gene gun [105]. 
Moreover, the pDNA/PEI/γ-PGA complex was highly taken up by the cells via a γ-PGA-specific 
receptor-mediated pathway and showed extremely high transfection efficiencies [212]. 
2.10. Nanoparticle-Antigen interaction 
Vaccine formulations comprising nanoparticles and antigens can be classified by nanoparticle 
action into those based on delivery system or immune potentiator approaches. As a delivery 
system, nanoparticles can deliver antigen to the immune cell in 2 ways, (a) co-ingestion of the 
antigen and nanoparticle by the immune cell, or (b) transient delivery, i.e. protect the antigen and 
its control release at the target location. For immune potentiator approaches, nanoparticles 
activate certain immune pathways that might then augment antigen processing and improve 
immunogenicity [208], [213]. The attachment of antigen has been achieved through simple 
physical adsorption or more complex methods, such as encapsulation or chemical conjugation. 
The physical adsorption of antigen onto a nanoparticle is performed on the basis of charge or 
hydrophobic interaction [213], [214], where the interaction between nanoparticle and antigen is 
relatively weak that lead to rapid disassociation in vivo. The stronger interaction is observed in 
the case of encapsulation and chemical conjugation of antigen to nanoparticles. The antigens are 
mixed with nanoparticle precursors during formulation, resulting in encapsulation of antigen into 
nanoparticles [208]. On the other hand, the antigen is chemically cross-linked to the surface of a 
nanoparticle which is released inside the cell after taken up together with the nanoparticle [215]. 
The attachment or interaction of antigen with nanoparticles are not essential for immune 
potentiator approaches and sometimes, it may be undesirable in cases modified antigenic 
structure that occurs at the nanoparticle interface. 
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Figure 2.4: Interaction of nanoparticle with antigen. Formulation of nanoparticle and antigen of interest can 
be through attachment (e.g. conjugation, encapsulation, or adsorption) or simple mixing. 
 
2.11. Nanoparticle-Antigen presenting cell (APC) interaction 
The incorporation antigenic component into nanoparticles has attracted extensive attention 
towards the mechanism for efficient antigen delivery to antigen presenting cells (APCs) and 
subsequently induce their maturation followed by cross-presentation of antigen to induce a 
potent immune response [176], [177], [216]. 
The APCs like dendritic cells (DCs) and macrophages are measure role in antigen processing as 
they efficiently uptake and process antigen. So, the better understanding of the mechanism 
behind nanoparticle and APCs interaction is very important for developing efficacious 
nanoparticle vaccines [217], [218]. 
DCs preferentially uptake virus-sized particles (20–200 nm) while macrophages preferentially 
uptake larger sized particles (0.5–5 µm) [219]. In the smaller the particle size, a higher 
percentage of the DCs interacted with the polystyrene spheres [220]. Similarly, PLA 
nanoparticles of size 200–600 nm were efficiently taken up by macrophages in comparison to 
microparticles [221]. 
Particle shape and surface charge are equally important particulate physicochemical factors and 
play crucial roles in the interaction between particles and APCs. In general, cationic particles 
induced high phagocytosis activity of APCs, because of the anionic nature of cell membranes 
[220]. Recently, particle shape has been identified as having a significant effect on the ability of 
macrophages to internalize particles via actin-driven movement of the macrophage membrane 
[222]. For larger particles (>1 µm), particle shape plays a central role in phagocytosis by 
macrophages as the uptake of particles is strongly dependent on the shape at the interface 
between particles and APCs [222]. The hydrophobic particles are reported to induce a higher 
immune response in comparison to hydrophilic ones [223], [224]. A number of other factors 
Chapter 2                                                                                                                                        Review of Literature 
 
28 
 
such as surface modification (e.g. PEGylation, targeting ligands) and vaccine cargo have been 
shown to influence the interaction between nanoparticles and APCs as well [225]. 
2.12. Nanoparticle-Biosystems interaction 
The knowledge of the interaction of nanoparticles with biological systems is very much essential 
in designing safe and efficacious nanoparticle vaccines as it determines the fate of nanoparticles 
in vivo. The physicochemical properties of nanoparticles including size, shape, surface charge 
density, and nature (hydrophobicity) affect the interaction of nanoparticles with immune cells 
[224] and plasma proteins [226], [227]. These interactions with nanoparticles, as well as the 
morphology of vascular endothelium, play a significant role in the distribution of nanoparticles 
in various tissues and organs of the body [208]. 
The lymph node targeted nanoparticle-based vaccine delivers the antigen at LN by direct 
drainage [228], [229] or by migration of activated peripheral APCs [230] for optimum induction 
of immune response. The delivery of nanoparticles to the LN is mainly influenced by size. 
Nanoparticles with a lower size range of 10–100 nm can easily pass through the extracellular 
matrix and move to the LNs where they are taken up by resident DCs for activation of the 
immune response [208]. However, the larger nanoparticle (>100 nm) linger at the administration 
point and are subsequently encountered by local APCs [208]. The biological environment and 
route of administration can also affect the draining of nanoparticles to the LN [208], [231]. After 
successful antigen delivery, the nanoparticles should undergo degradation and make it cleared 
from the body. If the nanoparticles are not degraded or excreted from the body, it accumulates in 
different tissues and organ causing adverse effects. Clearance of nanoparticles could be achieved 
through degradation by the immune system or by renal or biliary clearance [232]. 
2.13. Routes of administration 
The applications of the nanoparticle-based vaccine in oral and parenteral routes have been very 
well explored and applications in pulmonary and ocular delivery have been discovered. 
However, their applications in nasal, buccal and topical delivery are still awaiting exploration 
[233]. 
2.13.1. Mucosal Vaccination 
Oral delivery 
Oral delivery of drugs/antigen using nanoparticles has been shown to be far superior to the 
delivery of free drugs in terms of bioavailability, biodistribution and residence time [234]. The 
advantage of using polymeric nanoparticles is to allow encapsulation of bioactive molecules and 
protect them against enzymatic and hydrolytic degradation time [234]. The use of submicron-
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size particular systems in oral drug delivery, especially peptide drugs, has attracted considerable 
pharmaceutical interest. The efficacy of the orally administered drug mainly depends on its 
solubility and absorption through the gastrointestinal tract. So, a drug candidate that represents 
poor aqueous solubility and/or decomposition rate limited absorption is believed to possess low 
and/or highly variable oral bioavailability [226]. 
Pulmonary delivery 
The main problems with the nasal delivery of antigens are; a. the free antigen is readily cleared 
from the nasal cavity, b. poor absorption by the nasal epithelial cells, c. generate a low immune 
response. To overcome these problems, encapsulation of antigen into bioactive nanoparticles is a 
promising approach to nasal vaccine delivery[235]. Pulmonary drug delivery has many 
advantages, offering a large surface area for solute transport, rapid drug uptake, and improved 
drug bioavailability compared to other drug delivery strategies [236], [237]. Nanosuspensions 
may demonstrate to be an ideal approach for delivering drugs that display poor solubility in 
pulmonary secretions [226]. Furthermore, because of the nanoparticulate nature and uniform 
molecular distribution of nano-suspensions, it is very likely that in each aerosol containing the 
drug, leads to even distribution of the drug in the lungs as compared to the microparticulate form 
of the drug. Nanosuspensions could be exploited in all available types of the nebulizer[238]. 
2.13.2. Parenteral vaccination 
Parenteral routes commonly employed for vaccination purposes include the intramuscular (IM), 
subcutaneous (SC), and intradermal (ID) routes. 
Intramuscular route 
The IM route is a very popular route for routine vaccination to induce both cellular and humoral 
immune response. Myoblasts are antigen-presenting cells (APCs) found in the muscle tissue 
responsible for immune response generation after IM administration. However, due to the 
inadequate number of dendritic cells in the muscle in comparison to the skin, it is necessary to 
administer higher doses of antigen by the IM route in order to elicit an effective immune 
response [239]. Myocytes are incapable of activating T cells directly as they do not express 
major histocompatibility complex (MHC) class II molecules and are devoid of co-stimulatory 
compounds. Myocytes do not express major histocompatibility complex (MHC) class II 
molecules and are devoid of co-stimulatory compounds, rendering them incapable of directly 
activating T cells [240]. IM immunization results in a predominant Th2 response unless boosters 
are given subsequently [239]. Examples of vaccines which are currently administered via the IM 
route include hepatitis A, hepatitis B, diphtheria toxoid, inactivated polio vaccine, pertussis, 
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human papillomavirus (HPV), rabies vaccine, Streptococcus pneumonia, and tetanus toxoid 
[241]. 
Subcutaneous route 
The SC route is very valuable for antigen delivery due to the drainage of antigen from the 
injection site to lymph nodes that contain the immunocompetent cells. Nanoparticles have been 
explored extensively by the subcutaneous route for adjuvant vaccine purposes [242], [243]. 
Particles less than 100 nm in size are able to enter the lymphatic capillaries via the gaps between 
lymphatic endothelial cells. Particles between 100-1000 nm undergo phagocytosis by APCs, 
such as dendritic cells, followed by passage into lymphatic capillaries [241]. The antigen 
immunization through this route offers many advantages that include lower clearance and longer 
persistence at the site of administration resulting in prolonged antigen presentation to the 
immune system [244]. Examples of vaccines which are currently administered via the SC route 
include the anthrax vaccine.  
2.13.3. Intradermal route 
Intradermal route of vaccination is the most common method for the delivery of drugs and 
genes. It involves the injection in the outer layer of the skin to reach immunologically sensitive 
epidermis. Generally, the drug is emulsified with an adjuvant to form a depot so as to allow 
prolonged release of drugs in a controlled manner. The nanoparticle-based intradermal delivery 
is able to induce DC maturation and enhance immune responses after intradermal injection 
[245]. The intradermal injection of hen egg lysozyme (HEL)/CpG (cytosine-guanine tandems) 
nanoparticles induced a more pronounced Th1 immune response compared with the HEL and 
HEL/CpG topical formulations [246].  Similarly, the intradermal delivery of OVA-loaded 
stabilized thiolated N-Trimethyl Chitosan (TMC)- Hyaluronic acid (HA) particles have elicited 
superior immunogenicity compared to non-stabilized particles indicated by higher IgG titers  
[247]. 
 
2.14. The bacterial pathogen: Aeromonas hydrophila 
2.14.1. Systematic position 
Phylum: Proteobacteria 
Class: Gammaproteobacteria 
Order: Aeromonadales 
Family:Aeromonadaceae 
Genus: Aeromonas 
Species: hydrophila 
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The genus Aeromonas is one of the several medically significant genera that have increasingly 
become a troublesome group for physicians and microbiologists alike by virtue of their changing 
phylogenetic relationships, evolving taxonomy and controversial role in certain diseases 
[248].Aeromonads are ubiquitous, oxidase positive, facultatively anaerobic, glucose-fermenting, 
Gram-negative bacteria that are native to aquatic environments [249]. They have been found in 
brackish, fresh, estuarine, marine, chlorinated and unchlorinated water supplies worldwide, with 
highest numbers obtained in the warmer months [28], [249]. Aeromonads have been isolated 
from diseased cold- and warm-blooded animals for over 100 years and from humans since the 
early 1950s [250].The ubiquitous nature of Aeromonas species in aquatic environments provides 
ample opportunity for animals, particularly fish and amphibians, to come into contact with, and 
to ingest organisms. Such contact may lead to infection, which depends on the species and the 
virulence of the strains encountered, may have life-threatening consequences. 
2.14.2. Pathogenesis 
Aeromoniasis, an important fish disease is caused by this bacterium [29]. A. hydrophila has been 
associated with several disease conditions in fish, including tail rot, fin rot, dropsy, ulcers and 
haemorrhagic septicaemia. Haemorrhagic septicaemia is characterized by the presence of small 
surface lesions, often leading to sloughing off of the scales,  haemorrhaging in the gills and anus, 
ulcers, abscesses, exophthalmia (bulging eyes), and abdominal swelling (dropsy) often seen in 
European carp culture. Internally, there may be the presence of ascitic fluid in the peritoneal 
cavity, anaemia, and swelling of the kidney and liver [29], [251]. 
The bacteria multiply in the intestine, causing a haemorrhagic mucous-desquamative catarrh 
(excessive mucous secretion). Toxic metabolites of A. hydrophila are absorbed from the 
intestine and induced poisoning. Capillary haemorrhage occurs in the dermis of fins and trunk 
and in the submucosa of the stomach. Hepatic cells and epithelia of renal tubules show 
degeneration. Glomeruli are destroyed and the tissue becomes haemorrhagic, with exudates of 
serum and fibrin [251]. 
Aeromonas species produce many products that may be toxic to other cells. Some are released 
from viable cells in soluble form. Others may remain associated with the cell surface, and still 
others may be released upon cell death. Three of the extracellular proteins of Aeromonas species 
that have been implicated in pathogenicity have been cloned, sequenced, and characterized 
biochemically. These are aerolysin, GCAT (glycerophospholipid: cholesterol acyltransferase), 
and a serine protease [252], [253]. 
A. hydrophila produces other toxins such as αβ hemolysins and enterotoxins in host organisms 
as a well as enzymes such as phospholipases, proteases and acetylcholinesterase [254], [255] 
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which are very important for the development of resistant strains and pathogenicity for the host 
organisms while acetylcholinesterase is extremely lethal to fish. 
 
2.14.3. Prevention and control 
Chemotherapeutic agents are used for the treatment of A. hydrophila in fish farms. Isolates of A. 
hydrophila in fish have been found to be sensitive to chloramphenicol, florfenicol, tetracycline, 
sulphonamide, nitrofuran derivatives, and pyridine carboxylic acids [256], [257]. However, 
antibacterial therapy provides only short-term relief if adverse environmental conditions such as 
high water temperature, low water flows, low oxygen levels, or crowding are not promptly 
corrected. Prevalence of many serotypes in a locality complicates the process of developing 
vaccines to this pathogen. To-date no such commercial vaccine is available in the world to 
prevent aeromoniasis in fish. However, recent reports on the use of immunostimulatory 
substances in fish have shown promising results to protect from aeromoniasis in fish [258]. 
2.14.4. Outer membrane protein: A. hydrophila 
The Outer Membrane (OM) of A. hydrophila is a complex structure which mainly consists of 
lipopolysaccharide (LPS), phospholipids and a group of outer membrane proteins (Omps).The 
OM of pathogenic gram-negative bacteria is mainly responsible for establishing initial 
adherence, modulate host-pathogen interaction, overall survival of the organism and propagation 
of virulence factor [35]. It also has protective antigenicity, because OM components are easily 
recognized as foreign substances by immunological defense systems of the hosts. Omps are 
reported to be conserved among different serovars. Some of them serve as adhesins and play an 
important role in virulence [36]. Omps are located at host–bacterial interface in A. hydrophila 
and can be targeted for drug therapy [36]. 
2.15. The bacterial pathogen: Vibrio cholerae 
2.15.1. Systematic position 
Phylum: Proteobacteria 
Class: Gammaproteobacteria  
Order: Vibrionales 
Family: Vibrionaceae 
Genus: Vibrio 
Species: cholerae 
Vibrio cholerae is a "comma" shaped Gram-negative bacteria [31] with a single, polar flagellum 
for movement. It is a facultative anaerobic organism. It has two circular chromosomes, together 
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overall 4 million base pairs of DNA sequence and 3,885 predicted genes [31]. The genes for 
cholera toxin are carried by CTXphi (CTXφ), a temperate bacteriophage inserted into the V. 
cholerae genome. CTXφ can transmit cholera toxin genes from one V. cholerae strain to another 
through horizontal gene transfer. The genes for toxin coregulated pilus are coded by the VPI 
pathogenicity island (VPI). The main reservoirs of V. cholerae are human and aquatic sources 
such as brackish water and estuaries, often in association with copepods or other zooplankton, 
shellfish, and aquatic plants [259]. The primary association between humans and pathogenic 
strains is through water, predominantly in economically reduced areas that do not have good 
water sanitization systems [260]. There are two serogroups of V. cholerae; O1 and O139 can 
cause the occurrence of cholera. O1 causes the majority of outbreaks while O139 (first identified 
in Bangladesh in 1992) is restricted to Southeast Asia. There are some other serogroups of V. 
cholerae, with or without the cholera toxin gene (including the non-toxigenic strains of the O1 
and O139 serogroups), can also cause a cholera-like illness. Only toxigenic strains of serogroups 
O1 and O139 have been reported to cause widespread epidemics. V. cholerae O1 has two 
biotypes, classical and El Tor, and each biotype has two distinct serotypes, Inaba and Ogawa. 
The symptoms of infection are indistinguishable, although more people infected with the El Tor 
biotype remain asymptomatic or have only a mild illness. In recent years, infections with the 
classical biotype of V. cholerae O1 have become very rare and are limited to parts of Bangladesh 
and India [261]. Recently, new variant strains have been detected in several parts of Asia and 
Africa. Observations suggest these strains cause more severe cholera with higher case fatality 
rates. 
2.15.2. Pathogenesis 
V. cholerae enters the human body through ingestion of contaminated water or food. The 
bacteria enter the intestines; embed itself in the villi of intestinal absorptive cells, and releases 
cholera toxin. Cholera toxin (CT) is an enterotoxin made up of five B-subunits that form a pore 
to fits one A-subunit [262]. CT is made from filamentous phage gene, CTXφ [263]. A phage 
gene is also responsible for another virulence factor of V. cholerae, which is toxin co-regulated 
pilus (TCP) (a receptor for CTXφ) [264]. V. cholerae can cause syndromes ranging from 
asymptomatic to cholera gravis. Symptoms include abrupt onset of watery diarrhea (a grey and 
cloudy liquid), occasional vomiting, and abdominal cramps [32]. Dehydration ensues, with 
symptoms and signs such as thirst, decreased skin turgor, dry mucous membranes, hypotension, 
sunken eyes, weak or absent radial pulse, tachypnea, tachycardia, hoarse voice, cramps, oliguria, 
renal failure, somnolence, seizures, coma, and death. Dehydration can lead to death in a few 
hours to days in untreated children. The disease is also particularly dangerous for pregnant 
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women and their fetuses during late pregnancy, as it may cause premature labor and fetal [32], 
[263], [264]. In cases of cholera gravis involving severe dehydration, up to 60% of patients can 
die; however, less than 1% of cases treated with rehydration therapy are fatal. The disease 
typically lasts 4–6 days [32], [265]. Worldwide, diarrhoeal disease, caused by cholera and many 
other pathogens, is the second-leading cause of death for children under the age of 5 and at least 
120,000 deaths are estimated to be caused by cholera each year  [260], [266]. Cholera affects an 
estimated 3-5 million people worldwide and causes 100,000-130,000 deaths a year as of 2010 
[33]. 
2.15.3. Prevention and control 
Treatment includes rehydration and replacement of lost electrolytes, which are important ions, 
such as sodium and potassium, used in biochemical processes to keep the body alive. Because of 
the low quality of water treatment in many poverty ridden countries, rehydration with clean 
water can be impossible without medical aid and supplies. Oral cholera vaccines are increasingly 
used as an additional tool to control cholera outbreaks in combination with the traditional 
interventions to improve safe water supply, sanitation, hand washing and other means to 
improve hygiene. Cholera vaccines are vaccines that are effective in preventing cholera. 
However, since it does not provide 100% immunity from the disease, food hygiene precautions 
should also be taken into consideration when visiting an area where there is a high risk of 
becoming infected with cholera. Oral vaccines provide protection in 52% of cases the first year 
following vaccination and in 62% of cases the second year [267]. There are two variants of the 
oral vaccine currently in use: WC-rBS and BivWC. WC-rBS (marketed as "Dukoral") is a 
monovalent inactivated vaccine containing killed whole cells of V. cholerae O1 plus additional 
recombinant cholera toxin B subunit. BivWC (marketed as "Shanchol" and "mORCVAX") is a 
bivalent inactivated vaccine containing killed whole cells of V. cholerae O1 and V. cholerae 
O139. mORCVAX is only available in Vietnam. Bacterial strains of both Inaba and Ogawa 
serotypes and of El Tor and Classical biotypes are included in the vaccine. The vaccine acts by 
inducing 2 types of antibodies; the antibacterial intestinal antibodies that prevent the bacteria 
from attaching to the intestinal wall and the anti-toxin intestinal antibodies that prevent the 
cholera toxin from binding to the intestinal mucosal surface [268]. But still there exist problems 
for which new strategy and research is needed in this area. Currently, cholera research more 
focused for identification of Vc virulence factors and their regulation should lead to a universal 
and hopefully one dose cholera vaccine with high efficiency [269]. It has been appreciated for 
some time that Vc cells express protective antigens associated with their outer membrane (OM), 
yet new subunit or kW-C vaccines featuring OM structures have not been developed as 
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alternatives to the oral cholera vaccines that do not (or do not optimally) express Vc protective 
antigens [37]. 
2.15.4. Outer membrane protein: V. cholerae 
Virulence-related outer membrane proteins (Omps) are expressed in Gram-negative bacteria and 
are essential to bacterial survival within macrophages and for eukaryotic cell invasion. The outer 
membrane proteins of enteric pathogens are one of the several factors that are involved in the 
interaction between the bacterium and the epithelial cell surface and confers resistance to the 
bacterium to bile salts and to host defense factors such as lysozyme and leukocyte proteins 
The Outer Membrane (OM) of V. cholerae is a complex structure that mainly consists of 
lipopolysaccharide (LPS), phospholipids and a group of outer membrane proteins (Omps). . 
High levels of transcripts for OmpU and multiple OM structures (OmpS, OmpV, OmpK, OmpC, 
OmpW, and OmpA) were present along with a number of conserved hypothetical proteins [37]. 
Apart from major virulent factors (toxin-coregulated pilus; TCP and cholera toxin; CT), large 
number other factors associated with the outer membrane (OM), including lipopolysaccharide 
(LPS), OM porins (OMPs) and flagella are mainly responsible for establishing initial adherence, 
modulate host-pathogen interaction, overall survival of the organism and propagation of 
virulence factor [270]. The ToxR and ToxS regulatory proteins have long been considered to be 
at the root of the V. cholera virulence regulon, called the ToxR regulon. ToxR activates the 
transcription of OmpU and represses the transcription of OmpT, outer membrane porins 
important for V. cholerae virulence [271], [272]. OmpU is more protective (compared to OmpT) 
against the bactericidal effects of bile salts and other anionic detergents [273]. An OmpU (a 
general porin) prologue, vca1008, identified by IVET is required for mouse colonization [274]. 
OMVs are also promising immunogenic platforms and may play important roles in bacterial 
survival and pathogenesis [275]. OMVs, Outer membrane vesicles function in transport of 
virulence factors, adherence to and entry into host cells, or modulation of the host response. 
OMVs largely reﬂect the composition of the outer membrane and periplasm of their donor gram-
negative bacteria. Immunization with Vibrio cholerae outer membrane vesicles induces 
protective immunity in mice by inducing specific, high-titer immune responses of similar levels 
against a variety of antigens present in the OMVs [270], [276]. Omps are highly immunogenic 
due to their exposed epitopes on the cell surface. Virulence-related outer membrane proteins 
(Omps) are essential to bacterial survival within macrophages and for eukaryotic cell invasion 
that could be an alternative candidate for development of subunit vaccine against V. cholerae. 
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2.16. Challenges and future perspective 
The rapid advancement in the field of nanomedicine might be due to more focus on developing a 
whole new range of nanovaccines with novel delivery mechanisms. However, the application of 
nanoparticles in vaccine delivery is still at an early stage of development. The challenges with 
nanoparticle-based vaccine include many factors, e.g. difficulty in reproducibly synthesizing 
stable and non-aggregated nanoparticles having consistent and desirable properties, a lack of 
fundamental understanding about the role of physical properties of nanoparticles affecting 
biodistribution, targeting and nanoparticle- biosystem interactions at all levels from the cell 
through tissue and to the whole body. Again, the limitations of NPs for the delivery of vaccines 
range from concerns over the toxicity of the particles to difficulties in producing the materials 
and presenting antigens in their native form. Therefore, rational design in combination with the 
reproducible synthesis of nanoparticles with desirable properties, functionalities and efficacy 
become increasingly important, and it is anticipated that the adoption of new technologies will 
speed up the development of suitable nanoparticles for pharmaceutical applications. 
Furthermore, there is a need for developing novel vaccine systems by integrating some other 
essential properties, such as specific targeting, slow release, alternative administration methods 
and delivery pathways to fulfil the demand of the single-dose and needle-free delivery will 
become practical near future.  
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Chapter 3 
Preparation and characterization of PLA and 
PLGA loaded with model protein (BSA) or drug 
(Clindamycin hydrochloride) nanoparticles 
 
 
3.1. Introduction 
Biodegradable nanoparticles (NPs) are gaining increased attention for their ability to serve as a 
viable carrier for site specific delivery of drugs and vaccine. Recently nanoparticles (NPs) 
(diameter: 10 to 1000 nm) delivery system has been proposed as colloidal drug carriers [277], 
which  serve as excellent carriers by enhancing aqueous solubility, increasing resistance time in 
the body (increasing half-life for clearance/increasing specificity for its associated receptors) 
and targeting drug to specific location in the body. Moreover, polymeric NPs have been proved 
to enhance the oral bioavailability of orally inactive antibiotics [278].Various polymers have 
been employed in the formulation of NPs for drug delivery research to increase therapeutic 
benefits. Among them, poly (D, L- lactide-co-glycolide) (PLGA), polylactic acid (PLA), are 
considered to be highly beneficial because of their biodegradable and biocompatible nature 
[65].They are widely used for human research due to their FDA approval (The Food and Drug 
Administration, U.S.A.) [279]. 
Clindamycin hydrochloride (7-chloro-7-deoxylincomycin hydrochloride) is a semi-synthetic 
analogue of a natural antibiotic lincomycin. It is available as a white crystalline powder and 
administered orally. It is commonly used in topical treatment for acne and infections of the  
skin, soft tissue and infections and peritonitis [280]. In patients 
with hypersensitivity to penicillin, clindamycin is used to treat infections caused by 
susceptible pathogenic aerobic bacteria. It is widely used for the treatment of anaerobic 
infections caused by susceptible anaerobic bacteria, including dental infections [281] and 
infections of the respiratory tract, skin and soft tissue infections and peritonitis [282]. 
Clindamycin is also known to be useful in treating toxic shock syndrome in combination with 
vancomycin [283] and reducing the risk of premature births in women diagnosed with bacterial 
vaginosis [284]. Antimicrobial actions of clindamycin include a breakdown of bacterial cell 
membrane and inhibition of toxin synthesis [285]. The bacteriostatic effect of clindamycin is
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due to inhibition of bacterial protein synthesis by binding to the 50S rRNA of the large bacterial 
ribosome subunit that inhibits the ribosomal translocation [285]. 
Clindamycin is a time-dependent antibiotic; exerts its best bactericidal effect when the drug is 
maintained above the MIC value in the formulation or alone. Hence, the time at which the 
therapeutic drug concentration is above the MIC (T>MIC) value is considered as the primary 
parameter and should be kept as a minimum standard to achieve the desired clinical outcomes 
[76]. Therefore, sustained-release preparation has an important primary role in the clindamycin 
delivery. There are several problems associated with conventional methods of Clindamycin use. 
The drug could not reach the appropriate amount to the site of infection due to low 
bioavailability and drug loss. There are also incidences of low efficacy due to degradability. We 
hypothesize that if the drug can be encapsulated within a biodegradable system, it would 
enhance the drug efficiency to a greater extent by conserving its natural therapeutic property. It 
will not only protect the drug in its native structure but also be helpful in delivering the required 
amount of drug at the target site in an efficient manner. This can be monitored and compared by 
analyzing the changes in structural and physiochemical properties of the free drug and the 
encapsulated drug. In the current study, an attempt has been made to formulate CLH-PLA and 
CLH-PLGA NPs by a double emulsion solvent evaporation method with an aim to overcome 
the above mentioned demerits.  Here, we propose a better delivery model to offer several 
advantages over conventional administration and delivery methods, including the ability for 
drug delivery to a specific site such as an intracellular infection [73], [74], reducing systemic 
toxicity [75] and also to facilitate sustained release of an antibiotic, minimizing dosing regimens 
[76]. The characterization and comparison study of the above formulated NPs were performed 
in order to foresee possibilities to design further an endocytable controlled drug release system 
which would provide less alteration to the general structure of the drug and can be available in 
intact form at the molecular level. It might be useful in the treatment of various bacterial 
infections as well as it will reduce other related side effects. 
Bovine serum albumin (BSA) was used as model protein since it is one of the most stable and 
extensively used proteins for evaluating novel sustained release drug delivery system [286]. 
There are many types of research on the development of biodegradable nanoparticles 
encapsulating protein or peptide drugs. However, effects of critical parameters influencing the 
size and surface charge, protein encapsulation, preferred protein release pattern, extending the 
duration of release, the stability of proteins in the formulation, narrowing polydispersity of 
nanoparticles etc. are under investigation to formulate them commercially.  
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So, in an another attempt, formulation of PLA and PLGA NPs loaded with BSA was carried out 
by of double emulsion solvent evaporation and characterization studies were performed to 
optimize the physical parameters such as size, charge, PDI, drug loading etc. 
3.2. Materials and Methods 
3.2.1. Materials 
The drug, Clindamycin hydrochloride (CLH), polymer; polylactic acid (PLA; molecular weight: 
85,000- 160,000 Da), poly (D,L-lactic-co-glycolic) acid (PLGA50: 50; molecular weight: 
40,000-75,000 Da) and polyvinyl alcohol (PVA) were procured from Sigma-Aldrich, USA. 
Dichloromethane (DCM) and Acetone (analytical grade) were purchased from Merck India Pvt 
Ltd.  Ultrapure water from Milli-Q water system (Millipore, USA) was used throughout the 
study. 
3.2.2. Preparation of PLA-BSA and PLGA-BSA NPs 
PLA and PLGA nanoparticles were formulated by water-in-oil-in-water (W/O/W) multiple 
emulsion method. In brief, the polymer was dissolved in dichloromethane (DCM), which 
constituted the organic phase (OP) at a concentration of 50 mg/mL. Primary emulsion was made 
using sonication (40W, 80% duty cycle, 20 cycles) (Brason, sonifier 450, USA) between antigen 
solution in internal aqueous phase (IAP) with that of the polymer solution as OP. The ratio was 
optimized at 1:5, 1:8 and 1: 10 for bovine serum albumin (BSA). Bovine serum albumin (2.5% 
W/V), Sucrose (10% W/V) and Sodium bicarbonate (2% W/V) were added to internal aqueous 
phases during primary emulsion step. The resulting primary emulsion was added dropwise to 
external aqueous phase (EAP) containing (1% W/V) PVA and (10% W/V) Sucrose solution. 
The secondary emulsion was prepared by homogenization technique carried out at 10,000 rpm 
for 10 min (Virtis, Cyclone I. Q. USA) for nanoparticle preparation process. The ratio of 
primary aqueous phase (IAP) to external aqueous phase (EAP) during secondary emulsion step 
was maintained at 1: 4. After secondary emulsification process, the solution was stirred 
overnight at room temperature for the complete evaporation of DCM. The particles thus formed 
were washed three times with ice-cold MQ water and lyophilized to get free flowing powder of 
BSA-encapsulated particles. 
3.2.3. Preparation of CLH-PLA and CLH-PLGA NPs 
The CLH-PLA and CLH-PLGA NPs were prepared by following double emulsion solvent 
evaporation method according to Machado and Evangelista with little modifications [287]. For 
organic phase (OP), 0.4 gm of PLGA/PLA polymers were dissolved in 8ml organic mixture 
(dichloromethane: acetone; 85:15, v/v). For internal aqueous phase (IAP), CLH at varied 
concentration i.e. 20 mg (drug: polymer; 1:20), 40 mg (drug: polymer; 1:10). 80 mg (drug: 
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polymer; 1:5) were dissolved in phosphate buffered saline (PBS) (67mM, pH 6.0). The two 
solutions (OP and IAP) were mixed by ultrasonication (LABSONIC ® M, B. Braun Biotech) 
for 30 sec under cooling (output 4, 40% duty cycle) to form W1/O emulsion. The W1/O 
emulsion mixture was slowly added to 100 ml of 1% (w/v) aqueous PVA solution with a high-
speed homogenization at 8500 rpm for 8 min. The resulting w1/o/w2 emulsion was stirred at 300 
rpm overnight for the maximum evaporation of the organic solvent. Then the precipitated NPs 
were washed three times with ultrapure water at 12000 rpm for 15 min and the supernatants 
were stored for estimation of free drug. Finally, the pellet samples (NPs) were lyophilized and 
then used for further characterization. The prepared CLH- PLA NPs were named as CLH- PLA 
1(drug: polymer; 1:20), CLH- PLA 2 (drug: polymer; 1:10), CLH- PLA 3 (drug: polymer; 1:5). 
Similarly CLH-PLGA NPs were named as CLH- PLGA 1(drug: polymer; 1:20), CLH- PLGA 2 
(drug: polymer; 1: 10), CLH- PLGA 3 (drug: polymer; 1:5). 
3.2.4. Characterization of NPs 
Particle size, zeta potential and polydispersity index measurements 
The size (Hydrodynamic diameter), size distribution (Poly Dispersity Index) and zeta potential 
(Surface charge) of the NPs were analyzed by Zeta sizer (ZS 90, Malvern Instruments Ltd, 
Malvern, UK). The lyophilized samples were made an appropriate dilution with PBS (67 mm, 
pH 6.0). Aliquots from each preparation batch were sampled in dynamic light scattering (DLS) 
cuvettes and NPs were then examined for equivalent diameters, size distribution, zeta potential 
and polydispersity index. Particles diameters were assessed at a scattering angle of 90° and at a 
temperature of 25°C. Then determinations for diameter, zeta potential and polydispersity index 
were measured for each preparation (in triplicate) and the standard deviations were calculated. 
3.2.5. Determination of drug loading efficiency 
The loading efficiencies of CLH-PLA and CLH-PLGA NPs were calculated 
spectrophotometrically using standard curve method prepared by varying concentration of CLH 
[288]. For standard curve, different dilutions of the drug in PBS (3 ml) were taken and heated 
with 3 ml of 1% KIO4 solution, 2 ml of 30% H2SO4 and 10 ml of cyclohexane on a water bath at 
60° for 45 min then cooled and the cyclohexane layer was removed. The extraction was 
repeated (× 2) with 5 ml of cyclohexane and the combined extracts were diluted to 25 ml before 
the absorbance was measured at 520 nm. A similar procedure was followed for supernatants 
(containing free drugs) reserved for determination of drug. The OD value was put in the 
standard curve equation to find out the total drug content. 
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The amount of drug loaded in the NPs was calculated by subtracting the free drug present in the 
supernatant from the total drug added during the preparation of the NPs using the following 
formula 
 
Similarly, the antigen loading in NPs (PLA-BSA and PLGA-BSA) was determined from the 
total amount of antigen added in the formulation and the antigen amount that was not 
encapsulated. For this, the concentration of antigen (BSA) in the supernatant was analyzed by 
Pierce™ BCA (Bicinchoninic acid) Protein Assay Kit (Thermo Scientific) to determine free 
antigen concentration [289]. The amount of BSA protein encapsulated in the NPs was calculated 
by subtracting the free protein present in the supernatant from the total protein added during the 
preparation of the nanoparticles using the following formula 
 
 
3.2.6. In vitro drug release study 
The rate of CLH released from NPs was measured as a function of time during incubation in 1X 
PBS. Triplicate samples of 5 mg NPs were suspended in 1 ml PBS in a microcentrifuge tube and 
sonicated briefly in an ultrasonic water bath. The samples were then incubated on an orbital 
shaker (200 rpm) at 37°C. At defined time points the samples were centrifuged. The supernatant 
was collected and reconstituted by adding fresh PBS. The supernatant was collected and the 
pellet (NPs) was reconstituted by adding fresh PBS. The drug content in the supernatant was 
estimated [288]as discussed above. The percentage of drug release was plotted against time and 
the cumulative release was calculated. 
3.2.7. SEM Study 
The morphology of the NPs was investigated by scanning electron microscopy (Jeol 6480LV 
JSM microscope). The NPs were fixed on adequate support and coated with platinum using 
platinum sputter module in a higher vacuum evaporator. Observations under different 
magnifications were performed at 20kv. 
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3.2.8. DSC analysis 
The physical states of CLH-PLA 2, CLH-PLGA 2 NPs and blank polymeric NPs were 
characterized by differential scanning calorimetric thermogram analysis (Netzch DSC 200 F
s
).  
The samples (~12 mg) were sealed in aluminum pans and heated under nitrogen by heating rate 
of 10
0
C/min, the heat flow being recorded from 30
0
C to 200
0
C. Indium was used as standard 
reference material to calibrate the temperature and energy scales of the DSC instruments. The 
data were analyzed and DSC thermographs were plotted with the help of Microsoft excel. 
3.2.9. Fourier transformed infrared spectra 
FT-IR spectra (Shimadzu FTIR spectrophotometer: Model 8400 S) of CLH, CLH-PLA 2 and 
CLH-PLGA 2NPs were recorded in potassium bromide pellets. The spectrum was recorded 
between 4000 and 400cm
-1
 using a high energy ceramic source and DLATGS detectors. 
Characterization by Fourier Transform Infrared (FTIR) was specifically carried out to determine 
the adsorption of the drug in the prepared NPs by studying the chemical properties of CLH 
conjugated NPs. After knowing the functional groups, its bonding nature with NP was also 
characterized. 
3.2.10. Antibacterial activity   
The antibacterial activities of the CLH-PLA 2, CLH-PLGA 2 NPs and CLH were studied 
against Streptococcus faecalis and Bacillus cereus. The minimum inhibitory concentration 
(MIC) values were determined by following CLSI guidelines for the broth microdilution method 
[290]. Brieﬂy, bacterial strains were cultured onto Luria-Bertani Agar medium (containing 0.5% 
peptone, 0.5% yeast extract, 1% NaCl and 1.5% Agar, at pH 7.5 ± 0.2). The stock solution was 
prepared by suspending the NPs in 4 ml of aqueous solution (phosphate buffer 67 mM, pH 7.4, 
0.05% Tween 20 and 0.02% sodium azide) contained in borosilicate vials. The NPs were 
incubated at 37°C with shaking for 24 h. Supernatant samples of 500µl were collected by 
centrifugation and stored at 4°C until checked for antimicrobial activities. . Chloramphenicol (a 
common antibiotic) was used as the positive control and PBS was used as the negative control. 
Bacterial cultures were added to the sterilized Mueller-Hinton Broth (MHB) (containing 30% 
beef extract, 1.75% casein acid hydrolysate and 0.15% starch, pH 7.4 ± 0.2). The MIC was 
determined by using 2-fold serial dilutions in the medium (MHB) containing 1.95–1000 µg/ml 
of the test compounds. To each well of 96 well microtitre plate, 150 µl of medium (MHB) was 
taken in duplicate, to which 10 µl of 0.5 McFarland standard (1.5 × 10
8
 CFU/ml) culture 
pathogens from MHB was added. The inoculated plates were incubated at 37
0
C for 24 h. After 
incubation, the bacterial growth was monitored by measuring the turbidity of the culture by a 
microtitre plate optical colorimeter (OD600). The MIC was determined as the lowest 
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concentration of compound at which the visible growth of the organisms was completely 
inhibited. 
The results of experimental assays were expressed as mean value ± standard error (SE).  Student 
t’test or One-way ANOVA (analysis of variance) followed by Duncan’s multiple range tests 
(DMRT) was performed using SPSS18 software to compare the variations in various parameters 
at a significance level of difference (p < 0.05). 
3.3. Results  
3.3.1. Physical properties 
PLA-BSA and PLGA-BSA NPs 
PLA and PLGA micro and nanoparticles were prepared by a double solvent evaporation 
method. Then BSA (2.5%) (PI of 4.8) was used as a model protein. The BSA encapsulated PLA 
nanoparticles size was varied from 162.7±13.26 nm to 258.3±35.12nm. The particle size of PLA 
NPs (blank) was recorded as 43.73± 4.77 nm. When OP: IAP (2.5% BSA)  is maintained at 1:5, 
1:8, 1:10, the size of the formulated PLA NPs were 258.3±35.12 nm (PLA-BSA1), 196.8±23.22 
(PLA-BSA1) and 162.7±13.26 (PLA-BSA3) respectively. However, the loading efficiency (%) 
of PLA-BSA1, PLA-BSA1 and PLA-BSA3 were 61.6±5.25, 69.6±10.12 and 82.4±6.21 
respectively. Similarly, The BSA encapsulated PLGA nanoparticles size was varied from 
113.5±11.76 nm to 335.6±30.21 nm. The particle size of PLGA NPs (blank) was recorded as 
178.6±17.34 nm. When OP: IAP (2.5% BSA)  is maintained at 1:5, 1:8, 1:10, the size of the 
formulated PLGA NPs were 335.6±30.21 nm (PLGA-BSA1), 138.5±21.27 (PLGA-BSA1) and 
138.5±21.27 (PLGA-BSA3) respectively. The zeta potential values of PLA-BSA NPs were 
ranged from -24.7±3.21 mV to -32.7±5.32 mV, while for PLGA-BSA NPs; it varied from -
19.1±3.45mV to -30.1±2.14mV. The negative charge confirmed the surface charge of both PLA 
and PLGA NPs. The PDI values for all NPs were within good range. In the case of PLA-BSA 
NPs, the PDI value was lowest for PLA-BSA3 (0.337±.03). Similar results were also found for 
PLGA-BSA NPs, where PDI value was found lowest for PLGA-BSA3 (0.356±0.04). The 
physical properties of all the formulations are mentioned in Table 3.1. 
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Table 3.1. Physical properties of BSA loaded PLA and PLGA NPs 
 
CLH-PLA and CLH-PLGA NPs 
Various formulation factors were reported to play a key role on the physiochemical properties of 
polymeric nano/ microparticles formed [291]. In this study, CLH loaded in PLA and PLGA NPs 
were prepared by w/o/w double emulsion evaporation technique varying the drug to polymer 
ratio. The effect of the drug concentrations (1: 20, 1: 10, 1: 5) on the size of the obtained NPs 
was analyzed. The physical properties of all the formulations are mentioned in Table 3.2.The 
particle size of PLA NPs (blank) was recorded as 42.93± 1.77 nm. The particle size increased 
with the drug encapsulation into the NPs. The sizes of NPs were 203.35± 12.04, 323.5± 16.39, 
827.4 ± 10.20 nm at a different drug to polymer concentration i.e. 1:20, 1:10 and 1: 5 
respectively. In case of PLGA NPs (blank), the particle size was 178.6 ± 12.11 nm, while for 
CLH- PLGA 1( 1:20),  CLH- PLGA 2 (1: 10), CLH- PLGA 3 (1:5), the particle sizes were 
196.45 ± 8.78 , 258.3± 11.23 and 456.5 ± 12.36 nm respectively. The zeta potential values of 
CLH-PLA NPs were ranged from -17.6 ± 6.55 mV to -30.5 ± 4.95 mV, while for CLH-PLGA 
NPs; it varied from -21.7 ± 5.34 mV to -33.5 ± 3.0 mV. The negative charge confirmed the 
surface charge of both PLA and PLGA NPs. But very interestingly, the zeta potential were 
highest when the drug: polymer concentration was 1:10 (-30.5 ± 4.95 mV for CLH- PLA2 and -
33.5 ± 3.0 mV for CLH-PLGA2).The size and charge distribution patterns of CLH-PLA2, CLH-
PLGA 2 are shown in Figure 3.1 and 3.2 respectively. The PDI values for all NPs were within 
good range. In the case of CLH-PLA NPs, the PDI value was lowest for CLH-PLA 2 (0.219 ± 
0.01). Similar results were also found for CLH-PLGA NPs, where PDI value was found lowest 
for CLH-PLGA 2 (0.176 ± 0.01). 
 
Polymer Sample 
code 
Formulation 
code 
Ratio of 
Organic Phage: 
Internal 
Aqueous Phase 
(OP: IAP) 
Mean 
Particle Size 
PDI Zeta 
Potential 
Loading 
Efficiency 
(%) 
PLA 
 
1 PLA blank  43.73±5.77 0.303±0.07 -24.8±6.75 - 
2 PLA-BSA1 1:5 258.3±35.12 0.465±0.08 -32.7±5.32 61.6±5.25 
3 PLA-BSA2 1:8 196.8±23.22 0.403±0.06 -20.5±4.31 69.6±10.12 
4 PLA-BSA3 1:10 162.7±13.26 0.337±.03 -24.7±3.21 82.4±6.21 
PLGA 
 
5 PLGA Blank  178.6±17.34 0.324±0.06 -19.9±4.32 - 
6 PLGA-BSA1 1:5 335.6±30.21 0.537±0.05 -19.1±3.45 65.28±5.25 
7 PLGA-BSA2 1:8 138.5±21.27 0.518±0.04 -30.1±2.14 81.28±7.23 
8 PLGA-BSA3 1:10 138.5±21.27 0.356±0.04 -20.3±4.56 91.22±9.45 
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Figure 3.1 Size (a) and charge (b) distribution pattern of CLH loaded PLA NPs (PLA-CLH 2). The drug: 
polymer ratio is 1:10. The average size and zeta potential were 323.5± 16.39 nm and -30.5 ± 4.95 mV 
respectively. 
 
 
 
Figure 3.2 Size (a) and charge (b) distribution pattern of CLH loaded PLGA NPs (PLGA-CLH 2). The drug: 
polymer ratio is 1:10. The average size and zeta potential were 258.3± 11.23 nm and -33.5 ± 3.0 mV 
respectively. 
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Table 3.2.  Physical properties of CLH loaded PLA and PLGA NPs 
Polymer Sample 
(Code) 
Conc. 
of 
Drug 
(mg) 
Conc. of 
Polymer 
(mg) 
Ratio of 
drug: 
Polymer 
Mean 
Particle 
size 
(Diameter 
in nm ± 
SD) 
Zeta 
potential 
(mV) ± 
SD 
Poly 
Dispersity 
Index 
(PDI) ± 
SD 
Encapsulation 
efficiency (%) 
 
 
 
PLA 
Blank 
(PLA) 
- 400 - 42.93± 
1.77 
-24.8 ± 
7.67 
0.454± 
0.05 
- 
CLH- 
PLA 1 
20 400 1:20 203.35± 
12.04 
-19.8 ± 
3.88 
0.332± 
0.03  
7.2± 2.08 
CLH- 
PLA 2 
40 400 1:10 323.5± 
16.39 
-30.5 ± 
4.95 
0.219 ± 
0.01 
21.35± 3.17 
CLH- 
PLA 3 
80 400 1:5 827.4± 
10.20 
-17.6 ± 
6.55 
0.423 ± 
0.04 
24.5 ± 4.29 
 
 
PLGA 
Blank 
(PLGA) 
- 400 - 178.6 ± 
12.11 
-32.7 ± 
5.01 
0.524 ± 
0.03 
- 
CLH- 
PLGA 
1 
20 400 1:20 196.45 ± 
8.78 
-25.5 ± 
2.88 
0.650± 
0.05 
45 ± 3.45 
CLH- 
PLGA 
2 
40 400 1:10 258.3± 
11.23 
-33.5 ± 
3.0 
0.176 ± 
0.01 
65.69 ± 2.28 
CLH- 
PLGA 
3 
80 400 1:5 456.5 ± 
12.36 
-21.7 ± 
5.34 
0.353 ± 
0.03 
72.35 ± 2.31 
(CLH-PLA1-3, CLH-PLGA 1-3 were named according to the drug: polymer ratio. The drug: polymer ratio of 
CLH-PLA 1, CLH-PLA 2, CLH-PLA 3 were 1:20, 1:10, and1:5 respectively. Similarly The drug: polymer 
ratio of CLH-PLGA 1, CLH-PLGA 2, CLH-PLGA 3 were 1:20, 1:10, and1:5 respectively). The results were 
expressed as a mean ± standard deviation. 
3.3.2. Loading efficiency 
The loading efficiencies increased with the increase in drug concentration. In the case of CLH-
PLA NPs, the loading efficiency (%) increased from 7.2± 2.08 to 24.5 ± 4.29, when the drug: 
polymer concentration increased from 1:20 to 1:5. Similarly in case of CLH-PLGA NPs, the 
loading efficiencies (%) increased from 45 ± 3.45 to 72.35 ± 2.31, when the drug: polymer 
concentration increased from 1:20 to 1:5. This study showed the loading efficiency of CLH to 
PLGA was higher than CLH to PLA. CLH loading efficiency depended on the polymer type and 
the physical state of the drug (solid form or in solution form) during processing.   
 
 
 
Chapter 3                            Preparation and characterization of PLA and PLGA………………….nanoparticles 
 
47 
 
3.3.3. In vitro drug release 
In vitro release of CLH was assessed from PLA and PLGA NPs into PBS (pH 7.4). The release 
profile of CLH from PLA and PLGA NPs is illustrated in Figure 3.3. It is observed that CLH 
release profile from CLH-PLGA in a considerably slower than from CLH-PLA. In the case of 
CLH-PLA, 50 % of the drug was released within 4 hr. 75 % release of CLH was realized within 
a period of up more than 48 hr. But in the case of CLH-PLGA, 50% drug was released within 8 
h and 75% release of CLH was realized within a period of up more than 72 h.   
 
Figure 3.3.  In-vitro CLH release from CLH-PLA 2 and CLH-PLGA 2 NPs. 
3.3.4. SEM Study 
The morphology of CLH loaded PLA and PLGA NPs were analyzed by SEM study. The NPs 
were spherical structures as confirmed by scanning electron microscope (SEM) (Figure 3.4). 
The surface morphologies of the particles were rough and rounded. Particles were found to be 
regular and isolated in nature.    
 
Figure 3.4 SEM photograph of (a) CLH-PLA2 (Drug: polymer- 1:10) and (b) CLH-PLGA2 (Drug: polymer- 
1:10). 
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3.3.5. DSC studies 
Thermal analytical studies of polymeric drug delivery systems are vital since the processes used 
for their preparation are able to modify the organization of the polymer chains [292]. Figure 3.5 
shows DSC data of CLH, PLA NPs, PLGA NPs, CLH-PLA 2 and CLH-PLGA 2. In the current 
study, the blank PLA and PLGA polymer showed glass transition temperature (Tg) at 64.24
0 
C 
and 67.5 
0
C respectively. Thermal analysis data (figure 3.5) showed that pure CLH possesses an 
endothermic peak at 150
0
C related to the melting point.   CLH melting peak was depleted in the 
thermogram for the loaded PLA and PLGA NPs, indicating the presence of amorphous CLH in 
the NPs. The results also showed a decrease in glass transition temperature of PLA and PLGA 
polymer with respect to nano encapsulation of the drug.   
 
Figure 3.5 DSC data: a. Thermal analysis graph of Clindamycin hydrochloride (CLH), blank PLA,  CLH 
conjugated with PLA (CLH-PLA2); (b) Thermal analysis graph of Clindamycin hydrochloride (CLH), blank 
PLGA, and CLH conjugated with PLGA (CLH-PLGA 2). 
3.3.6. FTIR analysis 
FTIR analysis measures the selective absorption of light by the vibration modes of specific 
chemical bonds in the sample. The observation of vibration spectrum of encapsulated 
drug permits evaluation of the type of interaction occurring between the drug and polymer. This 
interaction is due to the vibrations of the atoms involved (in this interaction) can suffer 
alterations in intensity and frequency [293]. FTIR studies of CLH-PLA and CLH-PLGA NPs 
were performed to characterize the chemical structure of drug conjugated NPs. Figure 3.6 shows 
the FTIR spectra of CLH-PLA 2 and CLH-PLGA 2 NPs. Nearly similar peaks were observed in 
both the prepared NPs some of which occurred at 3648 cm
-1 
(O-H stretching), 3505 cm
-1 
(O-H 
stretching), 2946 cm
-1
(C-H stretching), 2996 cm
-1
(C-H stretching), 1761 cm
-1
( C=O stretching), 
1458 cm
-1
(C-H bending), 1386 cm
-1
(N=O bending), 1184 cm
-1 
(C-N stretching), 1080 cm
-1 
(C-O 
stretching), 870 cm
-1
 and 756 cm
-1
(N-H wags) for the CLH-PLA 2 NPs whereas 3644 cm
-1
 (O-
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H stretching), 2999 cm
-1
 (C-H stretching), 2955 cm
-1
 (C-H stretching), 1761 cm
-1 
(C=O 
stretching), 1458 cm
-1
(C-H bending), 1398 cm
-1 
(N=O bending),  1183 cm
-1
, 1086 cm
-1
(C-N 
stretching), 866 cm
-1 
and 749 cm
-1
 (N-H wags) for the CLH-PLGA 2 NPs. 
 
Figure 3.6.  FTIR data analysis of  CLH -PLA 2(a) and CLH -PLGA-3 (b). 
As drug has a secondary amine group on its general structure whose peak is also detected by 
FTIR studies. The analysis shows no alteration of secondary amine structure after conjugation 
with PLA/PLGA NPs. But changes have been found after conjugation with PLA/PLGA for 
some functional groups like C=O, OH those which are abundant in PLGA/PLA NPs. These 
functional groups were found very less in number in case of CLH drug alone.   
3.3.7. Antimicrobial activity 
The antibacterial activities were evaluated for the selected nano formulations (CLH-PLA 2, 
CLH-PLGA 2) and CLH drug alone by determining their minimum inhibitory concentration 
(MIC) values against pathogenic microorganisms. The MIC values are mentioned in Table 3.3. 
In this study, MIC values of CLH were found to be 0.48 ± 0.01µg/mL for Streptococcus faecalis 
and 1.95±0.04 µg/mL for Bacillus cereus. However, these MIC values were decreased when the 
drug was encapsulated into PLA and PLGA NPs. CLH-PLA 2 showed MIC values of 0.12± 
0.05 µg/mL and 0.97± 0.08 µg/mL, while CLH-PLGA 2 showed MIC values 0.24± 0.05 µg/mL 
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and 0.48±0.06 µg/mL against Streptococcus faecalis and Bacillus cereus respectively. MIC 
values of CLH were found to be increased when the drug was loaded into PLA and PLGA NPs 
as proved against Streptococcus faecalis and Bacillus cereus.   
Table 3.3 Antibacterial activity of Clindamycin hydrochloride conjugated with PLA (CLH-PLA 2), 
Clindamycin hydrochloride conjugated with PLGA (CLH-PLGA 2) and Clindamycin 
hydrochloride, in vitro MIC in µg/mL 
 
 MIC (µg/mL) ± Standard deviation 
Formulations Streptococcus faecalis Bacillus cereus 
Clindamycin hydrochloride 0.48± 0.01 1.95±0.04 
PLA-CLH 2 0.12±0.05 0.97±0.08 
PLGA-CLH 2 0.24±0.05 0.48±0.06 
3.4. Discussion 
NPs based drug delivery system is now becoming a useful tool for controlling various acute 
infectious stages, preventing complications and their relapse. Therefore, it is helpful in 
overcoming the sensible disadvantages with long-term therapies [294]. In addition, drugs 
delivered through nanospheres that target particularly to the infected cells should have reduced 
cytotoxicity associated with undesired biodistribution of the free drug. Depending upon the 
mode of action, NPs based drug delivery systems could perform better than microparticle based 
delivery system due to their size and better presentation of antigen [295], [296]. 
The particle size increased with the increase in drug concentration in the NPs. The sizes of NPs 
were 203.35± 12.04, 323.5± 16.39, 827.4 ± 10.20 nm at a different drug to polymer 
concentration i.e. 1:20, 1:10 and 1: 5 respectively. Similarly, for CLH- PLGA 1(1:20),  CLH- 
PLGA 2 (1: 10), CLH- PLGA 3 (1:5), the particle sizes were 196.45 ± 8.78 , 258.3± 11.23 and 
456.5 ± 12.36 nm respectively. From the particle size analysis report, it can be concluded that 
the particle sizes were dependent on the initial concentration of the drug used during the 
preparation process. Similar results were also documented earlier [291], [297]. Zeta potential is 
a scientific term for the measurement of electro-kinetic potential at the surface of the colloidal 
particles, which has a great significance in comparing the stability of colloidal dispersions [156]. 
The zeta potential indicates the degree of repulsion between adjacent particles and similarly 
charged particles in the dispersion. For molecules and particles that are small enough, a high 
zeta potential confers stability (dispersion will resist aggregation). When the zeta potential is 
low, the attraction between the particles exceeds repulsive force for which leads to flocculate. 
When the drug: polymer concentration was 1:10, the zeta potential were highest for both CLH- 
PLA (-30.5 ± 4.95 mV) and CLH-PLGA (-33.5 ± 3.0 mV) confirming highest stability. The zeta 
potential values of CLH-PLA NPs and CLH-PLGA NPs confirmed that the drug: polymer 
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concentration is important for the stability of drug loaded NPs. Hence, the current study 
confirmed that the drug: polymer concentration is important for the stability of drug loaded 
NPs.The polydispersity index (PDI) is a measurement of the distribution of NPs and it gives the 
distribution range from 0.000 to 0.500. Polydispersity index greater than 0.5 values indicates the 
aggregation of particles [298].The PDI values for all NPs were within good range. CLH-PLA2 
and CLH-PLGA-2 NPs have lowest PDI values confirmed the monodispersed nature of the 
formulated NPs. CLH loading efficiency depended on the polymer type and the physical state of 
the drug (solid form or in solution form) during processing. The loading efficiency of CLH to 
PLGA was higher than CLH to PLA. The enhanced microencapsulation in the case of more 
hydrophilic polymers might be ascribed to enhanced molecular interactions between the drug 
and the polymer [160], [299].This study showed the loading efficiency of CLH to PLGA was 
higher than CLH to PLA. This might be due to the reason that PLGA is more hydrophilic nature 
than PLA. 
It is observed that CLH release profile from CLH-PLGA in a considerably slower than from 
CLH-PLA. The rapid burst effect is very much delayed in case of CLH-PLGA.  That conferred 
that binding of the drug to PLGA was stronger than to PLA. In vitro release data indicated 
proper drug (CLH) encapsulation that avoided the burst effect and offered an extended release 
profile. A similar type of drug release studies was observed in etodolac loaded PLGA NPs [300] 
and minocycline-loaded PLGA NPs [301]. Thus, PLGA-drug can be a better oral delivery 
system as it could withstand the drug even after 4 hr which is the standard required time for 
retaining food in the stomach. The surface morphologies of the particles were rough and 
rounded. Particles were found to be regular and isolated in nature.  These regular and isolated 
forms of spherical structures were also observed earlier by Machado and Evangelista in case of 
cefoxitin loaded D, L-PLA NPs[287]. The smooth surface can also be correlated to lactide 
content that adds hydrophobicity to the polymer. So, that could prevent the retention of water 
and the shrinkage could be avoided while drying. Also, particle-particle contact formation was 
become less due to the presence of lactide (which causes hydrophobic) and ultimately prevents 
agglomeration [302]. 
Tg (glass transition temperature) represents the measurement of polymer chain flexibility for the 
lactic acid polymers that indicates the hydrolysis pattern of the ester bonds [303]. The usual Tg 
values reported for PLA and PLGA systems are more than 37 
0
C (so, they are glassy in nature) 
but can be clearly attributed to the presence of crystallites within the samples [304]. CLH 
melting peak (at 150
0
C ) was depleted in the thermogram for the loaded PLA and PLGA NPs, 
indicating the presence of amorphous CLH in the NPs. Similar results were also observed in 
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minocycline encapsulated PLGA NPs [301] and in cefoxitin loaded DL-PLA NPs [287]. With 
this, it can be suggested that the drug was more uniformly dispersed throughout the system in 
case of PLA and PLGA. The disappearance of the peak referred to the crystalline melting of the 
drug which indicates that the drug clindamycin is uniformly dispersed throughout the polymer 
matrix at a molecular level [287], [305]. The decrease in glass transition temperature of PLA 
and PLGA polymer was observed with respect to nano encapsulation of the drug. This may be 
due to increase in the size of the particles whereas the glass transition temperature is inversely 
related to the size of particles in case of the amorphous polymer [306]. 
From FTIR studies, it can be concluded that there is not much alteration in the general structure 
of CLH drug because of the presence of OH group and the drug is present in its native structure 
without forming any hydrogen bond with any other functional group. As CH group is also 
present in CLH drug, there is no alteration of CH group in the conjugated drug. C-O bond is 
common to both polymers and CLH drug. Therefore, it has no effect on to the CLH drug’s 
general structure. These observations confirmed that the intact form of CLH drug and it was not 
involved in any chemical interactions with the polymers which were also observed for 
nimesulide-loaded ethylcellulose and methylcellulose NPs and microparticles [291]. The 
antibacterial activities of selected nano formulations (CLH-PLA 2, CLH-PLGA 2) and CLH 
drug alone were evaluated by determining their minimum inhibitory concentration (MIC) values 
against pathogenic microorganisms. MIC values of CLH were found to be increased when the 
drug was loaded into PLA and PLGA NPs as proved against Streptococcus faecalis and Bacillus 
cereus. Therefore, this study confirmed the enhanced antibacterial activity of drug loaded NPs 
than the standard free drug.  Similar enhanced antimicrobial activities of drug loaded NPs were 
also observed by many researchers [74], [301], [307]. 
Hence, proving our hypothesis successful formulations of CLH loaded in PLA and PLGA NPs 
were carried out. From the DLS analysis, 1:10 dilution (Drug: polymer concentration) was 
proved to be the optimal ratio for the formulation of NPs. From CLH loading efficiency and 
release profile studies, more hydrophilic PLGA offers better encapsulation as well as extended 
CLH release profile confirming enhanced molecular interactions. Thermal analysis studies 
suggested that CLH was more uniformly dispersed throughout PLA and PLGA matrix at a 
molecular level. FTIR analysis confirmed the unaltered nature of drug CLH (no chemical 
interaction with polymer matrix), which was a very important parameter for better efficacy of 
CLH-PLA/PLGA nano complex. Enhanced antimicrobial activities of CLH-PLA/ CLH-PLGA 
NPs were proved against Streptococcus faecalis and Bacillus cereus measured through MIC 
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studies. Hence, the CLH drug was uniformly entrapped in PLA/PLGA NPs and the formulations 
were proven to exhibit more effective roles used at a lower concentration. 
3.5. Conclusion 
The therapeutic efficacy of the drug Clindamycin Hydrochloride was significantly enhanced by 
encapsulating into biodegradable polymer PLA/PLGA based nanoparticulate system when 
compared with the free drug. The hypothesis with which we initiated the work has been 
rightfully anticipated and we could successfully overcome the limitations of the drug when used 
alone. During the current investigation, CLH-PLA and CLH-PLGANPs of various sized 
particles were formulated by varying the drug to polymer ratio from 1:5 to 1:20. The size, zeta 
potential and polydispersity index values of CLH-PLA NPs and CLH-PLGA NPs confirmed 
that the drug: polymer concentration is important for the stability of drug loaded NPs. The drug 
to polymer ratio 1: 10 were found to be optimal ratio for the formulation to be stable and 
monodispersed CLH loaded PLA and PLGA NPs. NPs formulation (both CLH-PLA 2 and 
CLH-PLGA 2) showed a significantly higher drug loading efficiency and a controlled release 
profile extended up to 144 h. Higher drug loading and an extended CLH release profile were 
observed in the case of CLH-PLGA NPs which might be due to higher hydrophilic nature of 
PLGA that causes enhanced molecular interaction. The spherical and isolated structures of both 
CLH-PLA2 and CLH-PLGA2 NPs were confirmed by scanning electron microscope (SEM) 
study. The smooth surface and isolated nature of NPs can also be correlated to the presence of 
lactide that adds hydrophobicity to the polymer ultimately prevents agglomeration. The thermal 
behavior (DSC) studies of CLH-PLGANPs confirmed the disappearance of CLH endothermic 
peak (150
0
C) that indicated the uniform dispersion of drug at a molecular level within the 
system. From FTIR studies, it was found that there was not much alteration in the general 
structure of CLH drug (due to conserved OH, CH and C-O group etc.) after loading in PLA and 
PLGA NPs. The antimicrobial activities were enhanced in CLH-PLA NPs and CLH-PLGA NPs 
than the standard free drug evidenced from a decrease in MIC values tested against 
Streptococcus faecalis and Bacillus cereus. Our formulations are shown to be useful and 
effective To maintain a sustained release and drug concentration throughout medication process. 
Hence, we can conclude that by encapsulation of CLH into PLA and PLGA NPs, the various 
physiochemical properties of the drug increased to a satisfactory extent. The drug was more 
effective at lower concentration against pathogenic microorganisms which can be widely 
applied in a number of therapies by further designing successful endocytable controlled drug 
release system. 
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Chapter 4 
 
Parenteral immunization of PLA/PLGA nanoparticle 
encapsulating outer membrane protein (Omp) from 
Aeromonas hydrophila; Evaluation of 
immunostimulatory action in Labeo rohita (rohu) 
 
 
4.1. Introduction 
Today’s  leading research on vaccine approaches mostly focuses on the development of naturally 
acquiring immunity by inoculation of non-pathogenic but still immunogenic components of the 
pathogen or closely related organisms. The growing issues of vaccine safety are in alarming rate 
owing to their weak immunogenicity, poor immunization procedures and failure to acquire 
booster doses to potentiate prime doses. These are some of the strong reasons which have paved 
the way towards research for the development of new generation therapeutic vaccine. Adjuvants 
are used for development of new generation vaccine formulations to serve in multiple ways; to 
enhance immunogenicity, provide antigen dosesparing, to accelerate a robust  immune response, 
reduce the need for booster immunizations, increase the duration of protection, or improve 
efficacy in immunocompromised individuals in human and other live stocks. Hence, there is an 
urgent need for improved and effective, with or without adjuvant based novel vaccine 
formulations with minimal compositions like purified proteins, peptides, etc. for particular 
disease antigen in question. Because of the chemical nature and mode of action, the safety and 
efficacy of adjuvants in vaccine formulations vary to a greater extent. There are reports on 
adverse effects and hyperactivation of the immune system, neurotoxicity and detrimental effects 
when adjuvants are used for a prolonged period. Therefore, a relatively new system which is 
stable with antigen combination and can provide comparable immunity to that of adjuvants 
eventually can be treated as a complete replacement for the existing adjuvants in use should take 
the lead for development of advanced vaccine formulations. The strategy here is to develop such 
a system. 
Currently, controlled delivery systems consisting of biodegradable microspheres/nanospheres act 
as a promising vaccine carrier because it can potentially deliver the antigens to the desired 
locations at predetermined rates and durations to generate an optimal immune response. The 
strategies that have been tested include the use of polymeric carriers such as chitosan, poly-(D,
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L-lactide-co-glycolide) (PLGA), and poly(lactic acid) (PLA) as adjuvant or delivery carrier [5]. 
Indeed, polymeric micro- and nanoparticles have been used to develop vaccines against many 
infectious diseases [133], [297]. In fact, the immune response elicited by polymeric particles 
might be influenced by a number of factors, such as the inner structure of particulate carriers, 
use of an adjuvant, surface charge, particle size, and surface hydrophobicity. These parameters 
can also aﬀect diﬀerential uptake by macrophages and dendritic cells, which play an important 
role in generating the immune response [308]. PLGA/PLA polymers have the advantage of 
being well characterized and commercially available for drug delivery systems [309].Among the 
biodegradable microparticles, PLGA microparticles have been proved as a vaccine carrier in ﬁsh 
[310]. 
The growing bacterial infections in various aquaculture systems are gaining much more concern 
nowadays because of increased disease modalities affecting food market, human health and 
ultimately economic value including the added cost of controlling these diseases, recovery and 
wellbeing.  A. hydrophila is a pathogenic gram-negative bacterium associated with lower 
vertebrates like fish, amphibians [28]. Aeromoniasis, an important fish disease is caused by this 
bacterium [29]. A. hydrophila infections in fishes have been reported from time to time in many 
Asian countries including China, Philippines, Thailand, and India [30]. Fish are free-living 
organisms mainly dependent on their innate immune system for survival. Nonspecific immunity 
act as a primary defence mechanism in fish and also, it plays a key role in the development of 
acquired immune response [311]. Like mammals, humoral immunity in fish involves the 
secretion of specific immunoglobulin directed to neutralize antigens and to activate complement 
cascade in response to pathogens [312]. 
The Outer Membrane (OM) of A. hydrophila is a complex structure which mainly consists of 
lipopolysaccharide (LPS), phospholipids and a group of outer membrane proteins (Omps).The 
OM of pathogenic gram-negative bacteria is mainly responsible for establishing initial 
adherence, modulate host-pathogen interaction, overall survival of the organism and propagation 
of virulence factor [35]. It also has protective antigenicity, because OM components are easily 
recognized as foreign substances by immunological defense systems of the hosts. Omps are 
reported to be conserved among different serovars. Some of them serve as adhesins and play an 
important role in virulence [36]. Omps are located at host–bacterial interface in A. hydrophila 
and can be targeted for drug therapy [36]. 
Omps are highly immunogenic due to their exposed epitopes on the cell surface. There are safety 
concerns with the use of oil adjuvant (Freund´s incomplete adjuvant; FIA) in multivalent vaccine 
formulations for fish due to the generation of adverse side effects (e.g., adhesions). Therefore, 
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alternative molecules or certain combinations of them (targeting specific cellular responses) as 
adjuvants are desirable in order to enhance overall immunogenicity and efficacy without 
reducing protection levels [313]. There are only a few reports available on PLA/PLGA NP based 
vaccine formulations with adjuvant like effects and sustained target specific release to generate 
an optimal immune response for which more elaborate and conclusive studies are needed to 
define the protective roles of PLA/PLGA nanoparticulate system. In the present study, 
PLA/PLGA NPs encapsulating Omp antigen from A. hydrophila are compared with adjuvant 
formulations to develop a better antigenic carrier model in fish. The efficacy is also compared 
between PLA encapsulated and PLGA encapsulated OmpNP-immunized groups and a 
correlation is established evaluating the results of innate and adaptive immune response studies 
in L. rohita. 
4.2. Materials and methods 
4.2.1. Materials 
The polymer; polylactic acid (PLA; molecular weight: 85,000- 160,000 Da), poly (D, L-lactic-
co-glycolic) acid (PLGA 50: 50; molecular weight: 40,000-75,000 Da), N-Lauroylsarcosine 
sodium salt, trehalose dihydrate and polyvinyl alcohol (PVA) were procured from Sigma-
Aldrich, USA. Chloroform was purchased from Merck India Pvt. Ltd. Ultrapure water from 
Milli-Q water system (Millipore, USA) was used throughout the study. 
4.2.2. Preparation of OM proteins 
In order to isolate the proteins of the OM of A. hydrophila, the respective strain was grown to 
late exponential phase. Cells were harvested from I L culture (4,500 ×g, 15 min, 4°C), washed 
twice in 10 mM HEPES, pH 7.5, and resuspended in 10 mM HEPES, pH 7.5, with one Sigma 
FAST 
TM 
protease inhibitor cocktail tablet (EDTA free) per 20 gm cell mass. Cells were 
disrupted by ultrasonication for 30 min at 10 watts at an interval of 30 s. Unbroken cells were 
removed by centrifugation (4,000×g, 15 min). The supernatant containing the OM proteins was 
transferred to a new tube and centrifuged again (13,000 ×g, 30 min, 4°C). The pellet was 
resuspended in 0.8 ml 10 mM HEPES, pH 7.5, plus 1% N-Lauroylsarcosine sodium salt and 
incubated for 30 min. After centrifugation (13,000 ×g, 30 min, 4°C), the pellet was washed once 
with 1 ml of 10 mM HEPES, pH 7.5, and resuspended in 50 µl of 10 mM HEPES, pH 7.5. The 
protein concentration was determined by Pierce™ BCA (Bicinchoninic acid) Protein Assay Kit 
(Thermo Scientific). Puriﬁed OM proteins were lyophilized stored at -80°C for further use. 
4.2.3. Preparation of biodegradable and biocompatible based nanoparticles 
NPs containing different antigens were formulated using a double emulsion-solvent evaporation 
technique with little modification [314]. In this method, an aqueous solution of antigen dissolved 
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in 500 µl of citrate buffer (pH=8) was emulsified with 100 mg of PLGA/PLA in chloroform 
solution (3 ml) to get a primary emulsion. Emulsification was carried out by ultrasonicator 
(Sartorius LABSONIC
®
 M) at an amplitude of 5 for 20 seconds in an ice-cooled bath.The 
primary emulsion (w/o) was further emulsified in an aqueous PVA solution (10 ml, 2% w/v) in a 
drop-wise manner and then emulsified with a high-speed homogenizer for 2 min at 10000 rpm. 
The w/o/w double emulsion was added to 80 ml double distilled water and was stirred at 500 
rpm for 2 hours at room temperature to allow the organic solvent evaporation. The NPs were 
recovered by centrifuge at 37,500 g for 45 min and washed thrice with sterile deionized water. 
Then the particles were lyophilized using 2.5% trehalose dihydrate as a cryoprotectant. 
4.2.4. Characterization of nanoparticles 
Particle size, zeta potential and polydispersity index measurements 
The size (Hydrodynamic diameter), size distribution (Poly Dispersity Index) and zeta potential 
(Surface charge) of the NPs were analyzed by Zeta sizer (ZS 90, Malvern Instruments Ltd, 
Malvern, UK). The lyophilized samples were made an appropriate dilution with deionized nano-
pure water and sonicated at an amplitude of 40 and 0.5-sec pulse cycle for 5 min. Aliquots from 
each preparation batch were sampled in dynamic light scattering (DLS) cuvettes and 
nanoparticles were then examined for equivalent diameters, zeta potential and polydispersity 
index. Particles diameters were assessed at a scattering angle of 90° and at a temperature of 
25°C. Then determinations for average mean diameter, zeta potential and polydispersity index 
were measured for each preparation and the standard deviations were calculated.  
Encapsulation efficiency measurement 
The antigen loading in NPs (PLA-Omp and PLGA-Omp) was determined from the total amount 
of antigen added in the formulation and the antigen amount that was not encapsulated. For this, 
the concentration of antigen (Omp protein) in the supernatant was analyzed by Pierce™ BCA 
(Bicinchoninic acid) Protein Assay Kit (Thermo Scientific) to determine free antigen 
concentration (Janes and Alonso, 2003). 
The amount of Omp protein encapsulated in the NPs was calculated by subtracting the free 
protein present in the supernatant from the total protein added during the preparation of the 
nanoparticles using the following formula 
 
In vitro antigen release study 
The rate of antigen released from NPs was measured as a function of time during incubation in 
1X PBS. Triplicate samples of 50 mg of NPs were suspended in 3 mL PBS in a microcentrifuge 
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tube and sonicated at an amplitude of 40 and 0.5-sec pulse cycle for 2 min. The samples were 
then incubated on an orbital shaker (100 rpm) at 37°C. At defined time points, the samples were 
centrifuged. After centrifugation, the supernatant was collected and NPs were reconstituted by 
adding the same volume of fresh PBS. The protein concentration in the supernatant was 
estimated by BCA method as described earlier. The percentage of protein release was plotted 
against time and the cumulative release was calculated. 
SEM Study 
The surface morphology of the NPs was investigated by scanning electron microscopy (Jeol 
6480LV JSM microscope). The NPs were fixed on adequate support and coated with platinum 
using platinum sputter module in a higher vacuum evaporator. Observations under different 
magnifications were performed at 20kv. 
4.2.5. Immunization protocol 
Indian major carp, L. rohita (rohu), juveniles of average weight of 50 ±10 g were acclimatized in 
the wet laboratory 15 days prior to the start of the experiment. They were fed with a standard 
diet in two divided doses daily with constant aeration and daily one-third water exchange (to 
remove the waste feed and faecal matter) with water temperature 27-30
0
C. Fishes were separated 
into 7 groups (20 fishes in each group) and they were intraperitoneally immunized separately 
with 0.1 ml of different preparations @ 50 µg of Omp in PLA NPs (Group 1), 50 µg of Omp in 
PLGA NPs (Group 2), 50 µg of Omp in FIA-Omp (Group 3), 50 µg free native Omp (group 4), 
PLA NP (group 5), PLGA NP (group 6) and only PBS (group 7 as control). All the treated group 
fish (10 fish in each group) were bled at an interval of 3-weeks (at 21 and 42 days post-
immunization) to study various immune parameters. 
4.2.6. Preparation of anti-rohu-globulin rabbit serum 
The rohu immunoglobulin serum was obtained by ammonium sulphate precipitation method. 
Polyclonal antiserum (anti-rohu globulin) to purified rohu immunoglobulin was prepared in a 
one-year-old New Zealand white rabbit using standard immunization protocols [315]. L. rohita 
purified Ig (~200 µg) was emulsified with an equal volume of Freund’s complete adjuvant 
(FCA) and injected into the rabbit intramuscularly, followed by 2 booster doses (with Freund’s 
incomplete adjuvant) at day 14 and 28. After 14 days of the last injection, the rabbit was bled. 
The separated serum was aliquoted and preserved at -20 
0
C for future use. 
4.2.7. Immune responses study 
Bacterial agglutination titre 
Bacterial agglutination titre in the serum of individual fish was determined by plate agglutination 
technique [316]. Briefly, the heat-inactivated sera were diluted two-fold serially in PBS (pH 7.2) 
(with Ca
++
 and Mg
++) in a 96 well ‘U’-shaped microtitre plates. Then 50 µL of formalin-killed A. 
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hydrophila (adjusted to OD 2) was added to each well. The plate was incubated overnight at 25 
0
C. The bacterial agglutination titre was defined as the last dilution of serum showing maximal 
positive agglutinin. 
Haemolysin titre 
Haemolytic activity of unheated serum was determined by two-fold serially diluting with PBS in 
‘U’-shaped microtitre plates (pH 7.2) and using 1% freshly prepared rabbit RBC suspension 
[317]. Haemolysin titre was defined as the last dilution of serum showing maximum positive 
haemolysis. 
ELISA (enzyme-linked immunosorbent assays) 
An indirect ELISA assay was performed using 96 well microtitre polystyrene plates (Nunc, 
Denmark).The wells were separately coated with 50 µl of purified Omp (1 µg/well) diluted in 
carbonate-bicarbonate buffer (pH 9.6) overnight at 4 
0
C. The wells were washed thrice with 
TBST (TBS with 0.05% Tween 20) and blocked with 5% skim milk powder for 2 hr at room 
temperature. After blocking, the wells were further washed in TBST. The fish sera raised against 
various antigenic treatments were two-fold diluted from an initial dilution of 1:10 with TBS (pH 
7.2) and added to antigen-coated wells in duplicate (per each dilution). The plates were 
incubated at 37 
0
C for 1 hr and washed thrice in TBST. Then the adsorbed rabbit antiserum to 
rohu immunoglobulin (1:40,000) was added (1 hr incubation) followed by HRP conjugated anti-
rabbit immunoglobulin antibody (Genei) (1 hr incubation).   The wells were then thoroughly 
washed with TBST and the reaction was visualized after adding 100 µL/well of TMB/H2O2 
(Genei). The reaction was allowed to proceed for 10 min, stopped with 100 µL 1N sulphuric 
acid, and absorbance was read at 450 nm with an automatic plate reader (Imax Microplate 
Reader, Biorad). The antibody activity was expressed in terms of O.D value after subtracting the 
values obtained by unimmunized healthy sera. 
4.2.8. Challenge study 
For challenge study, the virulent strain of A. hydrophila isolate was grown in tryptone soya broth 
at 30 
0
C for 24 h. Two days after the last bleeding, all the fishes (20 fish) from each group were 
injected intraperitoneally with a dose of 7.5× 10
6 
CFU of A. hydrophila per gram body weight of 
fish. A control fish group was injected with 0.1 ml PBS. Mortality in any group was observed 
until 20 days and percent survival was calculated after 20 days post challenge. The cause of 
death and pathological signs were verified by re-isolation of bacteria from samples of from the 
kidney of 10% dead/infected fish as described by Sahoo et al. [318]. 
4.2.9. Statistical analysis 
The results of experimental assays (for each group) were expressed as mean value ± standard 
error (SE).  One-way ANOVA (analysis of variance) followed by Duncan’s multiple range tests 
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(DMRT) was performed using SPSS18 software to compare the variations in various immune 
parameters at a significance level of difference (p < 0.05) in different injected groups. 
 
4.3. Results  
4.3.1. Physico-chemical properties of antigen-loaded nanoparticles 
In this study, Omp loaded in PLA and PLGA NPs were prepared by w/o/w double emulsion 
evaporation technique. The Omp antigen was successfully encapsulated in PLA and PLGA NPs. 
All the physical properties like the size (Hydrodynamic diameter), size distribution (Poly 
Dispersity Index) and zeta potential (Surface charge) have been characterized by DLS analysis 
(Table 4.1). 
Table 4.1. Physical properties of Omp loaded PLA and PLGA nanoparticles. The results were expressed as 
mean± standard deviation. 
Polymer Sample(Code) Mean Particle 
size (Diameter in 
nm ± SD) 
Zeta 
potential 
(mV) ± SD 
Poly Dispersity 
Index (PDI) ± 
SD 
Encapsulation 
efficiency (%) 
 
PLA 
Blank (PLA) 125.23± 23.77 -23.8 ± 5.67 0.350± 0.05 - 
PLA-Omp 223.5± 13.19 -26.5 ± 4.75 0.147±0.06 44 ± 4.58 
 
PLGA 
Blank 
(PLGA) 
98.6 ± 12.11 -25.7 ± 5.01 0.424 ± 0.03 - 
PLGA-Omp 166.4± 21.23 -31.3 ± 6.5 0.308±0.05 59.33± 5.13 
 
The particle size of blank PLA NPs were recorded as 125.23± 23.77nm, whereas PLA 
encapsulated Omp NPs (PLA-Omp) possessed the average size of 223.5± 13.19 nm (Figure 4.1). 
Similarly, the particle size of blank PLGA NPs and PLGA encapsulated Omp NPs (PLGA-Omp) 
were 98.6 ± 12.11 nm and 166.4± 21.23 nm respectively (Figure 4.2). 
Zeta potential otherwise known as the electrokinetic potential at the surface of the colloidal 
particles has a great significance in comparing the stability of colloidal dispersions. The zeta 
potential values of blank PLA NPs and PLA-Omp NPs were -23.8 ± 5.67mV and -26.5 ± 4.75 
mVrespectively (Figure 4.1). Similarly, the zeta potential values of blank PLGA NPs and 
PLGA-Omp NPs were -25.7 ± 5.01mVand -31.3 ± 6.5mV respectively (Figure 4.2). 
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Figure 4.1. Size and charge (zeta potential) distribution pattern of Omp loaded PLA nanoparticles (PLA-
Omp) determined by dynamic light scattering (DLS) method. The average size and zeta potential were 223.5± 
13.19 nm and -26.5 ± 4.75 mV respectively. 
 
Figure 4.2. Size and charge (zeta potential) distribution pattern of Omp loaded PLGA nanoparticles (PLGA-
Omp) determined by dynamic light scattering (DLS) method. The average size and zeta potential were 166.4± 
21.23 nm and -31.3 ± 6.5mV respectively. 
The PDI values of blank PLA NPs and PLA-Omp NPs were 0.350 ± 0.05 and 0.147±0.06 
respectively. Similarly, The PDI values of blank PLGA NPs and PLGA-Omp NPs were 0.424 ± 
0.03and 0.308±0.05 respectively. Hence, the PDI values are within the good range confirming 
the monodispersity nature of the formulated nanoparticles. 
4.3.2. Loading efficiency 
The drug/antigen loading efficiency depends upon the polymer nature, the physical state of the 
antigen/drug and the molecular interactions between the drug and the polymer. Omp 
encapsulation efficiency (%) in PLA NPs was 44 ± 4.58(Mean ±SD), whereas in PLGA NPs it 
was 59.33± 5.13 (Mean ±SD) (Table 1). The encapsulation of Omp in PLGA is significantly 
higher (p < 0.05) than the PLA. 
4.3.3. In vitro drug release 
In-vitro release of Omp was assessed from PLA-Omp and PLGA-Omp NPs into PBS (pH 7.4). 
The release profile of Omp from PLA-Omp and PLGA-OmpNPs is illustrated in Figure 4.3. It 
could be seen that NPs release the Omp protein from PLA considerably slower than from PLGA. 
In the case of PLGA–Omp NPs, 50 % of the antigen was released within 4 hr of incubation 
whereas in the case of PLA-OmpNPs, it took almost 24 hr to release 50% of the total antigen. 
The initial burst release was rapid in PLGA-Omp NPs than that of PLA-Omp NPs. The burst 
release rates were; in PLA-Omp NPs 23% at 1hr, 25% at 2 hr, 28.17% in 3 hr, 35% at 4 hr, 42% 
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in 8 hr, 48% in 12 hr, 52% in 24 hr, 55.67% in 48 hr; in PLGA-Omp NPs 40.67% at 1hr, 43% at 
2 hr, 46 % in 3 hr, 49% at 4 hr, 51% in 8 hr, 55.33% in 12 hr, 59% in 24 hr, 66.33% in 48 hr. 
The rapid burst effect is very much delayed with PLA-Omp NPs. 
 
Figure 4.3. In vitro comparison of Omp antigen release from PLAand PLGA nanoparticles 
 
4.3.4. SEM study 
The morphology of PLA-Omp NPs and PLGA-Omp NPs were analyzed by SEM analysis 
(Figure 4.4). The NPs were spherical in structures as confirmed by scanning electron microscope 
(SEM). The particles were found to be round, uniform and isolated in nature. 
 
 
Figure 4.4. SEM photograph of (a) PLA-Omp nanoparticles (b) PLGA-Omp nanoparticles 
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4.3.5. Immune responses study 
The non-specific immune parameters of fish following the injection with different antigen 
preparations (PLA-Omp NPs, PLGA-Omp NPs, FIA-Omp, Omp, PLA NPs and PLGA NPs, 
control), at 21 and 42 days post-immunization are evaluated. A clear variation in few of the non-
specific immune parameters was observed. For each parameter, the mean value and standard 
error (Mean ± SE) was calculated separately. 
Bacterial agglutination titre 
The effect of different antigenic formulations for generation of specific immune response was 
measured through bacterial agglutination titre on day 21 and 42 of post immunization. The 
results revealed that the titre was significantly higher (p < 0.05) in all treated groups than 
control, PLA blank NPs and PLGA blank NPs (Figure 4.5). The bacterial agglutination titre was 
highest in the case of PLA-Omp NPs treated groups, which is significantly higher than all other 
treatments (FIA-Omp, Omp, PLA NPs and PLGA NPs, control), but the value was not 
significantly different from PLGA-Omp NPs treatment. Also, PLGA-Omp NPs treated groups 
showed significantly higher bacterial agglutination activity than FIA-Omp, Omp, PLA NPs, 
PLGA NPs and PBS treated groups. These parameters did not vary much in all treated groups at 
21 and 42 days post-immunization. 
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Figure 4.5.Variation in the bacterial agglutination activity of sera derived from different treated groups of L. 
rohita at 21 and 42 days post-immunization. Bars represent mean  S.E. Mean value bearing same 
superscript are not statistically significant (p > 0.05) at 21 and 42 days post-immunization. 
 
 
 
 
 
Haemolysin titre 
The haemolysin activity showed similar trend like that of bacterial agglutination titre. The mean 
haemolysin titre was highest in case of PLA-Omp NPs treated groups followed by PLGA-Omp 
NPs, FIA-Omp, Omp, PLGA NPs, PLA NPs, PBS (control) treated groups both at 21 and 42 
days post-immunization (Figure 4.6). The titre were significantly higher (p < 0.05) in all treated 
groups than the control. PLA-Omp NPs and PLGA-Omp NPs treated groups showed significant 
higher haemolytic activity than all other treated groups and were comparable to each other. This 
haemolysin titre did not deviate much in all treated groups at 21 and 42 days post-immunization. 
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Figure 4.6. Variation in haemolysin activity of sera from different treated groups of L. rohita at 21 and 42 
days post-immunization. Bars represent mean log2 titre values ±S.E. Mean value bearing same superscript 
are not statistically significant (p > 0.05) at 21 and 42 days post-immunization. 
 
 
 
Specific immune responses (Specific antibody titre) 
The serum antibody level in different antigen treated sera was measured by indirect ELISA.  The 
antibody level were expressed as mean OD (after subtraction the OD value obtained by 
unimmunized healthy sera) ± SE (Figure 4.7).  The antibody level were significantly higher (p 
<0.05) in PLA-Omp NPs, PLGA-Omp NPs, FIA-Omp treated groups than Omp, PLA NPs and 
PLGA NPs treated groups at 21 and 42 days post-immunization. The antibody level was higher 
in PLA-OMP NPs treated groups than PLGA-OmpNPs, FIA-Omp treated groups, although it 
was not significant. However, no significant difference (p > 0.05) in the antibody level at 21 and 
42 days post-immunization was recorded between these two groups. 
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Figure 4.7.Variation in the specific antibody level of sera collected from different treated groups of L. rohita 
at 21 and 42 days post-immunization. Bars represent mean OD values ±S.E. Mean value bearing same 
superscript are not statistically significant (p > 0.05) at 21 and 42 days post-immunization. 
 
 
4.3.6. Challenge study 
The infected fish injected with A. hydrophila showed typical signs of haemorrhagic septicaemia. 
The mortality reached its plateau after 48 hr of exposure to the bacterium. After 20 days post 
challenge, the percent survival values were calculated and expressed as Mean ± SE (Figure 
4.8).In challenge study, the % survivals were higher in the case of PLA-Omp NPs, PLGA-Omp 
NPs, FIA-Omp treated groups with 80, 75 and 75 respectively. But in case of PLA NPs, PLGA 
NPs, Omp and PBS (control) treated groups, the % survivals were 60, 55, 65 and 45 
respectively. However, % survival value was significantly higher in case PLGA-Omp NPs, 
PLA-Omp NPs, FIA-Omp treated groups in comparison to control (PBS treated) and Omp 
treated groups. 
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Figure 4.8. Challenge study: variation of % survival in different treated groups of L. rohita after 42 days 
post-immunization. Bars represent mean ±S.E. Mean value bearing same superscript are not statistically 
significant (p > 0.05) a 42 days post-immunization. 
4.4. Discussion 
Biodegradable NPs are gaining increased attention for their ability to serve as an excellent 
carrier for site specific delivery of small molecular weight drugs as well as macromolecules such 
as proteins, peptides or genes in the body using various routes of administration [319]. They can 
be easily taken up by the antigen presenting cells (APC) and can modulate body’s immunity to 
generate a protective response [5]. Among various NPs, PLA and PLGA based NPs have been 
used to develop protein and peptide-based nanomedicines, nano-vaccines, and genes for in-vivo 
delivery systems [320]. In the current study, the immunological effects of PLA and PLGA NPs 
as antigen carrier encapsulating Omp of A. hydrophila were investigated. 
The isolated Omp of A. hydrophila was encapsulated in PLA/PLGA NPs and the formulated 
nanospheres were characterized for evaluation of various physiochemical properties and 
comparative analysis of immune response generated to that of other antigenic preparations such 
as FIA-Omp, Omp, PLA NPs, PLGA NPs and PBS (as control).Various parameters; size, 
physical chemical morphological properties, encapsulation efficiency and the release profile of 
antigens are known to play a key function in the designing efficient polymeric nano/ micro 
particle based delivery system through molecular interaction [148].There was an increase in size 
observed for PLA-Omp NPs (from 125.23± 23.77nm to 223.5± 13.19 nm) and PLGA-Omp NPs 
(from 98.6 ± 12.11 nm to166.4± 21.23 nm). Although nanoparticles are considered to be in nano 
dimensions below 100 nm size, but relative increase in size (size >100 nm) is generally observed 
and accepted in the area of drug delivery systems when there is efficient drug loading and 
especially where sufficient amount of  drug may be needed to load onto the particles [57]. As the 
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formulated PLA Omp NPs and PLGA-Omp NPs were < 500 nm size range, these particles could 
be successfully endocytosed in the body [321]. Zeta potential (electro-kinetic potential), is an 
essential property of colloidal particles and plays a major role in the NPs stability [156]. The 
stable nature was confirmed by the zeta potential values of PLA-Omp NPs (-26.5±4.75 mv) and 
PLGA-OmpNPs (-31.3 ± 6.5mv).The polydispersity index (PDI) is a measurement of the 
distribution of NPs and gave a distribution range from 0.000 to 0.500. Polydispersity index more 
than 0.5 values indicates the aggregation of particles (poly disperses) [298]. The PDI value of 
PLA-Omp NPs (0.147±0.06) and PLGA-Omp NPs (0.308±0.05) confirmed the monodispersity 
nature. The spherical, regular and isolated nature of PLA-Omp NPs and PLGA-OmpNPs were 
revealed by SEM analysis. Similar morphology patterns were also observed earlier by Behera et 
al. in the case of PLGA-omp microparticles [322]. 
Encapsulation of protein antigens depends on series of factors like polymer nature, molecular 
interaction between polymers, method of formulations, etc. The amount of drug bound to NP 
depends on the chemical structure of the drug/polymer ratio and the conditions of drug loading 
[159]. Hydrophilic polymers show higher encapsulation than hydrophobic polymer due to 
enhanced molecular interactions between the polymer and the drug [160]. Significantly higher 
encapsulation of Omp protein (p < 0.05) was achieved in the case of PLGA-Omp NPs (59.33± 
5.13 %) than PLA-Omp NPs (44 ± 4.58 %).  
The design of PLA/PLGA based NP delivery system was mainly focused on overcoming some 
limitations like high initial burst, incomplete release and instability of the encapsulated proteins 
[294], [323].  In the current study, the Omp protein release profile in PLA NPs is comparatively 
slower than PLGA, which could be attributed to more hydrophilic nature of PLGA [324]. Also, 
high initial burst release was observed in the case of PLGA-Omp NPs that might be due to the 
diffusion of the protein through water-filled pores (facilitated water uptake from the release 
medium) in the PLGA matrix [324]. Higher protein loading may be another reason for high 
initial burst release by creating a protein concentration gradient between the polymeric particles 
and the release medium [325]. The rapid burst effect is very much delayed (almost took 24 hr to 
release 50% of total antigen) in the case of PLA-Omp NPs, which may be due to higher lactide 
content [324]. 
Both specific and non-specific immune parameters were evaluated in sera of L. rohita 
immunized with seven antigenic formulations (PLGA-Omp NPs, PLA-Omp NPs, FIA-Omp, 
Omp, PLA NPs, PLGA NPs and PBS as control) that elicited immune responses at varying 
levels at both 21 and 42 days post-immunization. PLA/PLGA particles can also act as adjuvant 
[297] and their use in humans and in veterinary medicine has been accepted by the FDA. 
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Antigen-loaded polymeric NPs represent an exciting approach to the enhancement of antigen-
specific humoral and cellular immune responses via selective targeting of the antigen to APCs 
like dendritic cells as well as macrophages [5]. 
The non-specific immune response offers more importance than the specific immune response to 
produce first line defense against all pathogens in fish. Nevertheless, specific immunity requires 
a longer time for antibody to build up and specific cellular activation. Different innate 
parameters such as bacterial agglutination titre, haemolysin titre showed a similar pattern of 
response at 21 days and 42 days post immunization. A significant higher immune response was 
observed in the case of PLA-Omp NPs and PLGA-Omp NPs than all other treatments. There is a 
significant difference in immune response of PLA-Omp NPS and PLGA-Omp NPs when 
compared to control. These results also confirmed that PLA-Omp NPs are better delivery 
systems as compared to all other treated groups, as the immune responses generated by PLA-
Omp NPs were higher despite its lower antigen loading. Many research have already been 
carried out for the evaluation of PLA/PLGA vaccine carrier system and its role in innate immune 
parameters [322], [326]. However, significantly enhanced (p<0.05) immune response generated 
in case of PLA-Omp NPs and PLGA-Omp NPs confirmed the activation of the innate immune 
system. This might be due to the adjuvant property of PLA/PLGA polymer itself as well as 
combined cellular action with NPs. Significantly higher titres in the case of PLGA-Omp NPs 
and PLA-Omp NPs were observed than FIA-Omp treated groups which again confirmed better 
immunogenicity of our formulated NPs. Similar higher immune response (bacterial agglutination 
titre and haemolysin activity) was observed in the case of PLGA-Omp microparticles over FIA-
Omp treated fish [310]. 
The specific antibody response was significantly increased and persisted up to 42 days of post-
immunization by either PLA-Omp/PLGA-Omp NPs or FIA-Omp. But no significant difference 
in antibody titre was observed between PLA-Omp/PLGA-Omp NPs treated groups and FIA-
Omp treated groups. However, comparable antibody response of PLA-Omp NPs and PLGA-
Omp NPs with that of FIA-Omp treated groups suggests that both PLA and PLGA could be a 
complete replacement for Freund’s adjuvants (for stimulating antibody response) to overcome 
many side effects [327] simultaneously offering a long-lasting immunity [310]. Again, enhanced 
antibody level in case of PLA-Omp NPs, PLGA-Omp NPs over respective PLA and PLGA 
blank NPs was achieved confirming the combined immune action PLA/PLGA with Omp protein 
antigen. Similar results were observed by using PLGA as protein/peptide vaccine carrier in fish, 
mice [322], [328]. 
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From the challenge experiments, the survival rates calculated (as % survival) in the case of PLA-
Omp NPs treated groups was 80%, which was significantly higher than all other treated groups. 
PLGA-Omp NPs and FIA-Omp immunized groups have shown same % survival (75±5) which 
was significantly higher than the control group. Hence, the better efficacy of PLA/PLGA-Omp 
NPs as increased protection system against A. hydrophila by activating immune responses was 
confirmed. A similar increase in protection was also observed by Behera and Swain, in the case 
of PLGA-Omp microparticles [322]. Here we have shown that among the nanoparticulate 
system, PLA-omp NPs shows better results than PLGA-Omp NPs. 
4.5. Conclusion 
PLA/PLGA NPs were evaluated for their ability to serve as an excellent carrier for site specific 
delivery of macromolecules such as Omp through parenteral immunization in L. rohita. PLA-
Omp NPs (size: 223.5± 13.19 nm) and PLGA-Omp NPs (size:166.4± 21.23 nm) were prepared 
using double emulsion method in which antigen was efficiently encapsulated reaching 
encapsulation efficiency 44 ± 4.58 % and 59.33± 5.13 % respectively. The physical properties 
like zeta potential values and polydispersity index (PDI) values confirmed the stability as well as 
monodisperse nature of the formulated NPs. The spherical and isolated nature of Omp loaded 
PLA and PLGA NPs were revealed by SEM analysis. Upon immunization in L. rohita, 
PLA/PLGA-Omp NPs showed encouraging results by activating both innate and specific 
immune response against A. hydrophila in fish without any side effects. Significant higher 
bacterial agglutination titre, haemolytic activity and specific antibody titre confirmed the 
combined immune activation. Considering the adverse side effects of oil adjuvant (FIA), the 
current study also proved the comparable antibody response of PLA-Omp NPs and PLGA-Omp 
NPs with that of FIA-Omp treated groups. Therefore, PLA and PLGA may be a replacement for 
Freund’s adjuvants (for stimulating antibody response) to overcome many side effects offering 
long lasting immunity. Again, thebetter efficacy of PLA/PLGA-Omp NPs system was confirmed 
by increased protection against A. hydrophila by activating immune responses by challenge 
study. In comparison to PLGA-Omp NPs, PLA-Omp NPs offered a better immune response in 
terms of higher bacterial agglutination titre, haemolytic activity, specific antibody titre, higher 
percent survival upon A. hydrophila challenge in L. rohita. It can be concluded that PLA/PLGA 
NPs based delivery system would be a novel antigen carrier for parenteral immunization in fish. 
This is probably the first report on the delivery of PLA-Omp and PLGA-Omp NPs against A. 
hydrophila inL. rohita. Hence, more focused research on designing and formulation would be 
attributed to PLA/PLGA NPs based on vaccine delivery system in fish model. 
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Chapter 5 
Evaluation of the immune responses (specific) in 
mice after intraperitoneal immunization of Omp 
antigen (Vibrio cholerae) encapsulated 
PLA/PLGA nano-particles 
 
5.1. Introduction 
The advanced therapeutic approach involves vaccines as effective interventions to control 
infectious diseases that were the leading cause of death in the worldwide [329]. The current 
vaccine research is mostly focused on the development of acquired immunity based on antigen 
specific antibody and cytotoxic T lymphocytes (CTL) response by the inoculation of 
immunogenic (non-pathogenic) components of the pathogen or closely related organisms [1], 
[2]. 
However, the existing issues of vaccine safety such as inadequate immunogenicity, poor 
immunization procedures and failure to acquire booster doses to potentiate prime doses 
necessitate the development of new generation therapeutic vaccine. A safer and attractive 
alternative to live attenuated vaccine, subunit vaccine have several desirable qualities, e.g. they 
(1) can be produced in a highly characterized state, (2) target immune responses towards 
specific microbial epitopes, (3) enable incorporation of unnatural components and (4) can be 
freeze dried, allowing non-refrigerated transport and storage. But, the inadequate ability of 
subunit vaccine to stimulate potent immune responses requires the addition of 
immunostimulatory agents (adjuvants) to ensure long-term protective immunity by serving in 
many ways; to enhance immunogenicity, provide antigen dose sparing, to accelerate a robust 
immune response, reduce the need for booster immunizations, increase the duration of 
protection, or improve efficacy in immunocompromised individuals in human and other live 
stocks [3], [4]. The recent advancement of novel vaccine adjuvant formulations, particulate 
based adjuvants system offers several advantages including: ability to form multimolecular 
aggregates that target antigen-presenting cells (APCs), protection against degradation, sustained 
release of antigen [330]–[332]. Polymer-based delivery systems (natural or synthetic) consisting 
of biodegradable microspheres/nanosphere act as a promising vaccine carrier for their controlled
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target specific delivery [330]. The polymeric carriers such as poly-(D, L-lactide-co-glycolide) 
(PLGA), and poly(lactic acid) (PLA) have been extensively investigated as adjuvants or 
delivery carrier for subunit-based vaccines [5], [333].The efficacy of the immune response 
elicited by particle-based vaccines might be significantly influenced by a number of 
physicochemical characteristics such as structures of particulate carriers [5], [334], particle size 
[169], [331], surface charge [220], hydrophobicity [335], route of administration [336], [337], 
antigen release kinetics [169], [338]etc. By regulating the antigen exposure to the immune 
system (slow and continuous antigen release kinetics), polymer based particles remarkably 
influence in eliciting optimal immune responses [297], [338]. 
Targeted and prolonged antigen delivery to effective antigen presenting cell (APCs) like 
dendritic cells (DCs) is one of the recent vaccine strategies, that have a crucial role in initiating 
adaptive immune response by internalizing antigens through major histocompatibility complex 
(MHC) class I to CD8+ T lymphocytes and MHC II to CD4+ T lymphocytes [5], [339]. These 
types of DCs mediated immune response have been successfully achieved by the use of 
combined association of the antigens with polymeric nanoparticles [340]. The immunization of 
antigen with poly(lactic-co-glycolic acid) (PLGA) nanoparticles displayed enhanced induction 
of  antibody mediated immune response as well as the improved memory T cell response that 
could be attributed to targeted antigen delivery, controlled antigen release and efficient 
induction of dendritic cell (DC) activation and follicular helper T cell differentiation [340]. 
Cholera, a life-threatening secretary diarrheal disease is caused by Vibrio cholerae transmitted 
via the oral fecal routes [341]. It has the ability to cause major outbreaks, particularly in African 
and Asian developing countries with poor sanitation. The Outer Membrane (OM) of V. cholerae 
is a complex structure that consists of mainly lipopolysaccharide (LPS), phospholipids and a 
group of outer membrane proteins (Omps). Apart from major virulent factors (toxin-coregulated 
pilus; TCP and cholera toxin; CT), large number other factors associated with the outer 
membrane (OM), including lipopolysaccharide (LPS), OM porins (OMPs) and flagella are 
mainly responsible for establishing initial adherence, modulate host-pathogen interaction, 
overall survival of the organism and propagation of virulence factor [270]. Immunization with 
Vibrio cholerae outer membrane vesicles induces protective immunity in mice by inducing 
specific, high-titer immune responses of similar levels against a variety of antigens present in 
the OMVs [270]. Omps are highly immunogenic due to their exposed epitopes on the cell 
surface. Virulence-related outer membrane proteins (Omps) are essential to bacterial survival 
within macrophages and for eukaryotic cell invasion that could be an analternative candidate for 
development of subunit vaccine against V. cholerae. 
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Considering the advantages of polymeric nanoparticles as adjuvant and novel delivery systems, 
the current study was carried out to explore the type and strength of immune responses elicited 
by PLA/PLGA nanoparticles encapsulated with OMP of V. cholerae. The formulation of 
antigen-polymeric particles needed to be focused on the generation of optimal immune response 
for which more elaborate and conclusive studies are needed to define the protective roles of the 
nanoparticulate system. Although there are some interesting positive reports available on 
PLA/PLGA NP based vaccine formulations, they still need more extensive investigation in 
terms of formulation, antigen encapsulation, molecular interaction, antigen exposure kinetics 
and resultant antigen-specific immune responses. 
So, we hypothesized that encapsulating OMP antigen in PLA/PLGA nanoparticles would 
increase the antigen persistence in vivo, improve the initial antigen exposure to immune system 
after immunization. The combined action of PLA/PLGA NPs and OMP would result in the 
generation of enhanced and prolonged adjuvant-induced, antigen-specific immune responses. 
Here, an attempt was made to formulate PLA/PLGA-Omp nanoparticles with desired 
physicochemical properties and evaluation of type and strength of immune responses elicited by 
formulated NPs was elucidated by comparing all possible combinations. The efficacy is also 
compared between PLA encapsulated and PLGA encapsulated OmpNP-immunized groups and 
a correlation is established evaluating the results of antigen-specific immune response studies in 
mice. The efficacy is also compared between PLA encapsulated and PLGA encapsulated 
OmpNP immunized groups and a correlation was established evaluating the results of antigen-
specific antibody response and cellular response studies in mice. 
5.2.  Materials and Methods 
5.2.1.Materials 
The polymer; polylactic acid (PLA; molecular weight: 85,000- 160,000 Da), poly (D, L-lactic-
co-glycolic) acid (PLGA 50: 50; molecular weight: 40,000-75,000 Da), N-Lauroylsarcosine 
sodium salt, trehalose dihydrate and polyvinyl alcohol (PVA) were procured from Sigma-
Aldrich, USA. Ethyl acetate was purchased from Merck India Pvt Ltd. Ultrapure water from 
Milli-Q water system (Millipore, USA) was used throughout the study. The medium for 
splenocytes culture was RPMI 1640 (Himedia) with 10% fetal bovine serum (Himedia). All 
ELISA antibodies were obtained from Santa Cruz biotechnology. Fluorochrome conjugated 
anti-mouse antibodies were obtained from Miltenyi Biotec Asia Pacific Pvt Ltd. 
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5.2.2.Preparation of OM proteins 
Preparation of major outer membrane proteins (Omp) 
In order to isolate the proteins in the OM of V. cholerae, the respective strain was grown to late 
exponential phase. Cells were harvested from I L culture (4,500 ×g, 15 min, 4°C), washed twice 
in 10 mM HEPES, pH 7.5, and resuspended in 10 mM HEPES, pH 7.5, with one Sigma FAST 
TM 
protease inhibitor cocktail tablet (EDTA-free) per 20 gm cell mass. Cells were suspended in 
a 10 ml lysis buffer (0.1 M Tris, 10 mM EDTA) and disrupted by ultrasonication for 30 min at 
10 watts an interval of 30s (4
0
C). The cell lysate was treated with DNase (100 μg/ml) and 
RNase (100 μg/ml) for 30 min at 37oC.The debris were removed by centrifugation (4,500×g, 15 
min). The supernatant containing the OM proteins were centrifuged again (100,000 × g, 1 h, 
4°C) (Sorvall Combi, USA). The crude cell pellet was resuspended in 0.8 ml 10 mM HEPES, 
pH 7.5, plus 1% N-Lauroylsarcosine sodium salt for 30 min at 37
o
C. After centrifugation 
(100,000 × g, 1 h, 4°C), the pellet was washed once with 1 ml of 10 mM HEPES, pH 7.5, and 
resuspended in 50 µl of 10 mM HEPES, pH 7.5. The protein concentration was determined by 
Pierce™ BCA (Bicinchoninic acid) Protein Assay Kit (Thermo Scientific). For determination 
of the LPS contamination, total carbohydrates in the purified protein were measured (Westphal 
and Jann, 1965). Puriﬁed OM proteins were lyophilized stored at -80°C for further use. 
5.2.3. Preparation and characterization of PLA-Omp and PLGA-Omp 
nanoparticles 
Preparation of PLA-Omp and PLGA-Omp nanoparticles 
NPs containing different antigens were formulated using a double emulsion-solvent evaporation 
technique with little modification [314]. In this method, 50 mg of antigen dissolved in 500 µl of 
citrate buffer (pH=8) was emulsified with 600 mg of PLGA/PLA in ethyl acetate solution (12 
ml) to get a primary emulsion. Emulsification was carried out by sonication (Sartorius 
LABSONIC
®
 M) at an amplitude of 5 for 20 seconds in an ice bath.The resulting primary 
emulsion (w/o) was further emulsified in an aqueous PVA solution (30 ml, 2% w/v) in a drop-
wise manner and then emulsified with a high-speed homogenizer for 2 min at 10000 rpm. The 
w/o/w double emulsion was added to 80 ml deionized water and was stirred at 500 rpm for 2 
hours at room temperature to allow the organic solvent evaporation. The NPs were recovered 
by centrifuge at 37,500 g for 45 min and washed thrice with sterile deionized water to remove 
residual PVA. Then the particles were lyophilized using 2.5% trehalose dihydrate as a 
cryoprotectant. Blank polymeric (PLA/PLGA) NPs were prepared by using only 500 µl 
deionized water as an internal aqueous phase. 
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5.2.4. Characterization of PLA-Omp and PLGA-Omp nanoparticles 
Particle size, zeta potential and polydispersity index measurements 
The size (Hydrodynamic diameter), size distribution (Poly Dispersity Index) and zeta potential 
(Surface charge) of the NPs were analyzed by Zeta sizer (ZS 90, Malvern Instruments Ltd, 
Malvern, UK). Then determinations for average mean diameter, zeta potential and 
polydispersity index were measured for each preparation and the standard deviations were 
calculated. 
Morphology 
The morphology of the nanoparticles was investigated by field emission scanning electron 
microscopy (FE-SEM; Nova Nano SEM 450/FEI). Observations were taken at different 
magnifications performed at 15 kV. 
Cellular uptake studies 
Cellular uptake of PLA-Omp and PLGA-Omp nanoparticles was observed by fluorescence 
microscopy using a hydrophobic dye; Coumarin 6 preloaded at the time of particle formulation 
step. 
Encapsulation efficiency measurement 
The antigen encapsulation in NPs (PLA-Omp and PLGA-Omp) was determined from the total 
amount of antigen added in the formulation and the antigen amount that was not encapsulated. 
For this, the concentration of Omp antigen in the supernatant was analyzed by Pierce™ BCA 
(Bicinchoninic acid) Protein Assay Kit (Thermo Scientific) to determine free antigen 
concentration. 
 
In vitro antigen release study 
The rate of antigen released from NPs was measured as a function of time during incubation in 
1X phosphate buffered saline (PBS). The samples (50 mg of NPs) were suspended in PBS (3 
ml) and carried out for sonication at an amplitude of 40 and 0.5-sec pulse cycle for 2 min. The 
samples were then incubated on an orbital shaker (100 rpm) at 37°C. At defined time intervals, 
the samples were centrifuged and the supernatant was processed for the estimation of protein 
(BCA method). The pelleted NPs were reconstituted by adding an equal volume of fresh PBS. 
The percentage of protein release was plotted against time and the cumulative release was 
calculated. 
 
Chapter 5                         Evaluation of the immune responses…………encapsulated PLA/PLGA nano-particles 
 
76 
 
FTIR study 
Fourier transformation infrared (FTIR) spectroscopy analysis was conducted to corroborate the 
possibility of interaction between the antigen and the polymer. The attenuated total reflectance 
(ATR)-FTIR spectrum was performed using a Bruker ALPHA spectrophotometer (Ettlinger, 
Germany) with a resolution of 4 cm
−1
and scan between 4000 and 500 cm
−1
 by taking an 
average of 25 scans per sample. The results were analyzed through OPUS software. 
5.2.5. Immunization studies 
Animals 
BALB/c mice were used in all experiments. Mice were housed with food and water ad libitum 
and monitored under full care and in accordance with the standard rules. All animals were 
acclimated for at least 1 week before use. 
Immunization protocol 
Seven-week-old mice were randomly divided into to12 groups (n=6) and intraperitoneally 
immunized at days 0, 14, and 28 with different formulations at the rate of 25 µg antigens in 50 
µl PBS for the initial immunization at day 0 and 0.25 µg antigen in 50 µl PBS at days 14 and 
28.  The formulations are PLA-Omp, PLGA-Omp, PLA, PLGA, Omp, PBS (as control). 
Another same set of combinations are used with alum (Aluminium hydroxide) to compare the 
adjuvanticity of PLA and PLGA nanoparticles. Mice were anesthetized by inhalation of 2.5% 
isoflurane gas prior to all immunizations.  All treated groups were bled at 0, 7, 14, 21, 28, 42 
and 56 days after ist immunization. Sera was separated and stored at -80 
0
C for further analysis. 
Splenocytes were collected at a particular time for flow cytometric assays. 
5.2.6. Determination of Omp specific IgG1 and IgG2a antibodies by ELISA 
Levels of immunoglobulin IgG1, IgG2 isotype antibodies to OMPs were determined by an 
enzyme-linked immunosorbent assay (ELISA) using 96 well microtitre polystyrene plates 
(Nunc, Denmark). The wells were separately coated with 50 µl of purified Omp (1 µg/well) 
diluted in carbonate-bicarbonate buffer (pH 9.6) overnight at 4 
0
C.The wells were washed thrice 
with TBST (TBS with 0.05% Tween 20) and blocked with 5% skim milk powder for 2 hr at 
room temperature. After blocking, the wells were further washed thrice in TBST. After 
washing, appropriate sera were two-fold diluted from an initial dilution of 1:10 with TBS (pH 
7.2) and added to antigen-coated wells in duplicate (per each dilution) and incubated at 37 
0
C 
for 1 hr followed by washing thrice in TBST.  Plates were then incubated with 100 µl HRP 
conjugated goat immunoglobulin antibody against mouse IgG (IgG1 or IgG2a) (Santa Cruz, 
CA, USA) with standardized dilutions for 1 hr. The wells were then thoroughly washed with 
TBST and the reaction was visualized after adding 100 µL/well of TMB/H2O2 (Sigma-Aldrich). 
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The reaction was allowed to proceed for 10 min, stopped with 100 µL 1N sulphuric acid, and 
absorbance was read at 450 nm with an automatic plate reader (Imax Microplate Reader, 
Biorad). The antibody activity was expressed in terms of O.D value after subtracting the values 
obtained by unimmunized healthy sera. 
5.2.7. Spleen cell analysis 
Spleen cell analysis was performed in splenocytes collected from immunized mice after 4 
weeks of 3
rd
 immunization. Cells were harvested according to standard protocol Single-cell 
suspensions of spleen, liver, and lung lymphocytes were generated for in vitro culture and flow 
cytometry by standard techniques, as previously described [342]. Cell viability was assessed by 
exclusion of trypan blue and flow cytometry using a commercially available kit (Live/Dead 
Staining Kit; Invitrogen). Cell surface phenotype was determined using a panel of murine cell 
surface markers,: APC-antiCD11C, FITC- anti CD45RA, PerCP- anti Gr1, PE-anti F4/80,  
Biotin- anti CD49b, Biotin-anti CD3 (Miltenyi Biotec). After washing, multiparameter analyzes 
were performed using a Becton, Dickinson LSR II flow cytometer (San Jose, CA) and analyzed 
using FCS Express software (DeNovo.). 
5.2.8. Determination of memory T-cell responses by flow cytometry 
Flow cytometry was performed to measure the percentage of memory T cells in splenocytes 
collected from immunized mice 10 days after the third immunization. Cells were cultured in 
RPMI 1640 supplemented with 10% fetal bovine serum and restimulated with Omp(50 µg/mL) 
for 60 h. Cells were then stained with the following set of fluorochrome-conjugated anti-mouse 
antibodies: FITC-anti-CD4, PerCP-anti-CD8a, PE-anti-CD44, and APC-anti-CD62L (Miltenyi 
Biotec). After washing, cell samples were examined by Becton, Dickinson LSR II flow 
cytometer (San Jose, CA) and analyzed using FCS Express software (DeNovo.). 
5.2.9. Expression of MHC and Co-stimulatory molecules on dendritic cells in 
spleen 
Balb/c mice (n ¼ 3) were intraperitoneally vaccinated with different vaccine formulations (25 
µg antigens in 100 µL buffer/mouse), and mice were euthanized at 1, 2, and 7 days post-
immunization. Spleen cells were harvested and processed into single cell suspension. Cells 
were stained with a mixture of anti-mouse antibodies (APC-anti-CD11c, FITC-anti-MHC I, PE-
anti-MHC II, and Biotin-anti-CD86; all from Miltenyi Biotec). Expression of MHC I, MHC II, 
and CD86 on CD11c 
+
 DCs was determined by Becton, Dickinson LSR II flow cytometer (San 
Jose, CA) and analyzed using FCS Express software (DeNovo.). 
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5.2.10. Determination of follicular helper CD4
+ 
T cells in spleen 
Balb/c mice (n ¼ 3) were intramuscularly vaccinated with different vaccine formulations (25 
µg antigen/100 µL buffer/ mouse, half dose at each site), and mice were euthanized 9 days after 
immunization. Spleen cells were harvested and processed into single cell suspension. Cells 
were stained with a mixture of anti-mouse antibodies (FITC-anti-CD4, APC-anti-CXCR5, and 
PE-anti-PD-1; all from Miltenyi Biotec). The percentage of follicular helper CD4
+
 T cells 
(CD4
+
CXCR5
hi
PD-1
hi
) was determined by Becton, Dickinson LSR II flow cytometer (San Jose, 
CA) and analyzed using FCS Express software (DeNovo.). 
5.2.11. Statistical Analysis 
All values obtained in the current study were expressed as the mean ± standard error (SE)/ 
Standard deviation (SD).The values were tested for normality (Kolmogorov−Smirnov test). If 
data showed a normal distribution, either student’s t-test or a one-way analysis of variance 
(ANOVA) was used to assess for statistical significance defined as P <0.05. If the data were not 
normally distributed, they were analyzed using a Kruskal–Wallis test with the same 
significance limit either the Kruskal–Wallis test with Dunn's multiple comparison post hoc tests 
or by the Mann–Whitney test using SPSS version 20(SPSS, Surrey UK). 
5.3.Results 
5.3.1. Formulation and Physico-chemical properties of antigen-loaded NPs 
In this study, PLA-Omp, PLGA-Omp, PLA and PLGA NPs were prepared by w/o/w double 
emulsion evaporation technique with successful encapsulation of Omp antigen. All the physical 
properties like the size (Hydrodynamic diameter), size distribution (Poly Dispersity Index) and 
zeta potential (Surface charge) have been characterized by DLS analysis (Table 5.1).The 
particle size of blank PLA NPs were recorded as 116.34± 15.23 nm, whereas PLA encapsulated 
Omp NPs (PLA-Omp) possessed the average size of 196.24± 34.25 nm (Figure5.1). Similarly, 
the particle size of blank PLGA NPs and PLGA encapsulated Omp NPs (PLGA-Omp) were 
107.36± 23.15 nm and 165.34± 3.5 nm respectively (Fig. 2).The zeta potential values of blank 
PLA NPs and PLA-Omp NPs were -21.3 ± 6.75 mV and -25.2 ± 5.45 mVrespectively (Figure 
5.1). Similarly, the zeta potential values of blank PLGA NPs and PLGA-Omp NPs were -25.3 ± 
5.15 mVand -32.5 ± 6.15 mVrespectively (Figure 5.2). The polydispersity index (PDI) values 
of formulated NPs were within the good range confirming the monodispersity nature of the 
formulated NPs. Scanning electron micrographs (SEM) revealed the spherical in structures of 
formulated NPs. The particles were very much isolated and uniformly distributed. 
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Table 5.1. Physical properties of Omp loaded PLA and PLGA nanoparticles. The results were 
expressed as mean± standard deviation. 
 
The antigen content in PLA-Omp and PLGA-Omp nanoparticles varied as antigen loading 
dependent upon the polymer nature, the physical state of the antigen/drug and the molecular 
interactions between the antigen and the polymer. Omp encapsulation efficiency (%) in PLA 
NPs was 57.85 ± 4.15 (Mean ±SD), whereas in PLGA NPs it was 69.18± 1.68 (Mean ±SD) 
(Table 5.1). The antigen encapsulation in PLGA NPs is significantly higher (p < 0.05) than the 
PLA NPs. 
In vitro release profile of Omp from PLA-Omp and PLGA-OmpNPs is illustrated in Figure3 
that revealed the sustained release of Omp antigen from both PLA and PLGA. It could be 
confirmed that the antigen release from PLA–Omp was in a considerably slower than from 
PLGA. In case of PLGA–Omp NPs, 50 % of the antigen was released within 8 hrs of 
incubation whereas in case of PLA-Omp NPs, it took almost 24 hrs to release 50% of the total 
antigen. The initial burst release was rapid in PLGA-Omp NPs in comparison to of PLA-Omp 
NPs. 
 
Polymer Sample(Code) Mean 
Particle 
size 
(Diameter 
in nm ± 
SD) 
Zeta 
potential 
(MV) ± 
SD 
Poly 
Dispersity 
Index 
(PDI) ± 
SD 
Encapsulation 
efficiency (%) 
 
PLA 
Blank (PLA) 116.34± 
15.23  
-21.3 ± 
6.75 
0.350± 
0.05 
- 
PLA-Omp 196.24± 
34.25 
-25.2 ± 
5.45 
0.147±0.06 57.85 ± 4.15 
 
PLGA 
Blank 
(PLGA) 
107.36± 
23.15 
-25.3 ± 
5.15 
0.424 ± 
0.03 
- 
PLGA-Omp 165.34± 
3.5 
-32.5 ± 
6.15 
0.308±0.05 69.18± 1.68 
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Figure 5.1. Physico-chemical properties of antigen-loaded NPs. Size and charge (zeta potential) 
distribution pattern of (A)PLA-OmpNp(size: 196.24± 34.25 nm; zeta potential: -25.2 ± 5.45 mV) and(B) 
PLGA-OmpNp(size: 165.34± 3.5 nm; zeta potential: -32.5 ± 6.15 mV)determined by dynamic light 
scattering (DLS) method.The morphology of PLA-Omp NPs (C) and PGA-Omp NPs (D) were 
investigated by field emission scanning electron microscopy. (E)Comparison of Omp release (in vitro) 
from PLA and PLGA nanoparticles.The burst release rates were; in PLA-Omp NPs 22.07% at 1hr, 
25% at 2 hr, 27.67% in 3 hr, 33.53% at 4 hr, 44.23% in 8 hr, 47.84% in 12 hr, 50.84% in 24 hr, 59.28 % 
in 48 hr; in PLGA-Omp NPs 35.06% at 1hr, 39.67 % at 2 hr, 44.01% in 3 hr, 48.02 % at 4 hr, 51.87 % 
in 8 hr, 54.83% in 12 hr, 58.04% in 24 hr, 64.25% in 48 hr. The rapid burst effect is very much delayed 
with PLA-Omp NPs. (F) Fluorescence microscopy images of HEK cells after 4 h of incubation with the 
coumarin 6-loaded PLA/PLGA-Omp nanoparticles. The coumarin 6-loaded nanoparticles were green 
(×100). a. HEK cells incubated with coumarin 6- PLA-Omp NPs for 12 hours; b. HEK cells incubated 
with coumarin 6- PLA-Omp NPs for 24 hours; c. HEK cells incubated with coumarin 6- PLGA-Omp 
NPs for 12 hours; d. HEK cells incubated with coumarin 6- PLGA-Omp NPs for 24 hours. 
From the FTIR spectrum; it was also observed that upon encapsulation of OMP to PLA and 
PLGA, the characteristic peaks associated with OMP, PLA and PLGA remained intact so 
there was no loss of any functional peaks between the absorbance spectra of OMP and OMP 
encapsulated NPs. Thus, it can be stated that there is no occurrence of molecular interactions 
that could alter the chemical structure of the OMP at the time of study (Figure 5.2). 
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Figure 5.2. ATR-FTIR spectrum of formulated NPs. Similar spectral bands were observed at 2337 cm-1 
(C≡N stretching- presence of nitriles), 1712 cm-1(C=O stretching- presence of carboxylic acid), 1529 
cm-1(N-H bending- presence of Amide-II), 1068 cm-1(C-H stretching- presence of aliphatic amines), 
891 cm-1 (C-H bending) for OMP, blank PLA and PLGA NPs. Apart from common bands observed in 
OMP and blank NPS some additional peaks were also observed in case of encapsulated PLA-OMP and 
PLGA-OMP nanoparticles at 2936 cm-1 (C-H stretching, the presence of alkanes), 1680 cm-1(C=O 
stretching, presence of amide -I). The characteristic peaks of PLA and PLGA were observed at 1710 
cm-1 and 1060 cm-1 that correspond to the presence of the α, β unsaturated esters and carboxylic acids 
and ethers. The common peak at 1064 cm-1 resulted from the overlapping of several bands including 
the absorption due to vibration modes of CH2OH and C-O stretching vibrations coupled to C-O 
bending.  It was also observed that upon encapsulation of OMP to PLA and PLGA the characteristic 
peaks associated with OMP, PLA and PLGA remained intact with no loss of any functional peaks 
between the absorbance spectra of OMP and OMP encapsulated PLA/PLGA NPs.  
5.3.2. Immune response study 
Antigen-specific antibody response in vaccinated mice 
The serum antibody level (IgG1, IgG2a) in different antigen-NP treated sera was measured by 
ELISA. The antibody level were expressed as mean OD (after subtraction the OD value 
obtained by unimmunized healthy sera) ± SE (Figure 5.3). The overall antibody titers (IgG1, 
IgG2a) increased during the vaccination period (from 7 days to 56 days). Antigen-specific 
IgG1, IgG2a titers were above control levels for intraperitoneally immunized mice for all 
groups (7-56 days). Both IgG1 and IgG2 titers in vaccinated mice followed the similar pattern, 
but theIgG1 response is higher than IgG2 response. 
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Figure 5.3. Antibody immune response induced after vaccination of BALB/c mice with different 
antigenic formulations (PLA-Omp, PLGA-Omp, Pmp, PLA, PLGA, PBS) at different time. A and B 
represents serum IgG1 levels in vaccinated mice (n=5/group). C and D representsSerum IgG2a levels in 
vaccinated mice (n=5/group). Data are the mean value (
*
p<0.05) for immunized mice vs control groups. 
All vaccinated mice had comparable Ig titers at all points except 0 days, which were 
significantly higher than those for the control (PBS group) mice (P< 0.05; Kruskal-Wallis test 
and post hoc Dunn multiple comparisons). The antibody level were significantly higher (p < 
0.05) in PLA-Omp NPs, PLGA-Omp NPs treated groups than respective PLA and PLGA NPs 
treated groups from 7 days to 56 days. PLA-Omp NPs and PLGA-Omp NPs induced 
significantly higher (p < 0.05) antigen-specific IgG titers than Omp antigen treated groups at 
all-time intervals except 0 days. In comparison between PLA-omp and PLGA-Omp NPs, the 
later one showed  higher antigen-specific IgG immune response although it is not significantly 
different (p >0.05). Another set of experiment that deals with immune response of all selected 
antigenic groups (PLA-omp, PLGA-Omp, PLA, PLGA, Omp, PBS as control) was performed 
in presence of alum (adjuvant) to compare the advancity of PLA and PLGA with Alum-treated 
groups showed similar pattern of antigen-specific IgG titer like alum untreated groups. Again 
PLA-Omp NPs-alum and PLGA-Omp NPs-alum showed slight higher antibody titer, but not 
significantly different (p >0.05). 
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IgG2a antibody level reveals a Th1 polarized immune response, and the ratio of IgG2a/IgG1 is 
indicative of Th1 biased immune response. Both PLA-Omp and PLGA-Omp NPs induced 
stronger IgG1 and IgG2a responses than Omp antigen (p < 0.05). However, IgG2a responses 
are less robust than IgG1 response. Taken together, PLGA-Omp NPs developed more potent 
antigen-specific antibody with high titers among all antigenic formulations. 
5.3.3. Splenocyte proliferation Assay 
In vitro proliferation of splenocytes was carried out to observe the influence of different 
antigenic formulations on splenocyte proliferation. Both PLA-Omp and PLGA-Omp NPs 
causes more efficient splenocyte proliferation in comparison to Omp antigen alone (p < 0.05), 
which confirmed more potent induction of antigen-specific immune responses. 
5.3.4.Spleen cell analysis 
A detailed analysis of spleen cell population after immunization showed an increase in the 
number of innate immune cells, such as myeloid DC and granulocytes (Figure 5.4). There was 
also an elevation in macrophage cell numbers, B cell, plasmacytoid DC. Interestingly, among 
the cell populations analyzed, the effector cells of the adaptive immune response (B cell) 
showed the highest expansion. Also PLA-Omp, PLGA-Omp NPs induced significantly higher 
cellular expansion than respective PLA and PLGA NPs. Again, a significant higher cellular 
activation was observed in the case of PLA-Omp and PLGA-Omp NPs in comparison to Omp 
antigen alone. However, no such significant difference was observed between PLA-Omp NPS 
and PLGA-Omp NPs except in the granulocyte cell subtypes. 
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Figure 5.4. Mice were injected intraperitoneally with PBS (control), PLA NPs, PLGA NPs, PLA-Omp 
NPs, PLGA-Omp NPs, Omp. Splenocytes were isolated after 0 and 7-day post immunization. Splenocytes 
were stained with various surface markers, as indicated, and analyzed by flow cytometry. The gating 
logic was as follows: plasmacytoid dendritic cells (CD11c+, B220+), myeloid dendritic cells (CD11c+, 
B220−), B cells (CD11c−, B220+), granulocytes (GR-1+, F4/80−), macrophages (GR-1−, F4/80+).  Cell 
numbers were normalized to day 0 values. Data are expressed as the mean ±SEM (n =3). *p < 0.05. 
        
5.3.5.Memory T cell responses 
Generation of Memory T cell response plays a crucial role in the case of successful vaccination 
to combat the reinfection. Memory T cells are major components of the memory immune 
responses. There are 2 important types of memory T cell: effector memory T cells (CD44
hi 
CD62L
low
) and central memory T cells (CD44
hi
CD62L
hi
) [340]. For both CD4
+
 and CD8
+
 T 
cells, the frequency of effector memory T cells and central memory T cells were similar among 
splenocytes harvested from mice immunized with all different antigenic formulations (Figure 
5.5). PLA-Omp and PLGA-Omp NPs induced higher (p < 0.05) percentage of CD44
hi 
CD62L
low 
(effector memory T cells) cells in comparison to Omp as well as control (PBS). Also, 
PLA-OmpNPs and PLGA-Omp NPs induced significantly higher (p < 0.05) response of 
CD44
hi 
CD62L
low 
(effector memory T cells) cells than respective PLA and PLGA NPs. Also, 
the percentage of effector memory cells (CD44
hi 
CD62L
low
) was higher than central memory T 
cells (CD44
hi
CD62L
hi
) in case all immunized groups. The FACS plots of the mean percentages 
were shown in figure X. As a conclusion, both PLA-Omp and PLGA-Omp induced stronger 
effector memory T cell response among all formulation and PLGA-Omp NPs induced 
significantly higher response (p < 0.05). 
Cell types 
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Figure 5.5. Frequency of central (CD44
hi
CD62L
hi
)/effector (CD44
hi
CD62L
low
) memory CD4
+
 and CD8
+
 T cells. Mice (n = 6) were immunized three times 
as described in the methods section. Splenocytes were harvested 10 days after the third immunization and restimulated ex vivo with antigen for 60 h. The 
frequency of CD44
hi
CD62L
hi
 CD4
+
 T cells,CD44
hi
CD62L
low
 CD4
+
 T cells, CD44
hi
CD62L
hi
 CD8
+
 T cells, and CD44
hi
CD62L
low
 CD8
+
 T cells (A) were 
measured by flow cytometry. FACS plots in B and C are representative of the mean percentages of 6 mice in each group. Data in (A) are expressed as the 
mean ±SEM (n =6). *p < 0.05. 
 86 
 
 
 
 
Figure 5.6. The frequency of follicular helper CD4
+
 T cells in the splenocytes of immunized mice. Balb/c mice (n = 3) were intraperitoneally vaccinated 
with different vaccine formulations. Mice were euthanized 9 days later, and splenocytes were isolated. The frequency of follicular helper CD4
+
 T cells 
(CD4+CXCR5hiPD-1hi) was determined by flow cytometry. (A) Percentage of follicular helper CD4
+
 T cells (CD4+CXCR5hiPD-1hi) in CD4+ T cells and 
(B). Representative flow cytometry plots. Data are expressed as themean±SEM (n ¼ 3). *p < 0.05. 
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5.3.6. Expression of MHC and the co-stimulatory molecule CD86 on DCs 
Targeted and prolonged antigen delivery to effective antigen presenting cell (APCs) like 
dendritic cells (DCs) have a crucial role in initiating an adaptive immune response by 
internalizing and presenting antigens through MHC-I to CD8+ T lymphocytes and MHC II 
to CD4+ T lymphocytes. In this case, an attempt was made to find out the mechanism of 
DCs activation in the spleen. So, the expression of MHC I and MHC II costimulatory 
molecules (CD86) on DCs in spleen were measured by flow cytometry. PLA-Omp and 
PLGA-Omp NPs induced significantly higher MHC I, MHC II, CD 86 expression than 
Omp. However, no such significant difference found in the case of alum-NPs formulations. 
Again PLA-Omp and PLGA-Omp showed little bit different behavior towards MHC 
expressions. PLA-Omp NPs elicited significantly higher (p < 0.05) MHC I, MHC II, CD86 
expression than PLGA-Omp. 
5.3.7. Frequency of follicular CD4+ T cells in spleen 
Follicular CD4 T cells are an important part of the generation of long-lived humoral 
immunity mediated by B cells. In this study, the activation of follicular CD4+ T cells by 
different antigenic formulations to favor the antibody production was elucidated (Figure 
5.6). The frequency of follicular CD4 
+
 T helper cells (CD4
+
CXCR5
hi
PD-1
hi
) was measured 
by flow cytometry. The frequency of CD4
+
CXCR5
hi
PD-1
hi
 cells in the splenocytes of PLA-
Omp and PLGA-OmpNP-immunized mice was significantly higher (p < 0.05) than other 
antigenic formulation immunized mice. Also PLA-OmpNPs and PLGA-Omp NPs induced 
significantly higher (p < 0.05) CD4
+
CXCR5
hi
PD-1
hi
 cells than respective PLA and PLGA 
NPs. Also, the percentage of follicular CD4 
+
 T helper cells was significantly higher in case 
the of PLA-Omp and PLGA-OmpNps in comparison to Omp. 
5.4. Discussion 
Disease control or elimination requires the induction of protective immunity in a sufficient 
proportion of the population, which can be accomplished by efficient vaccination. Long-
term immunity, a hallmark of adaptative immunity is conferred by the maintenance of 
antigen-specific immune effectors and/or by the induction of memory cells that may be 
capable of reactivating the immune effectors in the case of pathogen exposure. By playing a 
crucial role in vaccine development, NPs formulation allows improved not only antigen 
stability and adjuvanticity (leads to better immunogenicity) but also specifically targeted 
and sustained release [208]. Novel delivery system and adjuvants that boost 
immunogenicity are very much essential while designing advanced and sophisticated 
Chapter 5                   Evaluation of the immune responses…………encapsulated PLA/PLGA nano-particles 
 
88 
 
vaccines [3]. Polymeric NPs have been increasingly investigated in current vaccine 
research as promising adjuvant and ideal delivery system that could activate both humoral 
and cellular immune response [5], [340], [343]. 
Fabrication procedure and several physicochemical properties such as the type of polymer, 
molecular interaction (polymer-antigen), antigen exposure kinetics significantly affect the 
combination of adjuvanticity of the polymer as well as immunogenicity of the antigen. The 
current study was focused with an aim to elucidate the formulation of polymeric 
(PLA/PLGA)-Omp NPs and to evaluate the immune response (humoral and cellular) in 
terms of antigen processing and generation of a response. The antigen was a conserved 
antigenic outer membrane protein (Omp) from V. cholerae keeping in mind to develop a 
novel subunit vaccine and its better efficacy through polymeric NPs mediated delivery to 
the specific immune system. Our proposed hypothesis was proved by observation of 
successfully enhanced antigen-specific antibody responses and increased generation of 
memory T cell in the PLA/PLGA-Omp NPs immunized mice. 
Although particles of dimension below 100 nm are considered as nanoparticles, still 
relative increase in size (size~ 100-500 nm) can be essential in the area of drug delivery 
system for the efficient drug loading [57], [340]. Also, as the formulated PLA-Omp NPs 
and PLGA-Omp NPs were < 500 nm size range, these particles could be successfully 
endocytosed in the body.The lower size was observed in the case of fabricated PLGA-Omp 
NPs than PLA-Ompnanoparticles, which might be due to use of low molecular weight 
PLGA (50:50; 30-60 KDa). Surface charge density; zeta potential is essential to predict the 
fate of the NPs in vivo and to assess the stability of colloidal system through strong 
electrostatic repulsion of particles with each other [344]. PLA and PLGA being negatively 
charged polymers impacts anionic nature to formulated NPs (PLA, PLA-Omp, PLGA, and 
PLGA-Omp). Also zeta potential values more negative after successful encapsulation of 
Omp in both PLA and PLGA (PLA-Omp NPs: -25.2 ± 5.45 mV; PLGA-Omp NPs: -32.5 ± 
6.15 mV), that proves more stability. Again the formulated NPs were confirmed their 
monodisperse nature as polydispersity index was maintained below 0.5 even after antigen 
encapsulation that prevents particle aggregation [298].Higher antigen loading is one of the 
most desired qualities of successful design of NP-based vaccine delivery that reduces the 
amount of polymers and the loading of drug depends on the chemical structure (both 
polymer and drug) as well as the condition of loading [159]. Significantly higher 
encapsulation of Omp protein (p < 0.05) was achieved in the case of PLGA-Omp NPs 
(69.18± 1.68 %) than PLA-Omp NPs (57.85 ± 4.15%) like our previous studies [333] that 
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might be due to more hydrophilicity of PLGA causing enhanced intermolecular interaction. 
However, the Omp protein release profile in PLA-Omp NPs is comparatively slower than 
PLGA-Omp that could also be attributed to hydrophilic nature of PLGA (diffusion of the 
protein through water-filled pores) and higher antigen loading (create a concentration 
gradient with release medium). Higher lactide content in PLA might be an another cause in 
delaying the rapid burst effect as we observed in the case of PLA-Omp NPs (50% antigen 
release ≈ 24 hr). Surface morphology of the PLA and PLGA nanoparticles loaded with 
Omp were studied using a scanning electron microscope (SEM). The smooth surface can 
also be correlated to lactide content that adds hydrophobicity to the polymer. So, that could 
prevent the retention of water and the shrinkage could be avoided while drying. Also, 
particle-particle contact formation was become less due to the presence of lactide (which 
causes hydrophobic) and ultimately prevents agglomeration [302]. 
From the FTIR spectrum, it was also observed that upon encapsulation of Omp to PLA and 
PLGA the characteristic peaks associated with Omp, PLA and PLGA remained intact so 
there was no loss of any functional peaks between the absorbance spectra of Omp and Omp 
encapsulated nanoparticles. Thus, it can be stated that there is no occurrence of molecular 
interactions that could alter the chemical structure of antigen encapsulation to PLA and 
PLGA nanoparticles[345], [346]. 
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Chapter 6 
Development of DNA vaccines to boost 
antigenic outer membrane protein 
antigenicity 
6.1. Introduction 
Genetic/DNA immunization is a novel technique used to stimulate efficiently humoral and 
cellular immune responses to antigens [25], [202]–[204]. It involves the direct introduction 
into living host of a plasmid containing the DNA sequence encoding the antigen(s) against 
which an immune response is wanted, and relies on the in situ production of the target 
antigen. Ultimately, it results in the specific immune activation of the host against the 
delivered gene (antigen) [347]. This approach (the third vaccine revolution) provides a 
number of potential advantages over other traditional approaches, like generation of both 
humoral and cell-mediated immune responses, improved vaccine stability, the absence of any 
infectious agent and the relative ease of large-scale manufacture with high purity [6], [200], 
[201].The safety, simplicity, versatility, stability, ease of production, nontoxicity, and broad 
of immunity and long-lasting cytotoxic T lymphocyte responses make DNA vaccines very 
attractive for antiviral/antibacterial/anticancer immunization strategies[25], [202]–[204]. 
DNA vaccines are composed of bacterial expression plasmids that normally contain two units: 
the antigen expression unit that includes the promoter, antigen-encoding and polyadenylation 
sequences and the production unit including the bacterial sequences necessary for plasmid 
amplification and selection [348]. After successful construction, the vaccine plasmid is 
transformed into Escherichia coli to produce multiple plasmid copies. The plasmid DNA is 
then purified in large scale from the bacteria, by separating the circular plasmid from genomic 
DNA, RNAs, proteins and other impurities. This purified DNA acts as the vaccine. 
Regarding the clinical application of DNA vaccines, the difficulty for the vaccine to move 
through the cell membranes (after intramuscular administration) must be considered. 
Frequently, only small amounts of vaccine reach the antigen presenting cells (APC) to elicit 
immune responses [210], [349]. Hence, the current focus in molecular therapy has been to 
disclosure the reasons for the lack of potential for DNA vaccines. There is a clear need to 
improve the transfection efficiency in vivo to reduce the vaccination dose of plasmid DNA.
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Novel delivery systems for administration of pDNA vaccines are central to address the above 
discussed necessities [5], [205], [350]. This delivery system should be a modern and 
sophisticated form of an adjuvant with engineered immunological properties. Among possible 
delivery systems, nanoparticles (NP) based delivery of DNA vaccines to APCs, is an 
emerging and promising approach used for optimizing DNA vaccine formulation for 
immunotherapy [5], [350]. The biocompatible nanopolymers such as poly-(D,L-lactide-co-
glycolide)(PLGA) and chitosan are attractive for DNA delivery applications [5], [61], [207], 
[208]. Chitosan NPs hold promise because of their ability to protect encapsulated nucleic 
acid-based antigens from nuclease degradation and promote delivery of adsorbed DNA to 
APCs [209], [210]. In the case of synthetic polymers like PLGA, besides DNA protection, the 
encapsulation permits a controlled DNA delivery system to be designed with controllable 
degradation times and release kinetics of DNA for prolonged gene expression over a required 
time. For example, PLGA undergoes ester hydrolysis in the physiological environment with 
the formation of biocompatible monomers [211]. Nanoparticles based delivery systems for 
plasmid DNA (pDNA) (which encode target gene of interest) administration may be keys to 
improve the transfection efficiency in vivo even at a lower dose. 
A. hydrophila is a pathogenic gram-negative bacterium associated with lower vertebrates like 
fish, amphibians [28]. Aeromoniasis, an important fish disease is caused by this bacterium 
[29]. The Outer Membrane (OM) of A. hydrophila is a complex structure which consists of 
mainly lipopolysaccharide (LPS), phospholipids and a group of outer membrane proteins 
(Omps).The OM of pathogenic gram-negative bacteria is mainly responsible for establishing 
initial adherence, modulate host-pathogen interaction, overall survival of the organism and 
propagation of virulence factor [351]. It also has protective antigenicity, because OM 
components are easily recognized as foreign substances by immunological defense systems of 
the hosts. Omps are reported to be conserved among different serovars and are highly 
immunogenic due to their exposed epitopes on the cell surface. Some of them serve as 
adhesins and play an important role in virulence [351]. Omps are located at host–bacterial 
interface in A. hydrophila and can be targeted for drug therapy. 
The research described herein was undertaken to develop a pDNA vaccine to boost antigenic 
outer membrane protein –(OMP) antigenicity and develop a vaccine candidate for Aeromonas 
hydrophila.The current investigation aimed at developing a DNA vaccine as well as a 
delivery system to boost antigenic outer membrane protein (Omp) that would act as a 
potential vaccine candidate. Nanoparticles based delivery systems for plasmid DNA (pDNA) 
(which encode target gene of interest) administration may be keyed to improve the 
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transfection efficiency in vivo even at a lower dose. Two conserved protein sequences and 
their codon optimized sequences of antigenic outer membrane protein were cloned 
intopVAX-GFP expression vector and successfully transformed intoE. coli (DH5α). The large 
scale pDNA purification with high purity was achieved based on membrane hydrophobic 
interaction chromatography (HIC). The purified plasmid solutions were characterized in terms 
of final quality, physical properties (charge and size) of the pDNA molecule and its ability to 
transfect mammalian cells (CHO; Chinese hamster ovary) cultured in vitro. An attempt was 
made to formulate chitosan/PLGA-pDNA complex and the formulated polyplex were 
characterized in terms of size, size distribution and zeta potential by the dynamic light 
scattering (DLS) method. The effect of physicochemical properties of the polyplex 
nanoparticles on biologic stability, transfection efficiency and cytotoxicity was investigated. 
6.2. Materials & Methods 
6.2.1. Design of gene constructs for pVAX-GFP expression vector 
Design of omp DNA vaccines 
pVAX-GFP expression vector [352] was used for preparing the pVAX-GFP-based comp gene 
constructs. The vector consists of a pUC backbone, the CMV promoter, the BGH terminator, 
and a kanamycin resistance gene. The OMP sequences of all A. hydrophila serotypes were 
collected from NCBI database (GenBank; KF938895, JQ946882, JQ946885) and aligned to 
find out the conserved regions. These regions were analyzed for antigenicity by following 
bioinformatics tool VaxiJen v2.0 antigen prediction server. Among the conserved sequences, 
one was (KF938895211-382) selected on the basis of maximum VaxiJen score (higher 
predictable antigenicity). Another (KF938895703-999) was selected for comparison purposes. 
Two conserved outer membrane protein coding gene sequences [omp(211-382), omp(703-
999)] were successfully designed in preparing the gene constructs in a pVAX-GFP expression 
vector. The pVax-GFP expression vector was used for preparing the pVAX-GFP-based omp 
gene constructs. Start (ATG) and stop codons were added to the two antigen gene sequences. 
A ribosomal binding site (ACC) was added upstream of the start codon. Two restrictions sites 
(KpnI and EcoRI) in the pVAX1 multiple cloning sites were chosen that did not cut within the 
two antigen gene sequences. Those restriction sites were added respectively to the 5’ and 3’ 
end of the sequence and then checked for being in frame with GFP. 
The designed sequences were further optimized for fish in the database using codon 
optimization software (Entelechon; http://www.entelechon.com/bttool/bttool.html) and 
another one optimized sequence was generated. The four designed sequences, omp(211-382), 
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omp(211-382)opt, omp(703-999) and omp703-999)opt, were synthesized (NZYTech, 
Portugal). All four synthesized sequences were cloned into a pVAX-GFP expression vector as 
specified below, leading to plasmids pVAX-GFP-omp(211-382), pVAX-GFP-omp(211-
382)opt, pVAX-GFP-omp(703-999) and pVAX-GFP-omp(703-999)opt, respectively. 
The vectors containing the synthesized omp gene fragments and the pVAX-GFP vector were 
double digested with EcoRI and KpnI (Promega). The purified linearized vector fragment 
(3662bp)and the omp gene sequences were recovered from agarose gel after electrophoresis 
and using the QIAquick Gel Extraction Kit (Qiagen). The ligation of the vector to each 
antigen fragment was set up at a molar ratio of 3:1. The ligations were performed by using T4 
DNA ligase (Promega), following the manufacturer’s procedure. Following the enzymatic 
reaction, each ligation mixture containing the ligated molecules was used to transform 
competent DH5 cells previously prepared by the heat shock method. The transformed cells 
were thereafter plated onto kanamycin (30µg/mL) LB agar plates. The plates were incubated 
overnight at 37°C. Each well-isolated colony collected afterward from each Petri dish was 
inoculated into 5 mL LB broth with L-kanamycin (30 µg/mL). The plasmids from every 5 mL 
overnight cultures were isolated using High Pure Plasmid isolation Kit (Roche) and screened 
for the positive clones by restriction digestion with EcoRI and KpnI (Promega). The selected 
positive clones from gel electrophoresis analysis were further confirmed by sequence analysis 
(STAB Vida, Portugal). Positive clones were further cultured in LB with kanamycin for cell 
banking at -80ºC. 
6.2.2. Plasmid DNA production in E. coli DH5 transformants 
Aliquots from positive E. coli clones harboring omp(211-382), omp(211-382)opt, omp(703-
999) and omp(703-999)opt were withdrawn from the cell banks and inoculated in 5 mL LB 
broth for overnight culture. On the next day, these seed cultures were used for inoculation of 
30 mL of LB medium with 30 mg/mL kanamycin in 100 mL shake ﬂasks which grew 
overnight at 37ºC and 250 rpm. Larger culture volumes (250 mL in 2 L shake flasks) were 
inoculated with the appropriate amount of overnight culture to an optical density at =600 nm 
(OD600)  of 0.2 and incubated under the same conditions for 8 h to harvest the cells in late 
exponential growth phase; an OD600 of 3.2 was recorded at this stage. E. coli DH5α with 
pVAX-GFP was also grown under the same conditions; Cells were harvested in a refrigerated 
centrifuge at 3500g, 4ºC, for 15 min. 
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6.2.3. Plasmid DNA recovery and purification 
Recovery and purification of plasmids were performed by alkaline lysis, followed by 
precipitation/solubilization, membrane hydrophobic interaction chromatography (HIC) and 
final polishing steps, as described elsewhere [353].The harvested cells in the pellet were 
resuspended in 8 mL P1 solution (50 mM glucose, 25 mMTris-HCl, pH 8.0, 10 mM EDTA). 
After complete resuspension, the total volume was transferred to smaller centrifuge tubes. 
Then, 8 mL P2 solutions (0.2N NaOH, 1% (w/v) SDS) were added to perform alkaline lysis 
followed by gentle homogenization. The tubes were incubated at room temperature for 10 
min. After incubation, 8 mL P3 solution (5M potassium acetate, 6.8M glacial acetic acid) was 
added to stop lysis followed by gentle homogenization and the mixture was placed on ice for 
10 min. The neutralized alkaline lysate was centrifuged at 20,200×g for 30 min at 4ºC to 
remove cell debris and part of genomic DNA and proteins. The supernatant was placed in new 
tubes and again centrifuged to remove more debris. The resulting pDNA-containing lysate 
was stored at 20 ºC until further processing. 
To each defrosted pDNA-containing lysate (≈24 mL with pH 5.0) 16.8 mL of isopropanol 
(100% v/v) were added and carefully mixed. The tubes were left at 4ºC for at least 2 h to 
precipitate all nucleic acids (pDNA, RNA and traces of gDNA). The above mixture was 
centrifuged at 20,200×g and 4ºC for 30 min and the supernatant was discharged. The pellet 
was washed with 2 mL of ethanol 70% (v/v) and centrifuged again with the same procedures 
as before. The supernatant was discharged and the tubes were inverted on top of the absorbent 
paper to remove traces of ethanol. The final pellet containing pDNA was resuspended in 6mL 
of Tris-HCl (10 mM, pH 8.0) containing 1.52 g ammonium sulphate. The mixture was 
homogenized properly and left on ice for 2 h. Then the mixture was centrifuged at 
20,200×gand 4ºC for 30 min and the supernatant (≈6 mL) was used for further purification. 
A membrane adsorberSartobind® Phenyl Nano unit (3mL bed volume; Sartorius AG) was 
connected to a Äkta™ Purifier 10 FPLC system from GE Healthcare (Sweden), which 
continuously monitored the conductivity and UV absorbance at 260 nm.  Previously to the 
chromatographic runs the membrane adsorber was washed with 20% ethanol, and then with 
MilliQ H2O and then equilibrated with a binding buffer (BB) 1.8 M ammonium sulphate in 
10 mMTris-HCl, pH 8.0. Runs were performed at a constant flow rate of 1 mL/min.A volume 
of 5 mL of a preliminarily purified pVax1-GFP solution(>200ng/μL), obtained as described 
above, was injected into the membrane adsorber at 1 mL.min
-1
 and allowed to flow through 
for 15 min, leading to the clearance of unbound solutes. Then a 20 mL long (20 min) gradient 
Chapter 6                   Development of DNA vaccines to boost antigenic outer membrane protein antigenicity 
 
95 
 
from 0 to 40 % EB (elution buffer; 10 mMTris-HCl, pH 8.0) was applied followed by a step 
change in conductivity from 40 % to 100 % EB that also runs through for 20 mL. Membrane 
chromatography was therefore used to elute the plasmid isoforms selectively.Fractions of 0.5 
mL taken from the supercoiled-rich pDNA elution peak were collected and pooled (2 mL), 
analyzed by horizontal agarose gel electrophoresis (AGE) to confirm purity  and  then kept at 
20ºC for further use. Electrophoreses were run in  15 cm 1% (w/v) agarose gels at 90 V for 2 
h with TAE buffer (40mM Tris base, 20mM acetic acid and1mM EDTA, pH 8.0), and stained 
with ethidium bromide(0.5 g/mL). 
Pooled HIC fractions were concentrated to a final volume of 0.3 mL and desalted during 
centrifugation in a swing bucket rotor for 5min at  3,200×g and 4ºC in a 2 mL Amicon® Ultra 
centrifugal filters (Millipore, Ireland) bearing a 50 kDaUltracel® cellulose membrane. The 
diafiltration was performed stepwise by adding 10mM Tris-HCl pH 8.0 in 5 diafiltration 
volumes (V≈1.5mL) followed by centrifugation using the same settings as before [354]. 
Recovery of concentrated pVax1-GFP-derived plasmids was achieved by turning the 
respective Amicon upside down and centrifuging it again under the same conditions. 
The final plasmid DNA concentration in purified solution was assessed from 3L samples by 
spectrophotometry on a NanoVuePlus equipment (General Electric Healthcare, UK), after 
equilibration with 3μL of MiliQ H2O. AGE was performed to confirm the quality of purified 
pDNA, although the overall purification and polishing have been demonstrated to permit 
efficient CHO cells transfection [354]. 
6.2.4. In vitro culture and transfection of CHO cells 
In vitro expansion of CHO cells was performed by inoculating at a concentration of 1.5x10
6
 
cells/mL in a T-75 culture flask with 10 mL of Dulbecco´s Modified Eagle Medium (GIBCO) 
supplemented with 10% Fetal Bovine Serum (FBS from GIBCO, heat inactivated) and 1% 
penicillin and streptomycin (PenStrep from GIBCO) [355].CHO cells were seeded 24 h prior 
to transfection into a 24-well tissue culture plate at a density of ≈10 5 cells/mL, to obtain a 
confluence of 70-80% on the day of transfection (within 24 h). At the time of transfection, the 
cells were washed with 500 μL of PBS to remove dead cells and toxins. One microgram of 
pVAX-GFP, pVAX-GFP-omp(211-382), pVAX-GFP-omp(211-382)opt, pVAX-GFP-
omp(703-999) and pVAX-GFP-omp(703-999)opt, was complexed with 1.5μL Lipofectamine 
2000 (self-assembling) and added to each well. DMEM without FBS and antibiotics was 
added to a final volume of 500μL and incubated with the cells for a certain period of time (3 h 
and 6 h). After incubation, the medium was changed, the cells were washed with PBS, and 
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500 μL of the complete medium (DMEM supplemented with 10% FBS and 1% PenStrep) 
were added to each well. The transfection experiments were performed in duplicate. Cells 
incubated without pDNA lipoplexes or pDNA biopolymer NP were used as negative control. 
Cells transfected with Lipofectamine 2000™/pVAX-GFP DNA complexes were used as 
positive controls of the transfection. The transfection efficiency was evaluated using flow 
cytometry analysis after 24h or 48h of transgene expression. 
6.2.5. Flow cytometry analysis  
After 24 h or 48 h of transgene expression, the cells were washed with 500 μL PBS and 
trypsinized for 5 min at 37ºC. Afterward, complete medium was added to stop the action of 
trypsin, the cell suspension poured into Falcon tubes and the cells were centrifuged in a 
conventional bench top centrifuge (5 min, 1,500×g, room temperature). Then, the supernatant 
was discarded and the cell pellet carefully washed with a small amount of PBS, to remove any 
traces of trypsin, and resuspended in 500 μL2% paraformaldehyde (PFA; freshly prepared). A 
FACScan Scalibur flow cytometer (Becton-Dickinson, NJ, USA) recorded the forward scatter 
(FSC), side scatter (SSC) and green fluorescence (FL1) while running each sample of 
transfected CHO cells. Green fluorescence intensity, corresponding to GFP expression level, 
FSC and SSC data were analyzed and histograms and dot plots were generated with CellQuest 
Pro Software © (Becton Dickinson, NJ, USA). The data were expressed as a mean ± standard 
deviation. 
6.2.6. Chi/PLGA-pDNA Complex 
PLGA NPs were formulated using a double emulsion-solvent evaporation technique. The 
organic phase was prepared by dissolving 200 mg PLGA in 10 ml ethyl acetate (at 25 
0
C) 
with constant stirring at 400 rpm (2hr). An aqueous phase was made by dissolving PVA (100 
mg) in 10 ml water (with 0.1 mM ethyl acetate water) at 75◦C for 5 min, under stirring. After 
cooling 30 mg chitosan chloride was added to the PVA solution, and the mixture was stirred 
for 30 min at 1000 rpm. The solution was allowed to degas at room temperature until clear. 
2.5 ml of the organic phase was emulsified with 10 ml aqueous phase under stirring at 14,000 
rpm using high-speed homogenizer. Then, the emulsion sonicated for 10 min at 40% 
amplitude, 2 seconds on and 2 seconds off using ultrasonicator (Sartorius LABSONIC
®
 M) in 
an ice bath. The emulsion was stirred at 500 rpm for 2 hours at room temperature to allow the 
organic solvent evaporation. The NPs were recovered by centrifuge at 37,500 g for 45 min 
and washed thrice with sterile deionized water. The sample was purified by dialysis, using 
100,000 MWCO, 1.8 ml/cm dialysis membrane (HIMEDIA, India), against distilled water. 
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Dialysis was run for 8 hours, changing the water every 2 hours. The particle solution was 
recovered from inside the tube and place added with 2.5% trehalose dihydrate as 
cryoprotectant prior to freeze-drying. For Chi/PLGA-pDNA Complex Formation, 0.5 mg of 
dried NPs was 0.5 ml of deionized water. The solution was vortexed for 15 minutes at 1000 
rpm. NPs and pDNA were combined in Millipore water, vortexed for 30 seconds, and allowed 
to complex at pDNA/NP ratios of 1:50 by weight at room temperature undisturbed for 1 hour. 
6.2.7. Particle Size, Size Distribution, and Zeta Potential 
The size (Hydrodynamic diameter), size distribution (Poly Dispersity Index) and zeta 
potential (Surface charge) of the pDNA-NP complexes were analyzed by Zeta sizer (ZS 90, 
Malvern Instruments Ltd, Malvern, UK). The lyophilized samples were made an appropriate 
dilution with deionized nano-pure water and sonicated at an amplitude of 40 and 0.5-sec pulse 
cycle for 5 min. Aliquots from each preparation batch were sampled in dynamic light 
scattering (DLS) cuvettes and nanoparticles were then examined for equivalent diameters, 
zeta potential and polydispersity index. Particles diameters were assessed at a scattering angle 
of 90° and at a temperature of 25°C. Then determinations for average mean diameter, zeta 
potential and polydispersity index were measured for each preparation and the standard 
deviations were calculated. 
6.2.8. DNA Entrapment 
To each sample, 25 µl of OliGreen (OG) fluorescent nucleic acid stain (1X) was added to 
complexes containing a total of 4 ng of pDNA and incubated at room temperature in a dark 
for 5 minutes. After incubation, the total volume was raised to 500 µl using Millipore water. 
The relative fluorescence was determined using 490 nm excitation and 520 nm emission 
wavelengths in a Luminescence Spectrophotometer. 
6.2.9. Enzymatic Digestion Assays 
DNase I (1U) (HIMEDIA) was added to free pDNA and pDNA-NP complexes (1: 50 
pDNA/NP) in the supplied DNase buffer, followed by incubation for 10 minutes at 37◦C. 
Plasmid digestion was analyzed via 1% agarose gel electrophoresis as described above. 
6.2.10. SEM Study 
The surface morphology of the pDNA-NP complexes was investigated by scanning electron 
microscopy (Jeol 6480LV JSM microscope). The NPs were fixed on adequate support and 
coated with platinum using platinum sputter module in a higher vacuum evaporator. 
Observations under different magnifications were performed at 20kv. 
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6.2.11. Data analysis 
The results of experimental assays (for each group) were expressed as mean value ± standard 
deviation (SD)/ standard error. One-way ANOVA (analysis of variance) followed by 
Duncan’s multiple range tests (DMRT) was performed using SPSS18 software. For all tests, P 
< 0.05 was considered statistically significant. 
6.3. Results 
6.3.1. Design of omp gene constructs in pVAX-GFP expression vector 
 The successful design of the selected constructs; omp(211-382), omp(703-999) was 
performed as mentioned in figure 1.The designed sequences were further optimized in the 
database using codon optimization software (http://www.entelechon.com/bttool/bttool.html) 
and another  two sequences; omp(211-382)opt, and omp(703-999)opt were generated (and 
from now on designated “opt”). The designed optimized sequences were aligned with 
respective nonoptimized sequences (omp(211-382), omp(703-999)) to observe the nucleotide 
differences (Figure 6.1). 
 
Figure 6.1. Alignment of designed pVAX-GFP-omp(211-382) and pVAX-GFP-omp(703-999)  sequence 
with their respective optimized sequences [pVAX-GFP-omp(211-382)opt and pVAX-GFP-omp(703-
999)opt showing the nucleotide differences. 
Chapter 6                   Development of DNA vaccines to boost antigenic outer membrane protein antigenicity 
 
99 
 
Both the 2 designed sequences were crosschecked for restriction sites after inserting into 
pVAX-GFP plasmid sequence map. All above bioinformatics work was carried with the help 
of ApE (A Plasmid Editor software). All four designed sequences were synthesized 
(NZYTech, Portugal). 
6.3.2. Cloning 
In order to construct the corrected vectors pVAX-GFP and Omp insert were double digested 
with KpnI and EcoRI in order to create compatible cohesive ends in both structures. Due to 
the difference of activity of restriction enzymes, digestion conditions had to be optimized 
throughout a series of cloning experiments. Finally, the digestion procedures were 
accomplished by sequential digestion with KpnI at 37
o
C for 2hr followed by EcoRI at 37
o
C 
for 2hr. 
Following restriction digestions, the base vectors were purified by 1% agarose gel. The 
agarose extracts containing the linearized vectors were subsequently purified with the Qiagen 
Gel Extraction Kit (Qiagen). The successful ligation of gel-purified pVAX-GFP vector to 
desired antigenic insert was done by using T4 DNA ligase (Promega), at 3:1 molar ratios 
(Insert:Vector) for 3h at room temperature followed by an overnight period at 4
o
C. On the 
other hand, lower temperatures are responsible for bringing the DNA molecules together (due 
to lower mobility of molecules). The two temp methods used are therefore a balance between 
contradicting ideal temperatures. Too low temperatures would affect DNA ligase activity 
while too high temperatures would affect the cloning efficiency by melting the annealed DNA 
ends and by increasing molecular movement in the reaction [356], so room temperature 
incubation (25
0
C) followed by an overnight incubation at 4 
0
C would favor the reaction. Both 
ligation mixtures and negative controls were transformed by heat shock into E. coli DH5 α 
competent cells and plated in kanamycin-supplemented LB agar plates. The selected plasmids 
were isolated using High Pure Plasmid Isolation Kit (Roche) and screened for the positive 
clones by restriction digestion with EcoRI and KpnI by comparing compare the fragment 
sizes in 1% agarose gel (Figure 6.2). 
6.3.3. Sequence analysis 
All the positive clones (confirmed from gel photographs) were processed for sequencing. The 
obtained sequences were aligned with original sequences to observe the sequence similarity. 
From the sequence analysis, the successful cloning of omp(211-382), omp(211-382) opt, 
omp(703-999) and omp(703-999)opt sequences were confirmed. 
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Figure 6.2. Screening of positive clones based on pVAX-GFP for pVAX-GFP-omp(211-382) (a), pVAX-
GFP-omp(211-382)opt (b), pVAX-GFP-omp(703-999) (c), pVAX-GFP-omp(703-999)opt (d). Lanes 1: DNA 
ladder (200 bp-10,000bp) and other lanes; 2-5 (a), 2-7 (b), 2-7 (c), 2-7 (d): RE digestion (Eco R1 and Kpn 
1) of corresponding cloned plasmids. 
6.3.4. Plasmid DNA production and its up-scaled purification by 
hydrophobic interaction chromatography (HIC) 
The up-scaled production of plasmids was performed by culturing the four strains in larger 
culture volumes (250 mL in 2 ltr flask) for 8 h (OD600~3.2), harvesting the cells in late 
exponential growth phase. For the in vitro assays, the chosen pDNA purification approach 
was the hydrophobic interaction chromatography that correlated with more stable lipoplexes, 
higher plasmid transfection and GFP expression [353], [354]. Separation was accomplished in 
bind and elute mode using an optimized stepwise elution profile [354]. Plasmid-containing 
samples pre-conditioned with 1.8 M ammonium sulfate were injected at 1 mL/min in a 3 mL 
bed volume pre-equilibrated with 1.8 M ammonium sulfate in 10 mM Tris–HCl pH 8.0. The 
weakly retained molecules were washed with the equilibration buffer and the ionic strength 
was decreased stepwise by changing gradually to 10 mM Tris–HCl pH 8.0 in order to elute 
the bound impurities. Chromatography is performed using 1.8 M ammonium sulfate in10 mM 
Tris at pH 8 as running buffer (conductivity≈205 mS/cm) that promotes the hydrophobic 
interaction of the solutes present (pDNA, RNA, gDNA, and endotoxins) with the phenyl 
matrix. Relevant chromatographic fractions, for both flow through and eluted peaks, were 
analyzed by horizontal gel electrophoresis using 15 cm, 1% agarose gels run at 90 V for 2 h 
with TAE buffer (Figure 6.3). 
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Figure 6.3. Chromatogram and Gel photograph of sample pulls at the different peak in the chromatogram 
(a. pVAX-GFP-omp(211-382), b. pVAX-GFP-omp(211-382)opt, c. pVAX-GFP-omp(703-999), d. pVAX-
GFP-omp(703-999)opt.  M-Molecular weight marker, F- feed, FT- (A3-A4), PS1- (A9-A12), PP- (B3-B7), 
PS2- (B12-C6), PI- (C7-C10). 
The pure pDNA fractions collected from the eluted peaks were concentrated. The diafiltration 
step was performed by adding 10mM Tris-HCl pH 8.0 in 5 times the volume present in the 
Amicon (V≈1.5mL) followed by a centrifugation step using the same settings as before [354]. 
After purification, the final plasmid DNA concentration was measured on nanodrop (Thermo 
Fisher) and analyzed for purity by agarose electrophoresis. The quality parameters of the 
pDNA pool obtained (at 1 mL/min flow rate) are comparable with those reported by Pereira et 
al., 2014 for an identical system[354]. The final concentrated pDNA content were 407 ng/µL, 
574 ng/µl, 417.5 ng/µl and 375 ng/µl for omp(211-382), omp(211-382)opt, omp(703-999) and 
omp(703-999)opt respectively. 
6.3.5. In vitro Assays 
Transfection Efficiency 
The biological activity of purified plasmid fractions was evaluated by preparing lipoplexes by 
complexation with the cationic liposome-based reagent (Lipofectamine) and used to transfect 
CHO cells cultured in vitro. Higher percentages of transfected CHO cells were from the 
enhanced expression of GFP in the cell nucleus [355]. 
Positively charged liposome/DNA complexes (lipoplexes), formulated with the reagent 
Lipofectamine 2000TM, have been widely used as a safe transfection methodology. In vitro 
transfection assays have demonstrated to be improved by the use of cationic liposomes, due to 
its protective role of pDNA [357], [358] against nuclease attack, also enhancing cellular 
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uptake via endocytosis [355]. The outcome of the transfection was evaluated on the basis of 
two parameters: (i) the percentage of cells transfected and (ii) the mean intensity of individual 
cell fluorescence. After flow cytometry analysis, the mean value for % gated CHO cells  (% 
Transfection) and fluorescence MI (Mean Intensity) of positive control (pVAX-GFP), pVAX-
GFP-omp(211-382), pVAX-GFP-omp(211-382)opt, pVAX-GFP-omp(703-999) and pVAX-
GFP-omp(703-999)opt were calculated, after subtraction of respective negative control (only 
non-transfected CHO cells) values (Table 6.1). 
 
Table 6.1. Transfection study results (% Transfection, Mean Intensity and %T × MI values of positive 
control (pVAX-GFP), pVAX-GFP-omp(211-382), pVAX-GFP-omp(211-382)opt, pVAX-GFP-omp(703-
999) and pVAX-GFP-omp(703-999)opt transfected CHO cells) after 24 h and 48 h incubation 
 
After 24 h incubation, transfection efficiency was highest for pVAX-GFP-omp(211-382) (%T 
× MI: 3259.025 ± 816.242) among all the designed plasmids. After 48 h incubation, the 
transfection efficiency was increased only for pVAX-GFP-omp(211-382)  (%T × MI: 
19292.97 ± 1098.182) (Figure 4). In other cases, overall transfection efficiency decreased due 
to a decrease in mean intensity (although there is a slight increase in %T), meaning that there 
was less amount of expressed green fluorescent protein in the cells at 48 h post-transfection, 
although there was a higher percentage of the cell with expressed protein. Cells lose faster the 
ability to express the protein coded by the plasmid, except for pVAX-GFP-omp(211-382). 
Sample Incubation 
Time 
% Gated 
(% T) 
MI 
(Mean 
Intensity) 
%T× MI 
 
Positive control 
24 hr 11.39±.092 101.855 ± 5.190 1160.128 ± 49.753 
48 hr 11.17 ± 0.827 70.9 ± 11.816 791.953 ± 73.325 
 
Omp1 nonopt-
pVAX-GFP 
24 hr 17.655±2.022 184.595 ± 25.088 3259.025 ± 816.242 
48 hr 44.46 ± 0.290 433.94 ± 21.871 19292.97 ± 1098.182 
 
Omp1 opt-pVAX-
GFP 
24 hr 12.09±0.290 93.695 ± 19.322 1132.773 ± 260.891 
48 hr 15.03 ± 4.363 59.91 ± 3.415 900.447 ± 312.182 
Omp2 nonopt-
pVAX-GFP 
24 hr 10.357± 1.213 82.11± 28.235 850.413 ±392.059 
48 hr 15.04 ± 1.365 33.43 ± 3.076 502.787 ± 0.639 
Omp2 opt-pVAX-
GFP 
24 hr 20.125± 0.410 131.47 ± 23.568 2645.834 ± 528.222 
48 hr 7.945 ± 0.792 31.27 ± 7.347 248.440 ± 33.606 
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Figure 6.4. Transfection efficiency (%T×MI) of positive control (pVAX-GFP), pVAX-GFP-omp(211-382), 
pVAX-GFP-omp(211-382)opt, pVAX-GFP-omp(703-999) and pVAX-GFP-omp(703-999)opt transfected 
CHO cells after 24 hr and 48 hr of incubation. 
The results obtained for pVAX-GFP-omp(211-382) was again verified by a separate 
experiment, where in vitro transfection was carried out with pVAX-GFP-omp(211-382), 
pVAX-GFP-omp(211-382)opt and pVAX-GFP (as control) and transfected cells were 
incubated for 24 hr, 48 hr, 3day, 6 day, 8 days (table 2). In both the case [(pVAX-GFP-
omp(211-382), pVAX-GFP-omp(211-382)opt], the transfection efficiency was increased up 
to 24h incubation.  Subsequently, the transfection efficiency was decreased from 1 day to 8
th
 
day incubation. From the current experiment, it can be concluded that optimum incubation 
time for transfection is 24 hr (1 day). Therefore, the behavior of transfect pDNA constructs 
harboring all four gene constructs were tested for GFP expression, in order to achieve a 
quantitative understanding of the effect of such sequences in intracellular trafficking and 
protein expression. The difference in the transfection relies upon the gene expression and the 
efficient gene expression dependent on several factors, such as plasmid uptake, degradation 
rate of plasmid copies inside the cell, efficient delivery to the nucleus through successful 
intracellular trafficking and, finally, transcription and translation efficiencies. The ultimate 
goal of transfection is gene expression. Efficient gene expression, one of the setbacks of non-
viral vectors, is dependent on several factors, such as plasmid uptake, the degradation rate of 
plasmid copies inside the cell, plasmid access to the nucleus through successful intracellular 
trafficking and, finally, transcription and translation efficiencies. In the context of DNA 
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vaccination, one of the principal setbacks is the efficient delivery of pDNA to cell nucleus 
[359]. The analysis of GFP-positive cells, compared with control non-transfected cells 
exposed to the same amount of lipofectamine, confirmed the expected results regarding the 
most efficient plasmid uptake. Plasmid size is an important role in transfection, as in the 
number of cells presenting fluorescence, and plasmid copy number [357]. Significant smaller 
sizes are correlated with higher transfection efficiencies [357], [360]. The significant higher 
(p≤0.05) expression in pVAX-GFP-omp(211-382) might be due to the smaller antigenic 
insert. Regarding the percentage of transfection, the value was low for the positive control 
where pDNA is complexed with the transfection reagent Lipofectamine 2000. This is an 
established complex with transfection normally higher than 30% when GFP is used as a 
reporter gene [361].  The results obtained are probably related with the 100% cell confluency 
used for control assay. Too many cells might  result in contact inhibition, making cells 
resistant to the uptake of foreign DNA or due to pH variation as the ideal pH for CHO cell 
culture varies between 6.8 and 7.4 [362]. 
Table 6.2. Transfection study results (% Transfection, Mean Intensity & %T × MI values of   pVAX-
GFP-omp(211-382), pVAX-GFP-omp(211-382)opt transfected CHO cells) after 1day, 2day, 3 day, 6 day, 8 
day incubation. 
 pVAX-GFP-omp(211-382) pVAX-GFP-omp(211-382)opt 
 %Transfection 
(%T) 
Mean 
Intensity 
(MI) 
%T×MI %Transfection 
(%T) 
Mean 
Intensity 
(MI) 
%T×MI 
1 
day 
21.275± 0.417 251.725± 40.432 5363.88± 965.216 13.465± 1.675 96.462± 5.957 1293.876± 81.439 
2 
day 
22.78± 0.226 184.205± 21.913 4193.711± 457.503 15.8± 0.735 74.325± 8.690 1171.14± 82.649 
3 
day 
20.62± 4.652 113.915± 33.396 2271.234± 158.619 9.88± 1.824 77.095± 5.635 766.839± 196.327 
6 
day 
17.082± 0.866 71.95± 12.077 1234.317± 268.635 4.56± 0.233 21.32± 6.590 97.988± 35.026 
8 
day 
15.855± 5.451 45.23± 8.626 740.637± 383.361 3.025± 0.190 5.695± 1.774 17.057± 4.281 
 
6.3.6. Physico-chemical properties of pDNA-NP complex 
Size and charge (zeta potential) distribution pattern of pDNA-NP complex have been 
characterized by dynamic light scattering (DLS) method. The average size and zeta potential 
of pVAX-GFP-omp(211-382)-NP complex were 199.25 ± 22.29nm and 23.25± 33.59 mV 
respectively. Similarly, The average size and zeta potential of pVAX-GFP-omp(211-382)opt-
NP complex were 205.25 ± 3.59 nm and  26.35± 2.38  mV respectively (Figure 6.5). Zeta 
potential otherwise known as the electrokinetic potential at the surface of the colloidal 
particles has a great significance in comparing the stability of colloidal dispersions [333]. The 
high positive charge of formulated nano complex confirmed the complete exposure of 
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chitosan towards the surface in the complex and higher stability. The polydispersity index 
(PDI) is a measurement of particle distribution and gave a distribution range from 0.000 to 
0.500 [298]. The PDI value of pVAX-GFP-omp(211-382)-NP complex (0.152±0.06) and 
pVAX-GFP-omp(211-382)opt-NP complex (0.216±0.05) confirmed the monodispersity 
nature. 
 
Figure 6.5. Size and charge (zeta potential) distribution pattern of pDNAloaded Chi/PLGA NPs by 
dynamic light scattering (DLS) method. The average size of pVAX-GFP-omp(211-382)-NP complex was 
199.25 ± 22.29 nm (a) and zeta potential was 23.25± 2.25 mV. Similarly, The average size ofthepVAX-
GFP-omp(211-382)-NP complex was 205.25 ± 33.59 nm (c) and zeta potential was 26.35± 2.38 mV. 
 
Figure 6.6: DNA entrapment assay: The relative fluorescence of pDNA and pDNA-NP complex (n = 5; 
mean ± standard error). Maximum fluorescence is exhibited by free pDNA [pVAX-GFP-omp(211-382) 
and pVAX-GFP-omp(211-382)opt]. Decreasing pDNA/NP ratios yield decreasing fluorescence intensities. 
The value corresponding to fluorescence of water (negative control) indicates complete complexation of all 
free pDNA with NPs. 
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6.3.7. DNA entrapment assay 
The complex formation of pDNA and NPs was confirmed by fluorescence and gel 
electrophoresis. The relative fluorescence from the OliGreen nucleic acid stain is an 
indication of free, or incompletely complexed, DNA within the sample. Maximum 
fluorescence is exhibited by the sample that contained only free plasmid in water. As seen in 
Figure 6, a decrease in the fluorescence intensity was observed in PDNA-NP complex in 
comparison to the only pDNA. Such a decrease in fluorescence indicates that the pDNA is 
complexed to the point that DNA dye association and fluorescence are prevented In the case 
of pVAX-GFP-omp(211-382)-NP complex (pDNA/NP:0.02), a 91% decrease in fluorescence 
intensity is observed compared to that of the free pDNA. Similarly, in the case of pVAX-
GFP-omp(211-382)opt-NP complex, a 88% decrease in fluorescence intensity is observed 
compared to that of the free pDNA. The value corresponding to fluorescence of water 
(negative control) was same as complete complexation of all free pDNA with NPs. The 
complete uptake of all of the pDNA in pDNA-NP complex indicates the ideal ratio (1:50) for 
protection and delivery of the entire DNA load. Similar results regarding successful 
complexation of pDNA with Chi/PLGA NPs was confirmed by comparison of the relative 
fluorescence of samples containing pDNA-NP complexes (0.02 ratio) to a pure water sample 
that indicates the absence of free pDNA [363]. 
6.3.8. Enzymatic Degradation of pDNA and Complexes 
The protection from enzymatic digestion that NP complexes afford to pDNA was confirmed 
by gel electrophoresis after treatment with DNase [363]. In the case of free pDNA, no bands 
were observed after incubation with DNase I except a faint band of high mobility at the 
bottom of the gel (Figure 6.7). The smeared pattern in lane 5 is an indication that some of the 
pDNA in the complex was available for digestion, as fragments of various sizes with higher 
mobility than those of undigested plasmid are visible. A lesser degree of digestion occurs for 
complexes, as the smeared band does not contain fragments as small as those in lane 4. In the 
pDNA-NP sample exposed to DNase, there is still a large amount of remaining complexes 
that exhibit no electrophoretic mobility and are thus seen as bands in the gel well, suggesting 
protection from endonuclease digestion. The complete protection of pDNA in pDNA-NP 
complex was also observed through enzymatic degradation study (DNAse I) [363]. 
Complexes treated with the nuclease exhibit limited electrophoretic mobility, indicating that 
within the complex, some of the pDNA must be exposed to the introduced enzyme and the 
degraded DNA is located on the outside of the complex. 
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Such approaches could also prove useful in studying the delivery of the biological agents into 
cells via nanoparticle platforms and the release of the active therapeutics from polymeric 
nanosurfaces. 
 
Figure 6.7. Plasmid and pDNA/NP complexes after nuclease digestion using DNase I: lane A: 1 kb 
Molecular weight marker; lane B: 100 ng plasmid [pVAX-GFP-omp(211-382)]; lane C: pVAX-GFP-
omp(211-382)-NP complex; lane D: 100 ng pVAX-GFP-omp(211-382) with DNase I; lane E: pVAX-GFP-
omp(211-382)-NP complex with DNase I.  
6.3.9. SEM study 
The morphology of pVAX-GFP-omp(211-382)-NP complex and pVAX-GFP-omp(211-
382)opt-NP complex were analyzed by SEM analysis (Figure 6.8). The NPs were spherical in 
structures as confirmed by scanning electron microscope (SEM). The particles were found to 
be round, uniform and isolated in nature.  
 
Figure 6.8.  SEM photograph of (a) pVAX-GFP-omp(211-382)-NP complex (b) pVAX-GFP-omp(211-
382)opt-NP complex 
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Figure 6.9. Transfection efficiency (%T×MI) patterns of control (pVAX-GFP), pVAX-GFP-omp(211-
382)+ Lipofectamine 2000, pVAX-GFP-omp(211-382)-NP complex and pVAX-GFP-omp(211-382)opt-NP 
complex after 24 hr incubation. 
6.3.10. In vitro transfection study with pDNA-NPs complex  
The selection of those nanoparticles (Chi/PLGA), to be used in transfection assays, was made 
in order to obtain the maximum efficiency of this delivery process, i.e. high percentages of 
transfected CHO cells, resulting from the expression of GFP in the cell nucleus.The 
formulated nanocomplexpVAX-GFP-omp(211-382)-NP complex and pVAX-GFP-omp(211-
382)opt-NP complex were  transfected in the similar fashion in to CHO cells and transfection 
efficiency was evaluated and compared with transfection efficiency of Omp-pVAX-GFP plus 
transfection agent Lipofectamine 2000. The comparable transfection efficiency was observed 
in case of pVAX-GFP-omp(211-382)-NP complex and pVAX-GFP-omp(211-382)opt-NP 
complex with pVAX-GFP-omp(211-382)- Lipofectamine complex. 
6.4. Discussion 
The main goal of this study is to develop a DNA vaccine candidate, based on the outer 
membrane protein of A.hydrophila, for immunization along with characterization of self-
assembled polymeric-pDNA nanoparticles for improved vaccine delivery. The two antigenic 
coding sequences (KF938895211-381and KF938895703-999) were successfully inserted in 
pVAX-GFP expression vector. Codon optimization was performed for fish (D. rerio) to 
generate two other optimized sequences. Thus, the four conserved protein sequences 
[aha1(211-381), aha1(211-381)opt, aha1(703-999) and aha1(703-999)opt] of antigenic outer 
membrane protein were cloned into pVAX-GFP expression vector and successfully 
transformed into E. coli DH5α. Then, larger productions of plasmids were performed (250 
mL culture volumes) and pDNAs were purified by HIC membrane chromatography with high 
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purity and high concentration. The purified plasmids [pVAX-GFP-aha1(211-381), pVAX-
GFP-aha1(211-381)opt, pVAX-GFP-aha1(703-999), pVAX-GFP-aha1(211-381)opt] were 
transfected with Lipofectamine into CHO (Chinese hamster ovary) cells. 
Positively charged liposome/DNA complexes (lipoplexes) were obtained by complexation of 
purified pVAX-GFP (control) and of pVAX-GFP-aha1 derivative plasmids with the cationic 
liposome-based reagent Lipofectamine 2000™. Lipofectamine cationic lipoplexes have been 
widely used as a safe transfection methodology with the in vitro transfection assays 
demonstrating improved efficiencies due to its ability to protect pDNA against nuclease 
attack [357], [358] and to enhance cellular uptake via endocytosis [355]. 
Transient transfection efficiency was evaluated by fluorescence intensity measurement 
corresponding to GFP reporter expression level at different time intervals. The transfection 
with designed aha1-pVAX-GFP showed transfection efficiencies higher than the obtained for 
the positive control (pVAX-GFP), but in the same order of magnitude. Values of 850±392 to 
3,259±816 (Table 6.1) obtained with all of the four constructs points that these putative 
antigenic proteins can be easily expressed in eukaryotic cells. 
An independent experiment of transfection of CHO cells with aha1(211-381)-pVAX-GFP 
(Table 2) confirmed the highest transfection efficiency after 24 h incubation with a regular 
decrease of expressed Aha1-GFP from the 1st to the 8th day post-transfection (to 1.3% of the 
24 h expression level). However, the pVAX-GFP-aha1(211-381)opt clearly gives less fusion 
antigenic protein than the pVAX-GFP-aha1(211-381). There is a confirmed impact of the 
nucleotide composition on the transfection efficiency of the pVAX-GFP-aha1(703-999) and 
pVAX-GFP-aha1(703-999)opt. In this case, however, the plasmid containing the optimized 
sequence was the more expressed. As pVAX-GFP-aha1(211-381) and pVAX-GFP-
aha1(211-381)opt have the same size, the lower expression of Aha1(211-381)-GFP protein is 
probably due to the different nucleotide composition that may increase the susceptibility of 
the plasmid to nucleases or decrease the levels of the transcripts due to a lower transcription 
and/or a higher degradation. Although significant smaller plasmid sizes are correlated with 
higher transfection efficiencies [357], [360] the size differences between pVAX-GFP-
aha1(211-381) (3,850 bp) and pVAX-GFP-aha1(703-999) (3,976 bp) are not relevant in this 
system. 
Based on the transfection efficiency, aha1(211-381) and aha1(211-381)opt were selected for 
nanoparticle-based pDNA vaccine delivery studies. PLGA-chitosan nanoparticle/plasmid 
DNA complexes were formulated and characterized in terms of size, size distribution and 
zeta potential by dynamic light scattering. The formulated nanocomplexes (pVAX-GFP-
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aha1(211-381)-NP complex, d=171±73 nm and pVAX-GFP-aha1(211-381)opt-NP complex, 
d=153±54 nm) had overall positive charges, as confirmed from zeta potential measurements, 
which anticipates very stable nature. SEM analysis (Figure 6.8) revealed a spherical shape of 
the formulated nanocomplexes and sizes that correlate with DLS measurements (Figure 6.5). 
The ability of PLGA-chitosan nanoparticles to form complexes with pDNA was evaluated by 
using the fluorescent intercalating dye Oil Green to label free plasmid DNA. Fluorescence 
from the Oil Green nucleic acid staining is an indication of free, or incompletely complexed, 
DNA within a sample. Maximum fluorescence is exhibited by the sample that contained only 
free plasmid in water. As seen in Figure 6.6, a decrease in the fluorescence intensity was 
observed in pDNA-NP complexes in comparison to naked pDNA. Such decrease in 
fluorescence indicates that the pDNA is complexed to the point that DNA dye association and 
fluorescence are prevented. In case of pVAX-GFP-aha1(211-381)-NP complexes (pDNA/NP 
mass ratio of 1:50), a 91% decrease in fluorescence intensity is observed compared to that of 
the free pDNA. Similarly, pVAX-GFP-aha1(211-381)opt-NP complexes showed a 88% 
decrease in fluorescence intensity when compared to that of the free pDNA. The value 
corresponding to fluorescence of water (negative control) mimics the complete complexation 
of all pDNA within NPs. The complete uptake of all of the pDNA in pDNA-NP complexes is 
ideal for protection and delivery of the entire DNA load. Bordelon and coworkers (2011) also 
verified a 94% decrease in fluorescence intensity upon Chi/PLGA NP complexation of 
plasmid for the same pDNA/NP ratio of 1:50, by comparison of the fluorescence of samples 
towards that of pure water, proving that such successful complexation of plasmids is 
achievable [363]. 
The protection from enzymatic digestion that NP complexes confer to pDNA was confirmed 
by gel electrophoresis after treatment with DNase (Figure 6.7) [363]. In case of free pDNA, 
typical bands of open circular and supercoiled pDNA isoforms (lane B) were no longer 
observed after incubation with DNase I (lane D). Regarding the protection of plasmid pVAX-
GFP-aha1(211-381) within NPs (lane C), the smeared pattern that could be seen when DNase 
digestion was implemented (lane E) is an indication that some of the pDNA in the complexes 
was still freely available, as fragments of various sizes with higher mobility than those of 
undigested plasmid are visible. A lesser degree of digestion occurs for complexes. In the 
pDNA-NP sample exposed to DNase (lane E), there is still a large amount of remaining 
complexes that exhibit no electrophoretic mobility and are thus seen as bands in the gel well, 
suggesting protection from endonuclease digestion. The density of the stained pDNA in the 
well is very strong and comparable to that of lane C. A higher level of protection of pDNA in 
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pDNA-NP complex was observed through the same enzymatic degradation study by [363] 
who suggested that within a NP complex, some of the pDNA must be exposed to the 
introduced enzyme and the consequent degraded DNA is located on the outside of the 
complex. 
6.5. Conclusion 
The selection of those nanoparticles (Chi/PLGA), to be used in transfection assays, was made 
in order to obtain the maximum efficiency of this delivery process, i.e. high percentages of 
transfected CHO cells, resulting from the expression of GFP in cell nucleus. In CHO cells, 
the formulated nanocomplexes (pVAX-GFP-aha1(211-381)-NP complex and pVAX-GFP-
aha1(211-381)opt-NP complex) showed transfection efficiencies comparable with those 
found when using same plasmid with lipofection. This study will aid in designing and 
optimizing formulations of DNA therapeutics with major transfection efficiency and minimal 
degradation. 
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Chapter 7 
In silico identification of outer membrane 
protein (Omp) and subunit vaccine design 
against pathogenic Vibrio cholerae 
 
 
7.1. Introduction 
Vaccines have been demonstrated to be successful and effective medical strategies for 
preventing infectious diseases, reducing the incidence of diseases and mortality 
significantly.In recent years vaccine development exploration accelerates the new strategies 
based on genomics, proteomics, functional genomics and synthetic chemistry. With the 
advancement of vaccine technology, Reverse Vaccinology (RV) has provided a change in the 
perspective of vaccine design by targeting proteins either exposed on the surface of the 
pathogen or secreted into the extracellular milieu [364].This approach has been termed as 
“reverse vaccinology”, since the process of vaccine discovery starts in silico using genetic 
information rather than the pathogen itself to visualize all possible molecular interactions 
based on the pathogen genome, and any promising molecules/processes then selected for in 
vitro/in vivo studies. It reduces the time and cost required for the identification of vaccine 
candidates and provides new solutions for those diseases for which vaccines are not available. 
The demand and role of proteins and peptide specially designed for pharmacotherapeutics 
purpose are increasing in clinical practice to solve many of the currently untreatable diseases. 
Proteins are large molecular weight polypeptides which are susceptible to proteolysis, 
chemical modification, and denaturation during storage and administration. Nowadays, 
peptide-based vaccine are getting more importance due their many desirable properties. 
Peptide-mediated molecular therapeutic delivery systems have recently emerged as an 
alternative means to address effectively to current vaccine forms. Owing to their excellent 
specificity, low toxicity, rich chemical diversity and availability from natural sources, FDA 
has successfully approved a number of peptide-based drugs and several are in various stages 
of drug development [365]. The relative ease of construction and production, chemical 
stability, and lack of oncogenic or infectious potential has made the peptides attractive vaccine 
candidates [366]. Subunit peptide vaccines can be designed to contain the minimal microbial
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component necessary to stimulate an appropriate immune response. This has the advantage of 
removing unnecessary components, thus decreasing the risk of stimulating an autoimmune 
response or other adverse effects. Synthetic vaccines can also be tailored to stimulate a 
targeted immune response. Likewise, peptide-based vaccines can also be used as safer ways of 
inducing allergen-specific tolerance [367]. 
Vaccines work by inducing profound changes in the cellular components of adaptive 
immunity, comprising T- and B-cells. The concept of peptide vaccines is based on 
identification and chemical synthesis of B-cell and T-cell epitopes which are 
immunodominant and can induce specific immune responses [368]. Our increased 
understanding of antigen recognition at the molecular level has resulted in the development of 
rationally designed peptide vaccines.  
Consequently, focuses on vaccine design shifted to explore surface-exposed antigens 
susceptible to antibody recognition and T-cell induction through comparative pan-genome 
reverse vaccinology [369]. Peptides complexed with major histocompatibility complex class I 
molecules in the endoplasmic reticulum are then transported to the cell surface for recognition 
by cytotoxic T lymphocytes (CTLs) [370]. Since activation of CD4+ helper T-cells is essential 
for the development of adaptive immunity against pathogens [371], T-cell promiscuous 
peptides became a prime target for vaccine and immunotherapy [372]. 
Vibrio cholerae is a "comma" shaped Gram-negative  pathogenic bacteria mostly associated 
with humans that infect the intestine and increases mucous production causing diarrhea and 
vomiting which result in extreme dehydration and if not treated may lead to death.Cholera 
affects an estimated 3-5 million people worldwide and causes 100,000-130,000 deaths a year 
as of 2010 [33]. Cholera remains both epidemic and endemic in many areas of the world.High 
levels of transcripts for OmpU and multiple OM structures (OmpV, OmpS, OmpC, OmpA, 
OmpK and OmpW) were present in V. cholerae. ToxR activates the transcription of OmpU 
and represses the transcription of OmpT, outer membrane porins important for V. cholerae 
virulence [272]. 
Thus, identification of T-cell epitopes would significantly add to the development of novel 
subunit vaccines for V. cholerae. In the present study, computational analysis was performed 
to predict novel vaccine candidates of HLADRB, most prevalent HLA, among all pathogenic 
strains of V. cholerae to avoid barriers of cross-protection against different serovars. 
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7.2. Materials and Methods 
7.2.1. In silico epitope vaccine design 
To identify epitopes, a classical strategy was taken where the identified epitopes should be 
antigenic and have the ability to induce both the T-cell and B-cell mediated immunity.  
 
7.2.2. Sequence retrieval and B–cell antigenic site prediction 
Briefly, amino acid sequence of Outer Membrane Protein (Vibrio cholerae) was retrieved 
from Swiss-Prot protein database (http://us.expasy.org/sprot) and subsequently was analyzed 
for antigenicity using B-cell antigenic site prediction server “Antigenic” 
(http://bio.dfci.harvard.edu/ Tools/antigenic.pl).  
7.2.3. B-cell epitope prediction 
Using the default parameters of both the BCPred and AAP prediction modules of BCPreds 
[373], B-cell non-overlapping epitopes were identified from protein sequences. Primary 
selections of the predicted B-cell epitopes were done based on the scores. In the next step, 
overlapping epitope sequences from “Antigenic” and BCPreds were selected and sequences 
were aligned to get a continuous stretch of amino acid sequence that possess both antigenic 
sequences as-well-as the B-cell binding sites.  
7.2.4. T-cell epitope prediction 
This continuous stretch of the antigenic B-cell epitope was then analyzed using ProPred-1 
[374] and ProPred [375] with default parameters to identify MHC class I and MHC class II 
binding epitopes respectively. Selected numbers of MHC binding alleles were 47 and 51 
respectively for MHC class I and II. Proteasomal cleavage sites of identified epitopes were 
analyzed. Epitopes that can bind both the MHC classes and maximum MHC alleles were 
selected.  
7.2.5. Selection of epitopes 
The final selections of epitope sequences were done based on the criteria that the epitope 
sequence should have antigenic B-cell epitope binding sequences as-well-as both the MHC 
classes binding sequences. Therefore, the selected sequences, in this way, have the ability to 
generate both the B-cell and T-cell mediated immune responses. The strategy of the epitope 
prediction is represented in Figure 1.   
To confirm the parameters of epitopes, each epitope was further analyzed with VaxiJen v2.0 
antigen prediction server [376] for antigenicity. To verify MHC binding properties, less than 
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1000 nM IC50 scores for DRB1*0101 based on MHCPred v.2 
(http://193.133.255.13/mhcpred/) [377] was used. Exomembrane localization and fold level 
topology of epitopes were confirmed using TMHMM 2.0 
(http://www.cbs.dtu.dk/services/TMHMM-2.0/) [378]. The finally selected epitopes were used 
for structural characterization. 
 
7.2.6. Homology modeling and model validation 
To carry out homology modeling, automated Alignment, and Project modes of Swiss model 
server [379] was used. The resultant models were optimized using Swiss-PdbViewer [380] 
and Accelrys Discovery Studio (http://accelrys.com/). Best model were selected based on 
reliability assessment that was carried out using Procheck [381] tools at SAVS server 
(http://nihserver.mbi.ucla.edu/SAVS/). ProFunc [382] was used to predict domains, motifs, 
ligand binding clefts, and various other functional parameters of 3D structures. 
7.2.7. Characterization of epitopes 
Due to the short sequence (9-20 mars) of epitopes, it was difficult to find the template from 
PDB database and to make a homology model using Swiss-model server. Therefore, initially   
drug discovery studio was used to identify and determine the native site and the structure of 
epitopes within the protein. In another effort, the DISTILL server [383] that can predict the 3-
D structure of small fragments of proteins based on the similarity with PDB template was also 
be used for epitope modeling. Resultant epitopes were then validated with ProSA-web and 
PROCHECK. ProFunc, Motif Scan (http://myhits.isb-sib.ch/cgibin/motif_scan), and Inter 
ProScan [384] was used for domain, motif, and functionality assignment of epitopes. Protein 
Digest (http://db.systemsbiology.net:8080/proteomics Toolkit/proteinDigest.html) will be used 
to determine molecular weight, pI, and enzymatic degradation site (s) of epitopes. 
7.3. Results 
7.3.1. Antigen Selection 
One outer membrane protein (Genebank ID: H8JSM7) was retrieved from Genebank database 
and confirmed as antigenic (VaxiJen score = 0.528).TMHMM 2.0 based exo-membrane 
Chapter 7                      In silico identification of outer membrane protein……..pathogenic Vibrio cholerae 
 
116 
 
localization and topology of OMP shows that it is fully exposed to outside the cell 
(Figure7.1).  
Figure 7.1. TMHMM 2.0 based exo-membrane localization and topology of OMP 
7.3.2. Identified antigenic B-cell epitopes 
The common antigenic B-cell epitopes for each transporter were identified using “Antigenic” 
and BCPreds. It was found that the predicted B-cell epitope sequences by BCPred and AAP 
prediction modules of BCPreds highly varied. Therefore, the common sequences predicted by 
these two algorithms of BCPreds were considered to select B-cell epitopes. The variable 
lengths of antigenic sequences generated by “Antigenic” and the 20 mers length B-cell epitope 
sequences predicted by BCPreds were then analyzed to find common B-cell antigenic epitope 
sequences those are listed in Table 1.  The common B-cell epitopes were identified using AAP 
and BCPreds method of BCPREDS Server 1.0. This method generates a stretch of 26 mers 
sequence (RTRSNSGLLTWGDKQTITLEYGDPAL) (amino acid position 391-416) and 31 
mer sequence (FFAGGDNNLRGYGYKSISPQDASGALTGAKY) (amino acid position 464-
494)   that meets all selection criteria for the antigenic B-cell epitope. 
Table 7.1: Antigenic B-cell epitopes of V. cholerae OMP Epitopes are identified by B-cell epitope 
prediction with BCPreds (BCPred algorithm and AAP Prediction algorithm) 
Sequence Amino acid position Length (mers) 
B-cell epitope prediction with BCPreds 
BCPred algorithm 
DVGDAFNDNPEWKKGVGTGI 517 20 
LKWKKPWVNSQGHSFDSSFS 280 20 
IRGEAEGDRDFQRLIRRSGL 108 20 
GLLTWGDKQTITLEYGDPAL 397 20 
FFAGGDNNLRGYGYKSISPQ 464 20 
ISPVGPIRLDFAWGLDAAPG 539 20 
QTITAGYKIPLEDALNEYYR 305 20 
RPFKQGEPYLVSQVGEFNQN 206 20 
DNSQFLLPGMTYTRTRTRSN 376 20 
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ATSSIEYQYRLTGNWWAAMF 496 20 
AAP Prediction algorithm 
SPVGPIRLDFAWGLDAAPGD 540 20 
RTRSNSGLLTWGDKQTITLE 391 20 
VTRLSEVDIVIRGEAEGDRD 98 20 
GSLKWKKPWVNSQGHSFDSS 278 20 
ATSSIEYQYRLTGNWWAAMF 496 20 
GDPALLSETRVLRLQTGSSW 412 20 
EQTITAGYKIPLEDALNEYY 304 20 
RQGLQDDNSQFLLPGMTYTR 370 20 
VGDAFNDNPEWKKGVGTGIR 518 20 
YGYKSISPQDASGALTGAKY 475 20 
QRLIRRSGLRVDAPLNHSLY 119 20 
Common antigenic B-cell epitope (s) 
RTRSNSGLLTWGDKQTITLEYGDPAL 391-416 26 
FFAGGDNNLRGYGYKSISPQDASGALTGAKY 464-494 31 
 
7.3.3. Identified candidate peptide vaccines 
Selected antigenic B-cell epitope sequences were analyzed with ProPred 1 and ProPred to 
identify respectively MHC I and MHC II binding T-cell epitopes. The common T-cell 
epitope sequences those bind to both the MHC molecules were selected.Predicted peptides 
that would be considered for vaccine development based on MHC allele binding ability are 
listed in Table 2.MHC binding T-cell epitopes were identified using ProPred 1 (for MHC I) 
and ProPred (for MHC II) with default parameters. The two B-cell epitope sequences (26 mer 
and31-mer) were analyzed and the common epitope (s) that can bind both the MHC classes 
and covers maximum MHC alleles were selected. In this way only one 9-mer sequence 
(YKSISPQDA) spanning at amino acid position 477 to 485 of the OMP protein was 
selected.YKSISPQDA was found to bind 5 MHC I and 41 MHCII alleles.VaxiJen and 
MHCPredv.2 analysis of the epitope (YKSISPQDA) further confirm that the epitope is 
antigenic (VaxiJen score = 0.528) and can bind to DRB1*0101 allele (MHCPred nM IC50 
score =104.23) (Table 3). Another peptide LRGYGYKSI was able to bind 9 MHC I and 28 
MHCII alleles. But it was not antigenic as predicted by VaxiJen v2.0 antigen prediction 
server (VaxiJen score= 0.232). 
 
 
 
 
 
 
 
Chapter 7                      In silico identification of outer membrane protein……..pathogenic Vibrio cholerae 
 
118 
 
Table 7.2.  T-cell epitopes of OMP (V. cholerae). The common antigenic B-cell epitope 
“FFAGGDNNLRGYGYKSISPQDASGALTGAKY” was analyzed for its ability to bind MHC I and 
MHC II molecules using Propred I and Propred. A common epitope “YKSISPQDA” (9 mers) that 
generates both TCL and HCL mediated immune response was selected. 
ProPred 1 (MHC I) 
TCL epitope sequences Amino acid position No of MHC-I binding alleles 
GGDNNLRGY 467 5 
ASGALTGAK 485 6 
YKSISPQDA 477 5 
FFAGGDNNL 464 10 
ISPQDASGA 480 6 
SPQDASGAL 481 23 
NNLRGYGYK 470 4 
FAGGDNNLR 465 6 
NLRGYGYKS 471 4 
LRGYGYKSI 472 9 
SGALTGAKY 486 5 
KSISPQDAS 478 3 
DASGALTGA 484 4 
RGYGYKSIS 473 3 
ProPred (MHC II)   
HCL epitope sequences Amino acid position No of MHC II binding alleles 
YKSISPQDA  41 
ISPQDASGA 480 7 
YGYKSISPQ 475 33 
FAGGDNNLR 465 4 
FFAGGDNNL 464 5 
LRGYGYKSI 472 28 
 
Table 7.3. MHCPred Result of sequence YKSISPQDA 
The HLA allele used in the test is: DRB0101 
The query sequence 
YKSISPQDA 
Amino acid 
groups 
Predicted -
logIC50 (M) 
Predicted 
IC50 Value 
(nM) 
Confidence of 
prediction (Max = 
1) 
YKSISPQDA 6.982 104.23 0.89 
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7.3.4. 3-D modeling of V. cholerae OMP 
The 3D structure of V. cholerae OMP is not available and in this study, we have focused 3D 
modeling of OMP using homology modeling. Based on blast parameters, with highest 
similarity (PDB id: 2HUE) having 35% sequence identity with an E- value of 2e-69 was 
selected as the template. The X-Ray diffraction structure has 1.70 Å resolutions. The 
optimized 3D model of V. cholerae OMP consists of 9 helices, 15 strands and 23 turns (Figure 
7.2). The molecular weight and PI of the model were estimated to be 26.74kDa and 4.95 
respectively.   
  
Figure 7.2. The 3D model V. Cholerae OMP from various angles. 
7.3.5. Validation of the model  
To validate the model, initially ProSA-web was used that compares and analyzes the energy 
distribution in protein structure as a function of sequence position to determine a structure as 
native-like or fault. As shown in Figure 3 and the Z-scores, the model is of good quality of 
structure (Figure 7.3). The Procheck of SAVA master server was used for assessment of the 
stereochemical quality of the model. According to the Ramachandran plot, residues in most 
favored regions, residues in additional allowed regions residues in generously allowed regions, 
and residues in disallowed regions were respectively, 79.2%, 14.6%, 4.2%, and 1.9% that 
ensures the geometrically acceptable quality of the model (Figure 7.4). 
Chapter 7                      In silico identification of outer membrane protein……..pathogenic Vibrio cholerae 
 
120 
 
 
Figure 7.3. Validation of the 3-D model of V. cholerae OMP with ProSa-web. The upper panel is template 
(PDB id: 2HUE) and lower is OMP. (a) Overall model quality of 2HUE (Z=-5.77). (b) Local model quality 
of 2HUE. (c) Overall model quality of OMP (Z=-5.28). (d) Local model quality of OMP. 
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Figure 7.4. The Ramachandran plot for V. cholerae OMP. The plot shows the acceptability of the model 
7.3.6. Characterization of the epitope  
The epitope position within the V. cholerae OMP protein was determined using Accelrys 
Discovery Studio Visualizer (v1.7). Combining the results of the 3D model and TMHMM 2.0 
based topology analysis, it is evident that the epitope is exposed to the surface of the protein 
and therefore it also supports that the predicted sequence is a potential candidate peptide 
vaccine. Due to the very short length (9 mers) of the epitope, instead of Swiss model server, 
the DISTILL server was used to generate 3-D structure (Figure 7.5). Calculated molecular 
weight and pI of the 9 mers epitope are respectively, 1008.10 and 5.83.  As the focus of this 
study is on V.cholerae OMP, we have excluded 3D characterization of epitopes from other 
pathogens. But based on sequence homology and topology analysis, it is found that, epitopes 
identified from other pathogens are also antigenic, MHC II (DRB1*0101) binding, located at 
nearly same accessible region, and exposed to cell surface similar to the V. cholerae OMP. 
Therefore, they are also potential vaccine candidates. 
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Figure 7.5. 3-D structures of   9 mers (YKSISPQDA) epitopes created by DISTILL. 
 
7.4. Discussion 
Virulence-related outer membrane proteins (Omps) are expressed in Gram-negative bacteria 
such as V. cholerae and are essential to bacterial survival within macrophages and for 
eukaryotic cell invasion.The kW-C cholera vaccine stimulates good immunity in people living 
in endemic cholera areas, proving protective Vc OM immunogens exist [37]. OmpU is more 
protective (compared to OmpT) against the bactericidal effects of bile salts and other anionic 
detergents [273]. An OmpU (a general porin) prologue, vca1008, identified by IVET is 
required for mouse colonization [274]. Omps are also conserved in nature so that Omp based 
vaccine therapeutics would be beneficial for different serovars of V. cholerae. In this study, 
we developed and characterized 3D model of V. cholerae Omp for in order to understand 
structural identity which can be employed for the design of therapeutic molecules [385]. 
In general, earlier studies have reported either T-cell or B-cell based epitope designing for a pathogen 
[386]–[388]. Similarly, some vaccines can only activate helper T lymphocytes (HTL)/CD4+ / MHC II. 
But activation of CD8+ cytotoxic T- lymphocytes (CTLs)/ MHC I is also required in many cases [389]. 
Therefore, an epitope that can produce both the B-cell and T-cell (MHC I and MHC II) mediated 
immunity is highly useful in developing peptide-based vaccines. 
In the current experiment, VaxiJen and MHCPred were used to support the efficacy of 
epitopes. Similarly, using subtractive genomics and homology analysis, a single epitope was 
designed within a nearly same accessible region of corresponding Omp proteins in various V. 
cholerae serovars. So, the identified epitope may be useful against a wide range V. cholerae 
strains. The identified peptide (YKSISPQDA) from V. cholerae Omp may induce B-cell and 
both CD4+ and CD8+ T-cell mediated immunity. The sequence homology analysis 
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demonstrates that this epitope sequence is conserved in Omps of V. cholerae at the nearly 
same accessible region. Therefore, this peptide might be useful in designing a vaccine against 
all cholera pathogens by developing broad-spectrum peptide vaccine. 
7.5. Conclusion 
Immunoinformatics study of Omp from V. cholerae confirmed its antigenicity, hence plays a 
measure role in virulence. So it could be targeted as a vaccine. The successful design of 3D model of 
Omp leads to give more information about the structural interaction that can be employed for drug 
design.  Similarly, the identified epitope (YKSISPQDA) require proper design and subsequent 
validation for their uses as broad-spectrum peptide vaccine against V. cholerae. 
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Chapter 8 
Summary & Conclusion 
8.1. Summary 
In the present study, various NPs formulations of PLA and PLGA loaded with model protein 
(BSA) or drug (clindamycin hydrochloride) were prepared by solvent evaporation method 
varying drug/protein: polymer concentration and optimized for size, encapsulation efficiency, 
drug loading,  morphology, etc. Then, PLA/PLGA NPs encapsulating Omp antigen from A. 
hydrophila were formulated and their efficacy were compared with adjuvant formulations to 
develop a better antigenic carrier model in fish. Similarly, the efficacy is also compared 
between PLA encapsulated and PLGA encapsulated OmpNP-immunized groups and a 
correlation is established evaluating the results of innate and adaptive immune response 
studies in L. rohita. In another attempt, PLA/PLGA-Omp (Omp from V. cholerae) 
nanoparticles were formulated with desired physicochemical properties and evaluation of 
type and strength of immune responses (Humoral and cellular) elicited by formulated NPs 
was elucidated by comparing all possible combinations in mice. 
Thus, the specific objectives of the current study are 
1. Preparation and characterization of PLA and PLGA loaded with model protein (BSA) 
or drug (Clindamycin hydrochloride) NPs varying drug/protein:polymer concentration  
2. Preparation, Characterization and In vitro study of biodegradable and biocompatible 
based PLA and PLGA nanoparticles with encapsulation of OMP antigens. 
3. Parenteral immunization of PLA/PLGA nanoparticle encapsulating outer membrane 
protein (Omp) from A. hydrophila; Evaluation of immunostimulatory action in lower 
vertebrate (fish). 
4. Evaluation of the immune responses (specific) in mice model after intraperitoneal 
immunization of Omp antigen (V. cholerae) encapsulated PLA/PLGA nanoparticles 
5. Development of DNA vaccines to boost antigenic OMP (outer membrane protein) 
antigenicity 
6. In silico identification of outer membrane protein (Omp) and subunit vaccine design 
against pathogenic V. cholerae 
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The salient results have been presented below: 
Formulation and characterization of PLA and PLGA loaded with model 
protein (BSA) or drug (Clindamycin hydrochloride) nanoparticles   
CLH-PLA and CLH-PLGANPs of various sized particles were formulated by varying the 
drug to polymer ratio from 1:5 to 1:20. The size, zeta potential and polydispersity index 
values of CLH-PLA NPs and CLH-PLGA NPs confirmed that the drug: polymer 
concentration is important for the stability of drug loaded NPs. The drug to polymer ratio 1: 
10 were found to be optimal ratio for the formulation to be stable and monodispersed CLH 
loaded PLA and PLGA NPs. NPs formulation (both CLH-PLA 2 and CLH-PLGA 2) showed 
a significantly higher drug loading efficiency and a controlled release profile extended up to 
144 h. Higher drug loading and an extended CLH release profile were observed in the case of 
CLH-PLGA NPs which might be due to higher hydrophilic nature of PLGA that causes 
enhanced molecular interaction. The spherical and isolated structures of both CLH-PLA2 
and CLH-PLGA2 NPs were confirmed by scanning electron microscope (SEM) study. The 
smooth surface and isolated nature of NPs can also be correlated to the presence of lactide 
that adds hydrophobicity to the polymer ultimately prevents agglomeration. The thermal 
behavior (DSC) studies of CLH-PLGANPs confirmed the disappearance of CLH 
endothermic peak (150
0
C) that indicated the uniform dispersion of drug at a molecular level 
within the system. From FTIR studies, it was found that there was not much alteration in the 
general structure of CLH drug (due to conserved OH, CH and C-O group etc.) after loading 
in PLA and PLGA NPs. The antimicrobial activities were enhanced in CLH-PLA NPs and 
CLH-PLGA NPs than the standard free drug evidenced from a decrease in MIC values tested 
against Streptococcus faecalis and Bacillus cereus.  
 
Evaluation of immunostimulatory action in L. rohita (rohu) upon parenteral 
immunization of PLA/PLGA nanoparticle encapsulating outer membrane protein 
(Omp) from A. hydrophila 
PLA/PLGA NPs were evaluated for their ability to serve as an excellent carrier for site 
specific delivery of macromolecules such as Omp through parenteral immunization in L. 
rohita. PLA-Omp NPs (size: 223.5± 13.19 nm) and PLGA-Omp NPs (size:166.4± 21.23 nm) 
were prepared using double emulsion method in which antigen was efficiently encapsulated 
reaching encapsulation efficiency 44 ± 4.58 % and 59.33± 5.13 % respectively. The physical 
properties like zeta potential values and polydispersity index (PDI) values confirmed the 
stability as well as monodisperse nature of the formulated NPs. The spherical and isolated 
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nature of Omp loaded PLA and PLGA NPs were revealed by SEM analysis. Upon 
immunization in L. rohita, PLA/PLGA-Omp NPs showed encouraging results by activating 
both innate and specific immune response against A. hydrophila in fish without any side 
effects. Significant higher bacterial agglutination titre, haemolytic activity and specific 
antibody titre confirmed the combined immune activation. Considering the adverse side 
effects of oil adjuvant (FIA), the current study also proved the comparable antibody response 
of PLA-Omp NPs and PLGA-Omp NPs with that of FIA-Omp treated groups. Again, the 
better efficacy of PLA/PLGA-Omp NPs system was confirmed by increased protection 
against A. hydrophila by activating immune responses by challenge study. In comparison to 
PLGA-Omp NPs, PLA-Omp NPs offered a better immune response in terms of higher 
bacterial agglutination titre, haemolytic activity, specific antibody titre, higher percent 
survival upon A. hydrophila challenge in L. rohita. It can be concluded that PLA/PLGA NPs 
based delivery system would be a novel antigen carrier for parenteral immunization in fish. 
This is probably the first report on the delivery of PLA-Omp and PLGA-Omp NPs against A. 
hydrophila in L. rohita. Hence, more focused research on designing and formulation would 
be attributed to PLA/PLGA NPs based on vaccine delivery system in fish model. 
Evaluation of the immune responses (specific) in mice after intraperitoneal 
immunization of Omp antigen (V. cholerae) encapsulated PLA/PLGA 
nano-particles 
This study was focused with an aim to elucidate the formulation of polymeric (PLA/PLGA)-
Omp NPs and to evaluate the immune response (humoral and cellular) in terms of antigen 
processing and generation of a response. The formulated PLA-Omp NPs and PLGA-Omp 
NPs were < 500 nm size range; these particles could be successfully endocytosed in the body. 
The lower size was observed in the case of fabricated PLGA-Omp NPs than PLA-Omp 
nanoparticles. PLA and PLGA being negatively charged polymers impacts anionic nature to 
formulated NPs (PLA, PLA-Omp, PLGA, and PLGA-Omp). Also, zeta potential values were 
more negative after successful encapsulation of Omp in both PLA and PLGA (PLA-Omp 
NPs: -25.2 ± 5.45 mV; PLGA-Omp NPs: -32.5 ± 6.15 mV), that proves more stability. 
Significantly higher encapsulation of Omp protein (p < 0.05) was achieved in the case of 
PLGA-Omp NPs (69.18± 1.68 %) than PLA-Omp NPs (57.85 ± 4.15%). However, the Omp 
protein release profile in PLA-Omp NPs is comparatively slower than PLGA-Omp that could 
also be attributed to hydrophilic nature of PLGA and higher antigen loading. Higher lactide 
content in PLA might be an another cause in delaying the rapid burst effect as we observed in 
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the case of PLA-Omp NPs (50% antigen release ≈ 24 hr). Surface morphology of the PLA 
and PLGA nanoparticles loaded with Omp were studied using a scanning electron 
microscope (SEM). From the FTIR spectrum, it was also observed that upon encapsulation of 
Omp to PLA and PLGA the characteristic peaks associated with Omp, PLA and PLGA 
remained intact, so there was no loss of any functional peaks between the absorbance spectra 
of Omp and Omp encapsulated nanoparticles. 
The serum antibody level (IgG1, IgG2a) in different antigen-NP treated sera was measured 
by ELISA. Antigen-specific IgG1, IgG2a titers were above control levels for intraperitoneally 
immunized mice for all groups (7-56 days). Both IgG1 and IgG2 titers in vaccinated mice 
followed the similar pattern, but theIgG1 response is higher than IgG2 response. Both PLA-
Omp and PLGA-Omp NPs causes more efficient splenocyte proliferation in comparison to 
Omp antigen alone (p < 0.05), which confirmed more potent induction of antigen-specific 
immune responses. Again, a significant higher cellular activation was observed in the case of 
PLA-Omp and PLGA-Omp NPs in comparison to Omp antigen alone. PLA-OmpNPs and 
PLGA-Omp NPs induced significantly higher (p < 0.05) CD4
+
CXCR5
hi
PD-1
hi
 cells than 
respective PLA and PLGA NPs. Also, the percentage of follicular CD4 
+
 T helper cells was 
significantly higher in the case of PLA-Omp and PLGA-OmpNps in comparison to Omp. 
Development of DNA vaccines to boost antigenic outer membrane protein 
antigenicity 
The current investigation aimed at developing a DNA vaccine as well as a delivery system to 
boost antigenic outer membrane protein (Omp) that would act as a potential vaccine 
candidate. The conserved protein sequences [omp(211-382), omp(211-382)opt, omp(703-
999) and omp703-999)opt] of antigenic outer membrane protein was cloned into pVAX-GFP 
expression vector and successfully transformed into E. coli (DH5α). The large scale pDNA 
production was achieved with shake flask cultures and the pDNA was purified by 
hydrophobic interaction chromatography (HIC). The purified pDNA was transfected (with or 
without Lipofectamine 2000™) into CHO (Chinese hamster ovary) cells and transient 
transfection efficiency was evaluated by fluorescence intensity measurement corresponding 
to GFP expression level at different time interval. The transfection of CHO cells with Omp-
pVAX-GFP confirmed the highest transfection efficiency after 24 h incubation. PLGA-
chitosan nanoparticle/plasmid DNA complex were formulated and characterized in terms of 
size, size distribution and zeta potential by dynamic light scattering (DLS) method. The 
formulated nano complex of ~200 nm (199.25 ± 22.29 nm and 205.25 ±33.59) was 
transfected in the similar fashion into CHO cells that confirmed improved transfection 
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efficiency at a lower dose. The DNA entrapment assay demonstrated the possible protection 
of pDNA inside the pDNA-nanoparticle complex. The protection from enzymatic digestion 
that NP complexes afford to pDNA was evaluated by gel electrophoresis after treatment with 
DNase. However, more physicochemical characterization of formulated nano complex and 
extensive transfection studies are to be focused on observing the expression pattern of antigen 
that will facilitate future investigations into the functionality of the system in vitro and in 
vivo. 
In Silico identification of outer membrane protein (Omp) and subunit 
vaccine design 
Using in silico approaches, the 3-D model of the Omp was developed using Swiss model 
server and validated by ProSA and Procheck web server. B cell epitopes were identified by  
BCPred and AAP prediction modules of BCPreds  and sequences were aligned to get a 
continuous stretch of amino acid sequence (26 mer:   
RTRSNSGLLTWGDKQTITLEYGDPAL and 31 mer: 
FFAGGDNNLRGYGYKSISPQDASGALTGAKY) that and B-cell binding sites. Further, 
Selected antigenic B-cell epitope sequences were analyzed with ProPred 1 and ProPred to 
identify MHC I and MHC II binding T-cell epitopes respectively and the common epitope (9 
mer: YKSISPQDA) that can bind both the MHC classes (MHC I and MHC II) and covers 
maximum MHC alleles were identified. The identified epitopes can be useful in designing 
broad-spectrum peptide vaccine development against V. cholerae by inducing an optimal 
immune response (both B cell and T cell-mediated immune response). 
8.2. Future investigation 
The successful formulations of NP-based antigen delivery system with all suitable 
physicochemical characteristics were achieved with highly controlled conditions and 
reproducibility. The immunological evaluation studies suggest that PLA/PLGA NPs based 
delivery system could be a novel antigen carrier for fish and mice ensuring its application for 
commercial value and vaccine development. Further work based on present optimized results 
can be taken forward for next level vaccine design and approval. However, more 
physicochemical characterization of formulated nano-DNA complex and extensive 
transfection studies are to be focused on observing the expression pattern of antigen that will 
facilitate future investigations into the functionality of the system in vitro and in vivo. In 
Silico identification of outer membrane protein (Omp) and subunit vaccine design against 
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pathogenic Vibrio cholerae require proper design and subsequent validation for their uses as 
broad-spectrum peptide vaccine against V. cholerae. 
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